ABSTRACT
Diffuse idiopathic skeletal hyperostosis (DISH) is a non-inflammatory spondyloarthropathy and
the second most common form of arthritis characterized by formation of ectopic mineral along
the spine. Pathological findings in DISH include regional calcification of the anterior longitudinal
ligament, paraspinal connective tissues, and annulus fibrosus (AF) of the intervertebral disc
(IVD). Clinical symptoms of DISH include increased spine stiffness, decreased spinal range of
motion, and in severe cases dysphagia and spinal cord/nerve root compression. The molecular
pathways responsible for DISH have not been delineated and as such, there are no diseasemodifying treatments. Clinical treatment for DISH is limited to surgical resection of mineralized
tissue often requiring revision surgery. To identify the molecular pathology of DISH, we sought
to characterize the transcriptome, proteome and metabolome of the AF from wild-type (WT) and
ENT1-/- mice (mouse model of DISH). To do so, we needed to establish the baseline gene
expression of a healthy, aging IVD. We found that canonical cartilage markers Prg4, Cilp, Ibsp,
and Comp were enriched >50-fold in the AF compared to the NP, making these potential tissuespecific markers of the murine IVD (Chapter 2). We then used microarrays and showed that loss
of ENT1 is associated with increased cell proliferation in the AF, implicating the MAPK
signaling pathway (Chapter 3). To explore proteomic and metabolomic changes in ENT1-/- mice,
we first established and validated the necessary protocols. The protocols we developed increased
our quantification of proteins greater than 2-fold over previous methods, avoided bias of ECM
proteins, and identified >300 metabolites in the plasma and AF of mice which had not been
accomplished before (Chapter 4). Using these protocols, we showed that ectopic calcification in
the ENT1-/- mouse is associated with altered PI3K/Akt signaling, fatty acid metabolism, and that
lysophosphatidylcholine isoforms may serve as biomarkers of early-stage DISH (Chapter 5).
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Finally, we explored the symptoms associated with ectopic calcification in the ENT1-/- mouse
using behavioral assays and immunohistochemistry to find that these mice exhibit increased pain
and stiffness (Chapter 6). In summary, this work uncovered molecular pathways associated with
DISH, DISH biomarkers, and examined DISH symptoms using a mouse model.
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LAY SUMMARY
Diffuse idiopathic skeletal hyperostosis (DISH) is the second most common form of arthritis and
characterized by abnormal mineral formation along the spine. DISH results in mineralization of
spinal tissues including ligaments, and the annulus fibrosus (AF) of the intervertebral disc (IVD).
Clinical symptoms of DISH include increased spine stiffness, decreased spinal range of motion,
and in severe cases trouble swallowing and loss of sensation due to spinal cord compression.
However, the molecular mechanism responsible for DISH is unknown so there are no treatments
to slow or prevent mineral formation in DISH; treatment is limited to surgical removal of
mineralized tissue often requiring revision surgery. To identify the molecular mechanism of
DISH, we studied the gene expression, protein expression, and small molecule (metabolite)
composition of the AF from wild-type (WT) and mice lacking ENT1 (mouse model of DISH),
but first needed to establish the baseline gene expression of a healthy, aging IVD. We found that
cartilage marker genes Prg4,Cilp, Ibsp, and Comp were enriched >50-fold in the AF, making
these potential tissue-specific markers in the mouse IVD (Chapter 2). We then found that loss of
ENT1 is associated with increased cell proliferation in the AF (Chapter 3). We then wanted to
explore protein and small molecule (metabolite) changes, but first needed to establish protocols
to do so. In developing protocols, we were able to increase our quantification of proteins greater
than 2-fold, avoid bias of certain highly abundant proteins in the IVD, and identify >300
metabolites in the blood and AF of mice which had not been accomplished before (Chapter 4).
We then used these protocols to find that abnormal mineralization in mice lacking ENT1 is
associated with altered molecular signaling, fatty acid metabolism, and that certain fatty acids
may serve as biomarkers of early-stage DISH (Chapter 5). Finally, we explored symptoms in
mice lacking ENT1 using behavioral assays and protein stains to find that these mice exhibit
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increased pain and stiffness associated with abnormal mineralization (Chapter 6). In summary,
this work uncovered molecular mechanisms associated with DISH, DISH biomarkers, and
examined DISH symptoms using a mouse model.
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EPIGRAPH
Here s to the cra

ones. The misfits. The rebels. The tro blemakers. The ro nd pegs in the

square holes. The ones

ho see things differentl . The re not fond of r les, and the ha e no

respect for the status quo. You can quote them, disagree with them, glorify and vilify them. About
the onl thing o can t do is ignore them beca se the change things. They push the human race
forward. And while some may see them as crazy, we see genius. Because the people who are
crazy enough to think they can change the world, are the ones who do.
-
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1.2 Overview
This chapter will provide an overview of DISH and mineralization disorders, with a
specific emphasis on these disorders which affect the spine. Also described are the basics of IVD
biology, with a particular focus on molecular expression in IVD compartments as this is
particularly pertinent to this thesis. Additionally, the utility of “omics” methodologies will be
described briefly as these are critical to studies enclosed herein. Finally, the association between
DISH and pain will be discussed and behavioral assays of pain in rodents will be described as
these are needed to assess pain in our mouse model of DISH.

1.3 Spine Anatomy
The vertebral column composed of 33 vertebrae (7 cervical, 12 thoracic, 5 lumbar, 5
sacral and 4 coccygeal) linked by ligaments, cartilaginous interbody joints and paired synovial
facet joints1. The 24 presacral vertebrae, are connected by 23 intervertebral discs (IVDs).
External environmental factors, mechanical loading, genetics, metabolic, and hormonal factors
contribute to the morphological characteristics of the spine1. The vertebral column can be broken
down to functional units called motion segments, which are comprised of an IVD, the superior
and inferior vertebrae, and adjacent connective tissues2. Each vertebra is composed a vertebral
body, pedicles, articular processes, transverse processes, facets, lamina and spinous process2
(Figure 1.1A). In addition to the IVDs, the spine is connected by ligamentous structures. The
largest connective tissues of the spine are the anterior and posterior longitudinal ligaments, which
run from the first cervical vertebra to the sacrum. The only ligament on the anterior aspect of the
spine is the anterior longitudinal ligament, which serves to prevent extreme spinal
hyperextension. Similarly, the posterior longitudinal ligament prevents extreme spinal
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Figure 1.1. Anatomical rendering of the vertebral column.
A. Superior view of an individual vertebrae with the significant bony landmarks labelled. Note:
the counter “inferior articular process” is not visible in this schematic. B. Median sagittal view
of thoracic region, relevant connective tissues are labelled. Further identified are the specific
tissues of the intervertebral disc. Orientation is presented for each Panel via axis legend.
Courtesy of Dale Fournier.
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hyperflexion1. Both the anterior and posterior longitudinal ligaments are anchored into each
vertebra.

1.4 The Intervertebral Disc
1.4.1 Structure and Function
IVDs are specialized connective tissue structures that link adjacent vertebral bodies along
the spine and confer flexibility and mechanical stability during axial compression. The IVD is a
cartilaginous joint that consists of three structurally distinct, yet interdependent tissues: the
annulus fibrosus (AF), the nucleus pulposus (NP), and the cartilage endplates (CEP) (Fig. 1.1B).
The IVD develops in the embryo through coordinated patterning of two distinct cell lineages: the
notochord which develops into the NP and the sclerotome which develops into the AF and CEP3.
The mechanical properties of the IVD result from the specific microstructures of its component
tissues, which are maintained by distinct cell populations. Maintenance of IVD homeostasis and
structural integrity is dependent on multiple factors, including cellular responses to mechanical
load.
The AF is a heterogeneous fibrocartilaginous tissue that forms the periphery of the IVD4.
Its architecture and extracellular matrix (ECM) composition vary as a function of vertebral level
and intradiscal region. The outer AF is composed of a series of concentric lamellae, each formed
by parallel bundles of type I collagen fibers. These fibers are oriented at oblique angles that
alternate between lamellae to form an angle-ply structure providing tensile strength5. The inner
AF serves as a transition between the outer AF and the NP. Compared to the outer AF, it has a
higher type II collagen and proteoglycan content within the interlamellar matrix and this feature
provides resistance to compressive loading4,6. The AF encloses the NP, a gelatinous tissue
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composed of proteoglycans and water held together loosely by an irregular network of type II
collagen and elastin fibers. The major proteoglycan of the disc is aggrecan, which, due to its
highly anionic glycosaminoglycan content, provides osmotic properties enabling the NP to
maintain height and turgor against compressive loads7,8. The CEPs serve structurally to anchor
the IVD to the adjacent vertebral bone, and play an essential role in IVD nutrition. The adult IVD
is almost completely avascular9, forcing cells to function in an environment inherently low in
nutrients and oxygen, supplied to the IVD via passive diffusion through the CEPs10. Similar to
articular chondrocytes, cells within the endplates secrete a type II collagen- and proteoglycanrich ECM.
1.4.2 Defining the Phenotype of Distinct IVD Cell Types
A fundamental gap in our knowledge of IVD biology has until recently been the lack of
molecular markers to distinguish the different cell types present within this heterogeneous
structure. Transcriptional profiling of IVD cells from various species including rat11-13, rabbit14,
dog15, cow16 and humans17-20 has identified potential markers to demarcate NP and AF cells. The
results of these studies were recently reviewed21,22, leading to recommendations for NP markers
by the ORS Spine Research Interest Group23.
Based on the criteria of i) specific expression in healthy NP cells, ii) requirement for
proper NP cell function and relevance to NP cell physiology, and iii) mRNA and protein
expression validated across different species, the group proposed a list of primary NP markers
that included the stabilized hypoxia-inducible factors HIF1α and HIF2α, the glucose transporter
GLUT1, the signaling factor sonic hedgehog (SHH), the transcription factor Brachyury (T), the
carbonic anhydrases CA3 and CA12, the CD24 antigen, and the keratins KRT8, KRT18, and
KRT19. This group also proposed secondary NP markers, a subset of which has since been
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further validated. Proteomic analysis of healthy murine IVD tissues confirmed the presence of
proposed NP markers including the integrin b4 subunit ITGB4, the a2-macroglobulin A2M, the
synaptosomal-associated protein SNAP25, the transcription factors PAX1 and FOXF1, the
cadherin CDH2, and hemoglobin subunit beta HBB24. Several of these NP markers, including
PAX1 and FOXF1, have been validated in human cells25. Supporting its proposed used as a NP
marker, N-cadherin (CDH2) has been shown to mediate cell clustering behavior and to control
the maintenance of proper matrix production by NP cells26,27.
Fewer studies have proposed AF-specific markers, perhaps since the NP is site at which
degeneration is thought to initiate and thus is the prime target for disc degeneration therapies.
Glypican-3 (GPC3) is a cell surface heparin sulfate proteoglycan whose gene shows higher
expression in AF cells compared to NP cells in humans17, and in AF cells compared to both NP
and articular chondrocytes (AC) in dogs15 and cows16. Likewise, the gene for type V collagen
(COL5A1) shows higher expression in AF compared to NP and AC in rabbits21 and is detected
in human AF cells14,28. The list of potential AF markers can be expanded based on RNA
microarray data from bovine IVD that reported higher expression of CXCL1, EMCN, and KERA
in AF cells compared to both AC and NP16. CXCL1 encodes a member of the CXC subfamily of
chemokines and it has been associated with human IVD degeneration29. EMCN encodes
endomucin, a mucin-like sialoglycoprotein involved in focal adhesion and interactions between
cells and the ECM. KERA encodes keratocan, a keratin sulfate proteoglycan that has also been
detected in human AF tissue30. The current literature points to the need for further studies to
identify and validate AF-specific markers, using criteria similar to those used to identify NP
markers.
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Although it is critical for maintaining the health of the IVD, the molecular signature of
the CEP is even less well characterized than that of the AF. To our knowledge there have been
no transcriptome studies to specifically isolate CEP for the assessment of phenotypic markers.
This is likely due to the small size of the tissue compared to the NP and AF, making it challenging
to isolate. The extracellular matrix content of the CEP resembles hyaline cartilage and as such,
chondrocytes within the CEP are thought to express a phenotype typical to that of articular
chondrocytes. However, since chondrocytes within the CEP do not demonstrate the distinct strata
characteristic of articular cartilage, a direct comparison of cell phenotypes within these
cartilaginous tissues may provide interesting insight.
1.4.3 Proteomic Signature of the IVD
The proteomic composition of the healthy murine IVD has been reported24, identifying
1940 proteins expressed in the IVD primarily associated with the intracellular/plasma membrane
(35 %), organelle (30%), macromolecular complex (10%) and extracellular region (9%) based
on gene ontology terms. However, since the analysis was conducted on intact IVD tissue, the
relative proteomic composition of the AF compared to that of the NP has not been established.
Furthermore, this study was not able to report on relative abundance of the proteins in the IVD.
Recent studies have begun to investigate the proteomic signature associated with IVD
degeneration, reporting proteins whose levels differ in AF cells isolated from degenerative
human IVDs compared to healthy controls31. Among many other proteins, the G protein GNAI2,
the mitochondrial protein SOD2, and the transmembrane protein TMEM51 were notably overrepresented in human IVD degeneration. Proteins that were under-represented in degenerating
AF included the heat-shock protein HSPA8Q, glucose-6-phosphate dehydrogenase (G6PD), and
the calcium-dependent cell-adhesion protein DCHS231. Further studies are required to similarly
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investigate the proteome of degenerative human NP and CEP cells to better understand common
and cell-type specific changes associated with degeneration.

1.5 Disease of Ectopic Spine Calcification
Biomineralization is a process regulated by interactions of minerals and organic
extracellular matrix molecules leading to the production of a mineralized skeleton primarily
composed of calcium phosphate in the form of hydroxyapatite (HA)32. Physiological
biomineralization is tightly controlled by the balanced expression of promoters and inhibitors of
mineralization, and the ratio of inorganic pyrophosphate (PPi) to inorganic phosphate (Pi). When
this balance is disturbed, pathologic mineralization can occur in both humans and animals33,34.
Mineralization disorders of the spine are particularly problematic in elderly populations as they
typically result in lack of mobility, which adds to the difficulty of performing everyday tasks and
decreases quality of life. As the population ages, the management of such disorders is becoming
an increasing economic burden. Disorders associated with ectopic mineralization of spinal tissues
include ankylosing spondylitis (AS), ossification of the posterior longitudinal ligament (OPLL),
and diffuse idiopathic skeletal hyperostosis (DISH).
1.5.1 Ankylosing Spondylitis (AS)
Ankylosing spondylitis (AS) is an inflammatory spondyloarthropathy that involves the
sacroiliac joints, intervertebral discs (IVDs), and facet joints35. Estimates of AS prevalence vary
globally from 0.1% in Japan to 1.8% in Norway36. AS is characterized by spinal stiffness and
loss of spinal mobility due to inflammation and structural damage37. AS is diagnosed by the
presence of inflammation and associated back pain thought to involve the annulus fibrosus (AF)
of the intervertebral disc (IVD), and sacroiliitis as determined by MRI evidence of cartilage
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abnormalities and bone marrow edema in the sacroiliac joint35,37. AS is an inflammatory autoimmune disorder involving the axial skeleton, characterised by sclerosis and/or fusion of the
sacroiliac and facets joints. The formation of sclerotic regions ultimately leads to a reactive
pathological healing response that results in the ossification of the periphery of the annulus
fibrosus35. The pathogenesis of AS is largely unknown; there is a significant genetic component
as 90-95% of AS patients are positive for the HLA B27 allele (a mutation in the human leukocyte
antigen B locus)37, however, AS is only detected in less than 2% of HLA-B27 positive
individuals38. Treatment for AS consists mostly of physical therapy and pain management using
NSAIDs, although, anti-TNF therapy has also shown some beneficial effects35,37.
1.5.2 Ossification of the Posterior Longitudinal Ligament (OPLL)
OPLL is characterized by ossification of the posterior longitudinal ligament, particularly
in the cervical region of the spine39. OPLL is especially prevalent in the Japanese population and
affects twice as many men as women39. Although OPLL can occur independently, it is often
associated with other spondyloarthropathies such as AS and DISH with one study detecting
OPLL in 50% of DISH patients40. OPLL is typically diagnosed by radiographic detection of
ectopic mineral formation39. Symptoms of OPLL vary from patient to patient, ranging from no
patient-reported symptoms to neurological deficits including radiculopathy and myelopathy39.
Although the pathogenesis of OPLL remains unclear, there have been efforts to correlate genetic
predisposition to disease incidence based on a high level of concordance in twins41, albeit with
limited success. Increased serum levels of dickkopf-related protein-1 (DKK1) were reported in
one study42; however, a follow-up study could not reproduce these results43. Polymorphisms in
collagen types 11A2 and 6A1 were initially believed to be responsible for the development of
OPLL; however, a study evaluating 35 candidate genes in over 700 patients failed to find a
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correlation between these polymorphisms and OPLL41. There are currently no disease-modifying
treatments for OPLL; management typically consists of pain medication such as NSAIDs, with
surgical intervention to remove mineralized material in end-stage disease progression39.
1.5.3 Diffuse Idiopathic Skeletal Hyperostosis (DISH)
Diffuse

idiopathic

skeletal

hyperostosis

(DISH)

is

a

non-inflammatory

spondyloarthropathy that affects 15-25% of North Americans over the age of 5044-46. DISH is
diagnosed through radiographic detection of ectopic mineralization of spinal tissues including
the anterior longitudinal ligament and annulus fibrosus (AF) of the intervertebral disc (IVD)47-50.
Symptoms include spine pain and stiffness, and in severe cases, dysphagia (difficulty or inability
to swallow) and compression of the spinal cord51-53. Importantly, the etiology of DISH is
unknown, and no disease-modifying treatments exist. Mechanical, genetic, and environmental
factors as well as drug treatment history are all believed to contribute to the development of this
disease54,55.
In many ways, DISH is similar to AS which complicates diagnosis in early stages of the
disease as both manifest with spinal stiffness and hyperostosis. However, various criteria can be
used to distinguish the two diseases. In terms of onset of disease, AS is typically first detected in
young adults under the age of 40 whereas DISH is rarely detected before the age of 5035.
Additionally, AS, but not DISH, is an inflammatory pathology and is frequently accompanied by
pain35. Radiographic evidence can also differentiate the two diseases, as only AS presents with
ankylosis of facet joints and sacroiliac erosion35. It is also worth noting that both DISH and AS
may present with OPLL, suggesting potential overlap in the disease pathology underlying all
three of these conditions.
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1.6 Diffuse Idiopathic Skeletal Hyperostosis
1.6.1 Overview of DISH
The Arthritis Society lists DISH as the second most common form of arthritis after
osteoarthritis56. DISH is a non-inflammatory spondyloarthropathy characterized by ectopic
calcification of spinal and paraspinal tissues including longitudinal ligaments, rib entheses, and
the intervertebral disc (IVD). DISH is diagnosed by the detection of ectopic calcifications
involving the axial skeleton, using radiographic criteria first developed by Resnick and
Niwayama in 1976, as follows: (i) flowing calcifications and/or ossifications along the
anterolateral aspect of four contiguous vertebral segments, with or without osteophytes; (ii)
preservation of IVD height in involved areas of ectopic calcification (to differentiate from
degenerative disc disease pathologies); and (iii) the absence of bony ankylosis of facet joints,
sacro-iliac erosion, sclerosis or fusion (to specifically differentiate from ankylosing
spondylitis)46. Unlike many types of arthritis, DISH occurs more often in men than women (25%
of men versus 15% of women over age 50)45. Despite its prevalence, health professionals are
often unfamiliar with DISH, and it is underdiagnosed and often misdiagnosed48. This is likely a
result of DISH symptoms being poorly classified, limiting diagnostic ability and the assessment
of clinical outcomes of therapeutic intervention. he most commonly reported physical
impairment in DISH is limited motion of the thoracic spine57,58. Other symptoms include thoracic
spine pain and, in advanced cases, dysphagia and compression of the spinal cord and nerve roots.
Interestingly, mineral formations are commonly present on the right lateral aspect of the spine
and not the left. This has been attributed to a possible inhibitory effect of the pulsation of the
aorta on ossification, as patients with situs inversus (a disorder where the position of major
visceral organs is mirrored) develop ossifications primarily on the left lateral aspect49,59.
Importantly, the pathology of DISH is poorly characterized and as such the etiology is unknown.
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To date, no studies have evaluated the effectiveness of any therapy in this disease, likely
reflecting our poor understanding of its pathogenesis. As such, apart from surgical removal of
ectopic calcifications in severe cases60, there are no specific treatments for this common
disorder61.
1.6.2 Clinical Presentation and Associations
Symptoms of DISH often manifest as back pain and stiffness, and can interfere with
surrounding structures, including compression of the spinal cord and nerve roots62,63. DISH can
also cause dysphagia64, airway obstruction65, and is associated with an increased risk of spinal
fractures66 and postsurgical heterotopic ossifications48. However, overall, the burden of back pain
in people living with DISH is still equivocal with some studies suggesting DISH is painful57,67,68,
while others suggest DISH is not painful69,70. To date, there has only been one comprehensive,
controlled trial investigating the painful symptoms of DISH57. This group found that DISH
patients had an increased history of upper extremity pain, and more extremity and spinal stiffness
compared to healthy control patients57. Furthermore, the impact of spine stiffness on daily living
has only been investigated in one study of a specific elderly-living community58. In this study,
the major differences between DISH patients and other back pain patients is that both bending
ability and grip strength are reduced in DISH patients58.
DISH is also commonly comorbid with numerous disorders including metabolic
syndrome, cardiovascular disease, diabetes mellitus, and hypertension71,72. Therefore, the
prevalence of DISH is expected to rise in North America due to increased exposure to endemic
risk factors including obesity, and long life expectancy. Therefore, there is an urgent need to
better understand DISH pathophysiology and pathobiology in order to develop treatments in this
increasingly prevalent disorder.

14
1.6.3 DISH pathogenesis
The molecular mechanisms responsible for the ectopic mineralization in DISH are poorly
understood. A single nucleotide polymorphism in the COL6A1 gene has been correlated to the
presentation of DISH, although only in a Japanese sub-population which also has a strong
prevalence of OPLL73, making it difficult to ascertain the relative contribution of this
polymorphism to each disorder. Two main approaches have been explored to explain ectopic
calcification in DISH 1) excess of growth factors that could induce soft tissue calcification74,75
or 2) reduced activity of inhibitors of bone-promoting peptides i.e. DKK1 and MGP76. An
association between low serum Dickkopf-1 (Wnt–β-catenin pathway inhibition) has been
reported with DISH, but no mechanism has been proposed42. In contrast, elevated MGP levels
have been associated with DISH patients, although given that MGP is a potent inhibitor of
mineralization, it is difficult to explain this finding and no mechanism was proposed by the
authors77.
However, recent studies in humans and mouse models78 have begun to shed light on
dysregulated processes associated with the development of DISH. Recently, it has been reported
that humans homozygous for a null allele in the SLC29A1 gene (encoding ENT1) present with
ectopic calcification in the hands, hips and lumbar intervertebral discs79. This is in keeping with
the phenotype reported by our group of ENT1 (encoded by Slc29a1) knockout mice (ENT1-/-)
which exhibit ectopic calcification of the lumbar spine by 6 months-of-age80. ENT1 is a member
of the ENT family (or SLC29A family) of equilibrative nucleoside transporters (ENT1-4), which
are sodium-independent facilitated diffusion carriers that transport nucleosides bi-directionally
across the plasma membrane81. ENT1 is primarily localized to the cell membrane and is
ubiquitously expressed in almost every tissue type, including heart, brain, spleen, lung, liver,
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skeletal muscle, kidney, testis and the intervertebral disc81,82. Although numerous purine and
pyrimidine nucleosides can be transported by ENT1, it has the highest affinity for adenosine
amongst ENT1 family members with a Km of 0.12 mM in humans and 0.13 mM in mice81,83.
Interestingly, our group has recently shown that ENT1 is the primary adenosine transporter in
the IVD84.
1.6.4 Mouse Models of DISH
The etiology of DISH remains unknown and the molecular pathways responsible for the
ectopic mineralization associated with this disease have not been delineated. Understanding the
molecular pathogenesis of DISH is crucial for the development of therapeutic interventions to
halt or reverse the disease. Investigating molecular pathways involved in disease pathogenesis
can be challenging in patients, thus the use of preclinical animal models is necessary to develop
an understanding of these complex molecular phenotypes, two of which have been used to study
DISH.
ENT1-/- mouse
Our group has previously reported that deletion of the gene encoding ENT1 (Slc29a1)
results in a phenotype that resembles DISH in humans80. Mice lacking ENT1 (ENT1-/-) develop
calcified lesions associated with paraspinal tissues in the cervical-thoracic region of spine as
early as 2 months-of-age, extending to the lumbar and caudal regions at 6 and 12 months,
respectively80. Histological examination revealed large, irregular accumulations of eosinophilic
material in spinal fibrocartilaginous tissues including ligaments, entheses and the annulus
fibrosus (AF) of the intervertebral disc80. In subsequent studies, our group demonstrated that
ENT1 is the predominant adenosine transporter in the IVD84. Moreover, systemic adenosine
transport in ENT1-/- mice is dysregulated; increased plasma adenosine levels are detected in
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ENT1-/- mice compared to WT controls80. Our group has also found that intracellular adenosine
levels are increased in AF cells from ENT1-/- mice compared to WT controls.
Interestingly, stimulation of adenosine A185,86, A2B86,87, and A2A87 receptors increase
alkaline phosphatase activity and cell proliferation in human and rat mesenchymal stem cells.
This is in keeping with the characteristics we previously reported in ENT1-/- mice, as AF cells
isolated from ENT1-/- IVDs at 2 or 6 months-of-age demonstrated greater alkaline phosphatase
activity84 and increased cell proliferation compared to WT controls. Altered localization of
alkaline phosphatase activity was also detected in vivo in the AF of ENT1-/- mice84.
Twy mouse
Tiptoe walking mice (twy) are recessive mutants with truncation of the protein
ectonucleotide

pyrophosphatase/phosphodiesterase

1

(ENPP1)–a

membrane-bound

glycoprotein that produces inorganic pyrophosphate, a potent inhibitor of calcification–that
causes tiptoe walking, stiffness of the vertebral column and limb joints, and motor paresis88,89.
Mice with this spontaneous mutation were originally reported in 1981 with generalized ankylosis
of the axial and appendicular skeleton beginning as early as 3 weeks-of-age90 with premature
death in these mice by 9 months-of-age. These mice have since been used extensively to study
the molecular mechanisms regulating OPLL91-95. Induction of diabetes in twy mice increased
endochondral ossification of the posterior longitudinal ligament and the severity of OPLL92.
Furthermore, although this mouse is a model of hyperostosis, twy mice paradoxically show
regional osteopenia in the tibia, vertebrae and humerus96. In the IVD, twy mice show osseous
lesions, increased vascularity on the AF periphery, increased proliferation of inner AF cells,
increased expression of ALP-positive cells, and decreased expression of MGP that lead to
endochondral ossification95,97.
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The twy mice have also been studied as a model of DISH since the spinal hyperostosis
that develops resembles pathological changes also present in DISH. The twy mouse model was
used to investigate the increased frequency of vertebral fractures in DISH patients, a
characteristic of DISH that is not associated with OPLL. This study found that administering the
osteoporosis drug teriparatide effectively treats trabecular osteoporosis in twy mice, but
simultaneously increased the severity of spinal ankylosis78. Twy mice develop amorphous,
calcified lesions in the AF of the IVD characteristic of DISH in addition to extraspinal
manifestations of DISH not evident the ENT1-/- mice, such as calcification of knee articular
cartilage80,98. Therefore, it appears that Twy mice are a relevant model of the co-occurance of
both OPLL and DISH, while the ENT1-/- mice are primarily a model of DISH and not OPLL.
1.6.5 Mouse Models to Assess Back Pain
Numerous methods have been developed in recent years to assess behavioral indicators
of back pain in rodents, developed initially using the SPARC-null mouse model of intervertebral
disc degeneration99-101. Given the challenges of associated with interpreting behavioural metrics
in rodents, robust approaches combine multiple tests and are typically paired with molecular
analysis of neuroplastic changes associated with pain. In the context of IVD degeneration,
behavioral assays used to assess back pain include the tail suspension test, analysis of
spontaneous open field locomotion and rearing, motor impairment, temperature and mechanical
sensitivity as a measure of radiating hypersensitivity, analysis of nesting behavior, and wheel
running activity102-105. Specifically, reduced grip strength correlates to pain in rheumatoid
arthritis, and has been associated with pain in the mouse106. Additionally, the FlexMaze assay
was designed to force mice to undergo lateral flexion, allowing researchers to establish whether
mice are experiencing increased pain or stiffness101. Finally, behavioral assays are typically
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coupled with molecular analysis of pain-related changes in neural tissues such as the spinal cord
or dorsal root ganglion, including quantification of levels of the nociceptive peptide calcitonin
gene-related peptide (CGRP) and activation of microglia and astrocytes to confirm pain by
multiple modalities100.

1.7 Biomineralization
1.7.1 Models of Physiological Matrix Mineralization
Matrix mineralization has been explained by two basic models: cell-mediated or
extracellular matrix-mediated mineralization107. In the cell-mediated model, the primary sites of
mineral deposition are matrix vesicles (MVs) secreted by osteoblasts. MVs are enriched in tissue
non-specific alkaline phosphatase (TNAP), nucleotide pyrophosphatase/phosphodiesterase
(NPP1/PC1), annexins (ANX; principally ANX1, 5 & 6) and phosphatidylserine (PS) which
function together to initiate intravesicular mineral formation108. MVs promote mineralization by
concentrating calcium and inorganic phosphate at a protected site and promoting crystallization
into calcium phosphate with the help of enzymes such as alkaline phosphatase (ALP) and
hydroxyapatite which acts as a site of nucleation 107,109. The cell-mediated model then suggests
that when mineral crystals grow large enough, they rupture the MV and serve as potent nucleators
of mineral110. In contrast, the extracellular matrix-mediated model proposes MVs are not needed,
and that as long as calcium and inorganic phosphate are available, mineralization can initiate
spontaneously in between the spaces of collagen fibrils, which serve as nucleators111.
1.7.2 Adenosine Transport and Molecular Regulators of Biomineralization
Summarized in Figure 1.2, adenosine is a purine nucleoside, along with ATP and
ADP, which stimulates specific cell-surface G protein-coupled receptors (A1, A2A, A2B, and A3)
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Figure 1.2. Schematic representation of potential ways adenosine can influence
biomineralization. Adenosine can regulate cell behaviour through cell surface receptors.
Adenosine is primarily metabolised or converted by adenosine kinase (ADK) or adenosine
deaminase (ADA). ADK is the enzyme that catalyzes the transfer of a phosphate from ATP to
adenosine to form AMP. Ecto-5’-nucleotidase (Nt5e) generates adenosine from the breakdown
of AMP. Conversely, ADA metabolizes adenosine to inosine. ATP is released into the
extracellular fluid and is subsequently metabolized by cell-surface enzymes. Ectonucleotide
pyrophosphatase/phosphodiesterase 1 (ENPP1) metabolizes ATP into AMP and inorganic
pyrophosphate (PPi), an inhibitor of mineralization. Extracellular PPi is also regulated by the
progressive ankylosis protein (ANK), a transporter that mediates the efflux of PPi. PPi is
metabolized by another cell surface enzyme, alkaline phosphatase (ALP), which produces
inorganic phosphate (Pi), a substrate required for mineralization. The presence of Pi and Calcium
(Ca2+) promotes crystallization to form of calcium phosphate mineral. Additionally,
biomineralization is also regulated by the mineralization inhibitors matrix Gla protein (MGP)
and osteopontin (SPP1).
Courtesy of Neil Tenn
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to affect the activity of intracellular pathways such as cell cycle and biomineralization112.
Adenosine can be transported in and out of the cell by equilibrative nucleoside transporters or
generated by nucleotidase-mediated hydrolysis of adenine nucleotides113. ATP can be
metabolized by ectonucleotide pyrophosphatase/ phosphodiesterase 1 (ENPP1) resulting in the
production of PPi (an inhibitor of mineralization) and AMP, which can be subsequently broken
down to adenosine via ecto-5’ –nucleotidase (NT5E)114-116. Adenosine can be converted back to
AMP by adenosine kinase (ADK) or metabolized extracellularly to inosine by adenosine
deaminase (ADA)117. Apart from the production of PPi by ENPP1, PPi levels are also regulated
by progressive ankylosis protein (ANK) and alkaline phosphatase (ALPL). ANK is responsible
for the intracellular to extracellular efflux of PPi. Whereas, ALPL hydrolizes PPi to Pi which,
along with calcium (Ca2+), is a prerequisite for the formation of calcium phosphate mineral115,118.
Importantly, stimulation of adenosine receptors upregulates ALPL activity, which ultimately
leads to less PPi, more Pi, and calcium phosphate mineral formation115.

1.8 “Omics” Methodologies for Biomarker Identification and
Characterization of Molecular Pathology
The advent of “omics” technologies has transformed how molecular biology is investigated, and
consequently how diseases are diagnosed and treated based on comprehensive analysis of
biological systems119. This approach is particularly well suited to chronic, complex diseases such
as DISH120.
1.8.1 Transcriptomics
Transcriptomics refers to the study of heterogeneity of a cell’s transcriptome at a specific
time by high-throughput sequencing technologies121. High-throughput sequencing technologies
include microarrays122–which were the first platform technology to drastically increase the use
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of transcriptomics–and next generation sequencing (NGS)-based methods. NGS is used for RNA
sequencing (RNA-seq) without the need for probes, so theoretically allows for the detection of
every transcript in a sample123. Moreover, recent advances have made it possible to study the
transcriptome at the single-cell level, termed scRNA-seq, which promises to drastically increase
the resolution of molecular biology121. Microarrays have been used extensively for biomarker
discovery and understanding molecular biology, leading to advances such as the identification of
a novel biomarker for ovarian cancer124 or drivers of post-traumatic osteoarthritis125. RNA-seq
built on this foundation, enabling discoveries such as gene fusions and unique long non-coding
RNAs expressed in specific types of prostate cancer126. Spine research has also benefited from
the use of RNA-seq, establishing that IVD cells have an intrinsic circadian clock that is regulated
by age, inflammation and degeneration127. The use of scRNA-seq will allow for detailed
characterization of the response of specific cell types to perturbation such as an injurious insult,
tissue degeneration, aging, disease pathology128, particularly relevant to the study of complex
joint tissues.
1.8.2 Proteomics
Though the use of transcriptomics for molecular biology research is widespread,
transcript abundance alone cannot predict protein levels. Therefore, direct measurement of
proteins is necessary to explore disease biology. The proteome defines the complete protein
composition of a cell; mass spectrometry-based technologies have allowed for comprehensive
investigation of both steady-state and dynamic alterations in complex biological processes129.
For instance, in-depth proteomic studies demonstrated that the identity of cells and tissues is
based primarily on abundance of specific proteins as opposed to the presence or absence of
certain proteins130. Proteomics is particularly well-suited for biomarker discovery and has been
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used to identify biomarkers of mortality in older men131, biomarkers of sustained weight loss
related to inflammation132, and biomarkers of cardiac hypertrophy using a comparative study of
mouse models133. Recent advances in proteomics have also facilitated the integration of genomic
and proteomic data deemed “proteogenomics” to unravel complex molecular pathologies. For
example, proteogenomics was used to simultaneously map somatic mutations in breast cancer
patients to signaling pathway dysregulation for each sub-type of breast cancer. The study
demonstrated that each breast cancer sub-type has a unique set of copy number alterations and
kinase activity that could potentially be targeted in a personalized medicine approach134.
Proteomics has recently been applied to biomarker identification and disease mechanism
exploration in musculoskeletal conditions. Proteins related to macrophages, programmed cell
death, cytokine signaling and osteoclasts were all shown to be upregulated in rheumatoid
arthritis135. Furthermore, cartilage oligomeric matrix protein (COMP) and type 3 collagen
(COL3A1) neo-epitope levels were found to be increased in mechanically-induced posttraumatic osteoarthritis, elucidating the specific proteins responsible for the observed cartilage
degradation136.
1.8.3 Metabolomics
Metabolomics allows for the comprehensive analysis of all small molecule metabolites
in a tissue or in circulation, applicable to the development of a functional readout of the
pathological state of an organism119. It is estimated that there are over 19 000 small molecules in
the human body including metabolites directly linked to endogenous enzymatic activities,
metabolites derived from medication or food, and metabolites derived from the body’s
microbiota137. Mass spectrometry (MS) is one of the primary technologies used for metabolomics
in tandem with liquid chromatography (LC) or gas chromatography to identify and quantify small

23
molecule metabolites in addition to low molecular weight amino acids and lipids138. This
relatively nascent technology has been used to develop biomarkers and therapeutic targets for
numerous disorders including diabetic nephropathy, renal failure, cardiovascular disease, and
prostate cancer120. Recently, we used metabolomics to develop biomarkers of chronic kidney
disease139, muscle response to exercise in diabetes140, and kidney function141. Moreover, we have
recently used metabolomics to characterize the association of the microbiome to atherosclerosis–
a calcification disorder with intriguing similarities to DISH142.

1.9 Study Rationale and Hypotheses
DISH is extremely prevalent, yet the pathogenesis is not understood, therefore there are
no disease-modifying treatments. Furthermore, we know which tissues are affected but do not
understand the cellular changes associated with the induction or progression of calcification. The
literature on pain in DISH both suggests DISH is painful57,67,68; and that DISH is not painful69,70.
The lack of longitudinal studies evaluating the symptomology associated with DISH is attributed
to the inability of the clinical radiographic criteria to detect early stage disease55. The current
project aims to investigate the regulation of ectopic calcification observed in ENT1-/- mouse AF
tissue with using multiple unbiased “omics” modalities as well as to investigate symptoms of
pain and stiffness in both early and late-stage disease.

HYPOTHESES
1. Loss of ENT1 in fibrocartilaginous cells leads to cell autonomous and
microenvironmental changes in AF tissue that contribute to the induction of ectopic
calcification.
2. Ectopic calcifications in ENT1-/- mice lead to increased pain and stiffness compared to
WT control, similar to DISH in humans.
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1.10 Specific Rationales, Hypotheses and Objectives
Aim 1: Compare the Transcriptome of AF and NP cells and Establish Gene Expression
Changes Associated with the Aging IVD
Rationale 1: Understanding the cellular changes driving disease pathogenesis in the IVD requires
a thorough understanding of the baseline phenotype of the distinct cell types within each tissue
compartment. Transcriptomic analyses have provided important insight into changes associated
with IVD degeneration in humans, focused primarily on the AF19,143-145. Degenerative changes
in the NP have been characterized by immunohistochemistry and flow cytometry, approaches
limited to the investigation of candidate genes146,147. Furthermore, the analysis of human IVD
tissues is often limited to end stage degeneration, hampering the ability to detect early
degenerative and/or age-associated changes. The use of animal models overcomes these
limitations, yet transcriptomic changes occurring with age-associated degeneration have, to date,
only been studied in the rat148. Therefore, this study was designed to address key knowledge gaps
and establish a better understanding of the molecular phenotype of the distinct cell types within
the murine IVD.
Hypothesis 1: Transcriptional differences exist between different cell types of the disc, and the
transcriptional identity of these cells changes with age in a cell type-specific manner.
Objectives 1:
1) Compare the global patterns of gene expression in the murine NP and AF (tissues isolated at
2.5 and 6 months-of-age).
2) Identify gene expression changes in the NP occurring with age-associated IVD degeneration
(using tissues isolated at 2.5, 6, and 21 months-of-age).
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Aim 2: Investigate Transcriptional Changes Associated with Loss of ENT1 and Ectopic
Calcification in AF Cells
Rationale 2: Previous research by our lab demonstrated that mice lacking the equilibrative
nucleoside transporter 1 (ENT1) develop progressive ectopic calcification of spinal tissues
bearing remarkable resemblance to DISH in humans. The current study was designed to
capitalize on this model system and investigate the global transcriptional signature associated
with loss of ENT1 in AF cells, both prior to and coinciding with ectopic calcification of the IVD.
Our group previously showed that at 2 months-of-age, there is no radiographic detection of
ectopic calcification in AF tissue of the thoracic spine in ENT1-/- mice; however, at 6 months-ofage, ectopic calcifications are consistently detected in this region80. Therefore, we compared
differences in gene expression in thoracic AF tissue isolated from wild-type and ENT1-/- mice at
these time points.
Hypothesis 2: Loss of ENT1 in AF cells leads to transcriptional changes in AF tissue that
contribute to the induction of ectopic calcification.
Objectives 2:
1) Investigate gene expression signatures associated with loss of ENT1 (2 months-of-age, ENT1/-

compared to WT).

2) Investigate gene expression signatures coinciding with ectopic calcifications (6 months-ofage, ENT1-/- compared to WT).
3) Investigate gene expression signatures associated with the progression of tissue calcification
(6-month-old ENT1-/- compared to 2-month-old ENT1-/-).
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Aim 3: Establish a Method for the Parallel Assessment of Proteomic and Metabolomic
Changes in Murine IVD Tissues
Rationale 3: The comprehensiveness of data collected by “omics” modalities can drastically
transform our understanding of the molecular mechanisms of disease, how biomarkers are
identified, and how therapeutic targets are developed. The development of standardized protocols
within specific fields of research can enable comparisons between findings reported by different
research groups and move the application of these technologies forward. One such field of
research is intervertebral disc (IVD) biology, which lacks standardization of disease models and
model organisms. The use of proteomics to study IVD degeneration has been limited to a few
studies in humans31,149,150. Similarly, the metabolomics analysis of human IVD tissues is limited
to a single unbiased metabolite screen151. Despite the limitations to the starting quantity of sample
associated with the small size of the mouse, it is possible to gain novel insights into mechanisms,
biomarkers and therapeutic targets of IVD pathologies using optimized protocols for proteomic
and metabolomic analyses. Building from the combined expertise of a collaborative team, we
sought to develop a protocol for parallel proteomic and metabolomic analysis of mouse IVD
tissues.
Hypothesis 3: Modifications to standard proteomic and metabolomics protocols can allow for
the robust analysis murine IVD tissues.
Objectives 3:
1) Evaluate the validity of using proteomics to study murine IVD biology to overcome the
potential bias of ECM proteins associated with fibrous tissues.
2) Evaluate the validity of using metabolomics to study murine IVD biology.

27
Aim 4: Investigate Proteomic and Metabolomic Changes Associated with Loss of ENT1 and
Ectopic Calcification in AF Cells
Rationale 4: This study was designed to investigate the global proteomic and metabolomic
signature associated with loss of ENT1 in AF cells, both prior to and coinciding with ectopic
calcification of the IVD. Our group previously showed that at 2 months-of-age, there is no
radiographic detection of ectopic calcification in AF tissue of the thoracic spine in ENT1-/- mice;
however, at 6 months-of-age, ectopic calcifications are consistently detected in this region80.
Therefore, we examined differences in protein and metabolite expression in thoracic AF tissue
from wild-type and ENT1-/- mice at these time points.
Hypothesis 4: Loss of ENT1 in AF cells leads to proteomic and metabolomic changes in AF
tissue that contribute to the induction of ectopic calcification.
Objectives 4:
1) Investigate proteomic and metabolomic signatures associated with loss of ENT1 (2 monthsof-age, ENT1-/- compared to WT).
2) Investigate proteomic and metabolomic signatures associated with ectopic calcification (6
months-of-age, ENT1-/- compared to WT).
3) Investigate proteomic and metabolomic signatures associated with the progression of tissue
calcification (6-month-old ENT1-/- compared to 2-month-old ENT1-/-).
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Aim 5: Investigate Pain and Stiffness in the ENT1-/- Mouse Model of DISH
Rationale 5: The burden of back pain in people living with DISH is still equivocal with some
studies suggesting DISH is painful57,67,68, while others suggest DISH is not painful particularly
in early stages of the disease69,70. Advances in the field of behavioral measurement in preclinical
animal models have established robust metrics whereby mice can be reliably evaluated for painassociated changes. For example, genetic knockout mouse models of IVD degeneration show
increased pain-associated behaviors compared to wild-type controls, correlated to the severity of
degeneration99,101,152. Furthermore, administration analgesics reduces measures of cutaneous
hypersensitivity and axial discomfort in mice with IVD degeneration, demonstrating the ability
of these assays to detect pain-related behavioral changes153. Moreover, nociceptive innervation
and sensory nervous system plasticity are associated with behavioral indicators of back pain100.
We conducted a comprehensive longitudinal evaluation of pain and mobility in the ENT1-/mouse model of DISH using an array of behavioral and molecular testing modalities. This study
was designed to evaluate symptoms of DISH throughout the disease continuum, determine if the
ENT1-/- mouse model recapitulates symptoms described in humans, and specifically determine if
pain is a feature of early-stage disease.
Hypothesis 5: Ectopic calcification in the ENT1-/- mouse model of DISH is associated with pain
and stiffness.
Objectives 5:
1) Assess behavioral indicators of axial discomfort in ENT1-/- mice over time.
2) Assess behavioral indicators of physical function in ENT1-/- mice over time.
3) Assess behavioral indicators of cutaneous sensitivity in ENT1-/- mice over time.
4) Assess neuroplastic changes in the cervical spinal cord of ENT1-/- mice.
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CHAPTER TWO

TRANSCRIPTIONAL PROFILING OF THE MURINE INTERVERTEBRAL DISC AND
AGE-ASSOCIATED CHANGES IN THE NUCLEUS PULPOSUS

_____________________
Sections of this chapter have been reproduced with permission from:
Veras M.A., McCann M.R., Tenn N.A., Séguin C.A. Transcriptional profiling of the
murine intervertebral disc and age-associated changes in the nucleus pulposus. Connect
Tissue Res (2020) 61:1, 63-81, with some modifications.
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2.2 Chapter Summary
The intervertebral disc (IVD) is composed of cell types whose subtle phenotypic
differences allow for the formation of distinct tissues. The role of the nucleus pulposus (NP) in
the initiation and progression of IVD degeneration is well established; however, the genes and
pathways associated with NP degeneration are poorly characterized.
Using a genetic strategy for IVD lineage-specific fluorescent reporter expression to
isolate cells, gene expression and bioinformatic analysis was conducted on the murine NP at 2.5,
6, and 21 months-of-age and the annulus fibrosus (AF) at 2.5 and 6 months-of-age. A subset of
differentially regulated genes was validated by qRT-PCR.
Transcriptome analysis identified distinct profiles of NP and AF gene expression that
were remarkably consistent at 2.5 and 6 months-of-age. Prg4, Cilp, Ibsp and Comp were
increased >50-fold in the AF relative to NP. The most highly enriched NP genes included Dsc3
and Cdh6, members of the cadherin superfamily, and microRNAs mir218-1 and mir490. Changes
in the NP between 2.5 and 6 months-of-age were associated with up-regulation of molecular
functions linked to laminin and Bmp receptor binding (including up-regulation of Bmp5 & 7),
with the most up-regulated genes being Mir703, Shh, and Sfrp5. NP degeneration was associated
with molecular functions linked to alpha-actinin binding (including up-regulation of Ttn & Myot)
and cytoskeletal protein binding, with the overall most up-regulated genes being Rnu3a, Snora2b
and Mir669h.
This study provided insight into the phenotypes of NP and AF cells, and identified
candidate pathways that may regulate degeneration.
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2.3 Introduction
Low back pain is the most common musculoskeletal disorder, with a reported global
lifetime prevalence as high as 84%1. The occurrence of low back pain increases with age2, which
correlates with the detection of intervertebral disc (IVD) degeneration3,4. It is thought that
degenerative changes in the IVD initiate in the central nucleus pulposus (NP)5,6. The NP is a
highly-hydrated gelatinous tissue that contains high levels of proteoglycans within a loose type
II collagen-rich extracellular matrix (ECM). Notably, the NP contains abundant aggrecan core
protein, formed by multiple glycosaminoglycan side chains (chondroitin sulfate and keratin
sulfate) that provide turgor to maintain disc height and withstand compressive mechanical
loading forces7. The annulus fibrosus (AF) is a fibrocartilaginous tissue composed primarily of
concentric lamellae formed by type I collagen fibers. Cells of the AF are located within the
interlamellar space, surrounded by matrix containing the large aggregating proteoglycans
aggrecan and versican as well as elastin. The structure of the AF provides tensile resistance in
response to radial expansion of the NP during compressive loading of the IVD7. During aging,
changes in the ECM composition of the NP lead to a reduction in the tissue’s ability to resist
compressive forces which are consequently transferred to the adjacent annulus fibrosus (AF), a
process that in turn leads to progressive structural failure and degeneration of the AF8.
Although the cellular pathways that regulate age-associated changes in NP ECM
composition have not been fully elucidated, it is hypothesized that the loss of notochord cells
from the NP is an important contributing factor9,10. During development, the notochord forms
the primitive anterior/posterior axis of the embryo and, following patterning and segmentation
of the sclerotome-derived mesenchyme, serves as the progenitor for the NP9,11. Within the IVD,
notochord cells secrete growth factors that are thought to protect the NP from degeneration and
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maintain the specialized ECM milieu of this avascular and aneural tissue12,13. It has been
suggested that terminal differentiation of notochord cells to chondrogenic NP cells is associated
with the initiation of degeneration, although this transition in cell phenotype is not completely
understood14. Work by our group15,16 and others14,17-25 demonstrate that the mouse is a useful
model to study IVD biology, but one important caveat is that notochord cells are retained into
adult life in mice26. The persistence of these cells is thought to be related to the timeline of ageassociated degeneration in mice – though impacted by the strain of mouse examined, work by
our group and others have reported signs of advanced degeneration detected between 14 and 18
months-of-age including loss of MRI signal intensity in the IVD and histopathological changes
such as the accumulation of fibrous material in the NP, reversal of lamellae in the AF, and loss
of demarcation between NP and AF15,27. Unbiased global analysis of NP cell gene expression at
key stages of development and degeneration will broadly inform on cellular pathways regulating
disc biology.
To better understand the cellular mechanisms responsible for tissue-specific changes
associated with age and degeneration in the IVD, it is critical to better characterize the phenotypic
differences between its component cell types. Numerous groups have proposed specific markers
for both NP and AF cells focusing on specific candidate genes or classes in human primary
cells28-32, and animal models commonly used to study IVD biology including mouse33, rat32,
pig32,34 and cow35,36. Unbiased whole transcriptome approaches have also been used to
characterize IVD cells from humans37-41, rat42-44, dog45, and cow46. Although these studies have
identified a common subset of markers that have helped to define IVD cell phenotypes, their
findings also highlight differences across species41,46-48. Despite the increased use of mouse
models to study IVD biology due to the benefits of genetic manipulation, there have been no

44
studies to date applying an unbiased transcriptomic screen to directly compare the patterns of NP
and AF gene expression.
Transcriptomic analyses have also provided important insight into changes associated
with IVD degeneration in humans, focused primarily on the AF49-52. Degenerative changes in the
NP have been characterized by immunohistochemistry and flow cytometry, but these approaches
are limited to the candidate genes investigated30,31. Furthermore, the analysis of human IVD
tissues is often limited to end stage disease in adults, hampering the ability to detect early
degenerative and/or age-associated changes. The use of animal models overcomes these
limitations, yet transcriptomic changes associated with age-associated degeneration have, to date,
only been studied in the rat44. To address key knowledge gaps and establish a better
understanding of the molecular phenotype of the distinct cell types within the murine IVD, the
current study developed a transcriptomic-based approach to: i) compare global patterns of gene
expression in the murine NP and AF (in tissues isolated at 2.5 and 6 months-of-age); and ii)
identify gene expression changes in the NP over time (using tissues isolated at 2.5, 6, and 21
months-of-age). The resulting bioinformatic analyses identified previous and novel cell typespecific markers as well as molecular functions and biological processes that underlie these
differences. Additionally, we characterized intriguing transcriptomic signatures associated with
progressive age-related NP degeneration and applied bioinformatic analyses to better understand
the pathways and transcriptional regulators that may mediate these cellular changes.

2.4 Materials and Methods
2.4.1 Mice
The notochord-specific NotoCre/WT mouse strain53 (derived on a CD1(ICR) background)
was mated to the conditional ROSA26 (R26) mT/mG reporter mouse (Gt(ROSA)26Sortm4(ACTB-
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tdTomato,-EGFP)Luo

/J; 129X1/SvJ background)54 to generate mice in which notochord-derived cells

are marked by EGFP expression and all other cell types express tdTomato. Therefore, the
NotoCre/WT;Rosa26mTmG/WT mice used for all experiments were on a mixed background, with
genotyping performed as previously described53,54. To eliminate potential variability in the
timing and severity of degeneration, our study used only male mice. Mice were housed in
standard cages and maintained on a 12-hour light/dark cycle, with rodent chow and water
available ad libitum. Mice were euthanized by a lethal dose of sodium pentobarbital at 2.5, 6, or
21 months-of-age for tissue isolation. All aspects of this study were conducted in accordance
with the policies and guidelines set forth by the Canadian Council on Animal Care and were
approved by the Animal Use Subcommittee of the University of Western Ontario (protocol 2017154; Appendix C).
2.4.2 Histology
Intact lumbar spinal segments (L1-L5) were isolated from mice postmortem (n = 3 mice
per age group) and fixed overnight in 4% paraformaldehyde. Spinal segments were decalcified
for 5 days in Shandon™ TBD-2™ (Thermo Fisher Scientific, Waltham, MA), washed with PBS0.2% TWEEN® 20 (Sigma-Aldrich, St. Louis, MO), processed and embedded in paraffin. Spines
were sectioned sagittally at a thickness of 5 µm using a microtome (Leica Microsystems, Wetzlar,
Germany) and mounted on Fisherbrand™ Superfrost™ Plus slides (Thermo Fisher Scientific).
Sections were deparafinnized in xylene and rehydrated by successive immersion in descending
concentrations of alcohol. Slides were stained with hematoxylin and eosin (H&E) or Safranin
O/ Fast Green as previously described15,53,55,56 and images were acquired using a Leica DM1000
microscope. For evaluation of IVD degeneration, Safranin O/ Fast Green-stained IVD tissues (3
IVDs/mouse) were scored using a modified Thompson grading scale by 2 independent blinded
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observers, as previously reported by our group15,55,57. This grading scale is based on criteria
specific to each tissue compartment, where a lower score corresponds to a healthier tissue: NP
grade 1 = aggrecan-rich bulging tissue, grade 2 = peripheral fibrous tissue, grade 3 = consolidated
fibrous tissue, grade 4 = horizontal clefts parallel to the endplate, grade 5 = clefts through NP
and AF. AF grade 1 = discrete fibrous lamellae, 2 = mucinous material between lamellae, 3 =
extensive mucinous material between lamellae and loss of NP-AF demarcation, 4 = focal lamellar
disruptions58.
2.4.3 RNA Isolation and Purification
Lumbar and thoracic spines were dissected from 2.5-, 6-, and 21-month-old mice. The
surrounding musculature and ligaments were removed from the vertebral column, exposing the
IVDs. Cleaned spinal segments were placed in sterile PBS and transferred to the Leica M165 FC
stereoscope for imaging and microdissection. For each IVD, the AF was lacerated on the anterior
side, allowing for the gelatinous NP (containing EGFP+ cells) to be collected with a micropipette
(Supplementary

Material:

https://www.tandfonline.com/doi/suppl/10.1080/03008207.2019.1665034?scroll=top). The AF
was subsequently removed by slicing at the superior and inferior cartilage end plate junctions.
Following microdissection, AF and NP tissues (n=5-6 IVDs per mouse) were placed in separate
Eppendorf tubes containing RNAlater™ (Thermo Fisher Scientific) on ice. Samples were
centrifuged for 5 min at 2,500 g, RNAlater™ was aspirated and tissues were stored in
PureZOL™ (Bio-Rad Laboratories, Hercules, CA) at -80°C for subsequent RNA extraction using
the Aurum™ Total RNA Fatty and Fibrous Tissue Kit (Bio-Rad Laboratories). RNA was
quantified using a NanoDrop™ 2000 spectrophotometer (Thermo Fisher Scientific) and quality
was verified using a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). NP RNA
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samples with RIN (RNA integrity number) values greater than 7 were used for subsequent
microarray analysis (n=2-3 mice per time point). Remaining NP and AF samples were used for
subsequent qPCR validation.
2.4.4 Microarray Analysis
Microarray analysis was performed on NP samples at the London Regional Genomics
Centre (Robarts Research Institute, London, Canada). Briefly, single stranded complementary
DNA (sscDNA) was prepared from 200 ng of total RNA using the Ambion® WT Expression Kit
for Affymetrix® GeneChip® Whole Transcript (WT) Expression Arrays (Thermo Fisher
Scientific) and the Affymetrix® GeneChip® WT Terminal Labeling Kit (Thermo Fisher
Scientific). Total RNA was first converted to cDNA, followed by in vitro transcription to cRNA.
5.5 µg of sscDNA was synthesized, end labeled and hybridized for 16 h at 45°C, to GeneChip®
Mouse Gene 2.0 ST arrays (Thermo Fisher Scientific). All liquid handling steps were performed
using the GeneChip® Fluidics Station 450 (Thermo Fisher Scientific) and GeneChips were
scanned with GeneChip® Scanner 3000 7G (Thermo Fisher Scientific) using Command Console
v3.2.4 (Thermo Fisher Scientific). Probe level (.CEL file) data were generated using Affymetrix®
Command Console v3.2.4 (Thermo Fisher Scientific). Probes were summarized to gene level
data in Partek® Genomics Suite® v6.6 (Partek, St. Louis, MO) using the robust multi-array
average (RMA) algorithm59. Partek® was used to determine gene level ANOVA p-values and
fold changes. Genes demonstrating at least a 2.0-fold change with a p<0.05 were considered
(Supplementary Material). The full data set has been deposited in NCBI’s Gene Expression
Omnibus (GEO accession number GSE132182). Gene expression data for the AF was generated
as above for a previous study from our group60 (GEO accession number GSE124650), and used
for all NP-AF comparisons.
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2.4.5 Bioinformatic Analyses
Probes demonstrating a significant change (fold-change ³2, p<0.05) between groups (2.5month-old AF vs. 2.5-month-old NP (Supplementary Material); 6-month-old AF vs. 6-monthold NP (Supplementary Material); 2.5-month-old NP vs. 6-month-old NP (Supplementary
Material); 21-month-old NP vs. 6-month-old NP (Supplementary Material); and 2.5-monthold NP vs. 21-month-old NP (Supplementary Material) were used for functional categorization.
Only transcripts with an annotated gene symbol (hereby referred to as genes) were included.
Database categories were generated based on the Mus musculus annotations for Gene ontology
(GO) analysis (geneontology.org). GO analyses were performed using a Fisher’s exact test and
the data are presented as enrichment scores. The Integrated System for Motif Activity Response
Analysis (ISMARA)61 was used to predict transcription factors responsible for gene expression
changes. Microarray .CEL files were uploaded to the ISMARA online tool to computationally
predict regulatory sites for transcription factors associated with differentially expressed genes
between groups. Data are presented in ranked order by Z-value. Based on genes identified by
Partek® and ISMARA analyses, genes of interest were selected for subsequent validation.
2.4.6 qRT-PCR Analysis
Real-time PCR analysis was performed on lumbar AF or NP tissues (5-6 IVDs pooled
per mouse) from 2.5-, 6-, or 21-month-old mice (n=3-5 mice per group). cDNA was synthesized
using the iScript cDNA kit (Bio-Rad Laboratories) from 128 ng RNA/sample (for AF vs. NP
comparisons), 158 ng RNA/sample (for NP over time comparisons), or 500 ng RNA/sample (for
samples used to generate standard curves). Gene expression was determined by SYBR-based
real-time PCR using the Bio-Rad CFX384 system. PCR reactions were run in triplicate using
310 nM forward and reverse primers (sequences provided in Supplementary Material) with 2X
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SsoFast™ EvaGreen® Supermix (Bio-Rad Laboratories). The PCR program consisted of the
following: initial 3 min denaturation at 95°C; 10 s at 95°C denaturing; and 30 s
annealing/elongation at 60°C, for a total of 45 cycles. Gene transcript levels were determined
relative to a six-point calibration curve. For the analysis of AF vs. NP gene expression, standard
curves were made from cDNA generated from equal inputs of RNA from IVDs of WT mice at
embryonic-day 16 (E16), post-natal day 7 (p7), and 6 months-of-age. For the analysis of NP gene
expression over time, standard curves were generated from cDNA generated from equal inputs
of RNA from intact IVDs of WT mice at 2, 6, and 24 months-of-age. For each, the starting
concentration of the cDNA standard was inputted into the Bio-Rad CFX Manager 2.0 software
to generate the standard curve (1/5 serial dilution). Transcript levels are expressed relative to the
respective calibration curve (ng/µL).

2.5 Results
2.5.1 Age-associated Murine IVD Degeneration
To examine age-associated changes to the structure and morphology of the murine IVD, we first
performed histological assessment of IVD tissues at 2.5, 6, and 21 months-of-age. Using
histopathological evaluation based on the modified Thompson grading scale58, we detected a
progressive increase in NP and AF degeneration in the lumbar IVDs of mice with age (Figure
2.1). At 2.5 months-of-age, the NP contained predominantly large, physaliferous notochord cells
located in clusters throughout the NP (Figure 2.1A, left panel). At this time point, the fibrous
lamellae in the AF remain discrete, with no apparent signs of tissue degeneration (Figure 2.1A,
left panel). At 6 months-of-age, the organization of the NP was altered, marked by the
accumulation of peripheral fibrous material in the NP, populated predominantly by smaller NP
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Figure 2.1 Characterization of histopathological indicators of IVD degeneration with age.
A. Representative sagittal sections of lumbar IVDs stained with hematoxylin and eosin
demonstrate the histological changes in IVD appearance and cellular composition with age.
Images are oriented with rostral portion of the lumbar spine on top and dorsal portion on the left.
At 2.5 months-of-age, large, vacuolated notochord cells are present in the NP and the lamellae
of the AF remain discrete (image corresponds to Thompson grade 1). At 6 months-of-age, the
NP is composed predominantly of small NP cells clustered in the center of the tissue
compartment surrounded by regions rich in extracellular matrix with evidence of fibrous tissue
accumulation (image corresponds to Thompson grade 2/3). In the AF, mucinous material is
detected between lamellae (Thompson grade 2). At 21 months-of-age heterogeneity is evident in
the extent of degeneration across the lumbar region, representative images correspond to NP
Thompson grades 2 and 4. Hallmarks of advanced degeneration were however detected in >50%
of discs evaluated. In IVD tissues corresponding to grades 4/5, degeneration-associated changes
included loss of tissue architecture, decreased cellularity, and altered cell morphology with the
detection of hypertrophic chondrocyte-like cells in the NP (arrows). Specifically, in the NP,
horizontal clefts (arrowhead) parallel to the endplate are detectable. In the AF, there is a general
loss of the NP/AF boundary (image corresponds to AF Thompson grade 3). Bottom panels
present high magnification views of the NP from the top panel for each time point. B.
Histopathological evaluation using the modified Thompson score demonstrates a significant
increase in indicators of IVD degeneration with age in both NP and AF. Values are presented as
the percentage of discs with the indicated Thompson grade. n = 3 mice per group; 3 IVDs/mouse.
Asterisk (*) indicates p-value <0.05.

51
cells (Figure 2.1A, middle panel). Signs of mild AF degeneration including the accumulation
of mucinous material between lamellae of the inner AF were noted. Histological examination of
NP tissues at 21 months-of-age revealed heterogeneity in the degree of degeneration at individual
IVDs, resulting in a range of histopathological hallmarks detected and resultant scores, with
greater than 50% of IVDs examined showing signs of advanced degeneration (Thompson score
3-5) (Figure 2.1A, right panels; Figure 2.1B). IVDs corresponding to advanced degeneration
demonstrated marked changes in architecture, including the presence of horizontal clefts parallel
to the endplate (Figure 2.1A, arrowhead), decrease in NP cellularity, and the accumulation of
fibrotic tissue throughout the NP. Interestingly, in these tissues, the NP was populated by
dispersed clusters of hypertrophic cells (Figure 2.1A, arrows). In the AF, degenerative changes
become more prevalent, with a higher percentage of IVDs showing the accumulation of
mucinous material between lamellae and loss of NP-AF boundary. Together, these changes
resulted in a significant increase in histopathological scores in both the NP and AF with age
(Figure 2.1B).
2.5.2 Genetic Labeling and Isolation of Notochord-derived Cells
Given the changes in NP tissue structure and composition, we proceeded with the
isolation of NP cells at each of these time points in order to examine changes in global gene
expression. Our strategy involved breeding the notochord-specific NotoCre/WT mouse strain 53 to
the Rosa26mTmG/WT double-fluorescent Cre reporter mouse54 to isolate NP cells based on
fluorescence (Supplementary Material). The Rosa26mTmG mouse ubiquitously expresses
membrane-targeted tandem dimer Tomato (mT); following Cre-mediated excision, cells express
membrane-targeted green fluorescent protein (EGFP). When crossed with NotoCre/WT mice, EGFP
expression is induced in notochord and notochord-derived cells. To verify Cre-mediated
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recombination, we assessed fluorescence in tail segments of NotoCre/WT;Rosa26mTmG/WT mice at
2.5 months-of-age (Supplementary Material) and confirmed that EGFP+ cells were localized
specifically to the NP. Using this transgenic model, we developed protocols to isolate the EGFP+
NP and tdTomato+ AF from the IVD (Supplementary Material).
2.5.3 Comparison of Gene Expression Profiles Between NP and AF
To identify markers of NP and AF, we compared their global gene expression signatures
to identify differentially expressed genes (DEGs). At 2.5 months-of-age, 1,015 genes were
significantly up-regulated and 642 genes were significantly down-regulated in the AF compared
to the NP (Figure 2.2A; Supplementary Material). The five most up-regulated genes in the AF
compared to the NP were all extracellular matrix-related genes: proteoglycan 4 (Prg4), cartilage
intermediate layer protein (Cilp), integrin binding sialoprotein (Ibsp), osteomodulin (Omd), and
cartilage oligomeric matrix protein (Comp) (Figure 2.2A; Table 2.1). The five most up-regulated
genes in the NP compared to the AF were desmocollin 3 (Dsc3), the sialyltransferase ST6
(St6galnac3), micro-RNAs 218-1 (Mir218-1) and 490 (Mir490), and the predicted gene 14267
(Gm14267) (Figure 2.2A; Table 2.1). At 6 months-of-age 1,286 genes were significantly upregulated and 922 genes were significantly down-regulated in the AF compared to the NP
(Figure 2.2A; Supplementary Material). Importantly, four of the five most up-regulated genes
in the AF compared to the NP at 6 months-of-age, were common with the same comparison at
2.5 months – Cilp, Ibsp, Prg4, and Omd (Figure 2.2A; Table 2.1) – in addition to complement
component factor h (Cfh). Of note, Comp was still within the top 10 most up-regulated genes in
this comparison at 6 months-of-age, while Cfh was within the top 10 most up-regulated genes in
the comparison of samples at 2.5 months (Table 2.1). This suggests remarkable consistency with
age in the genes differentially expressed between AF and NP tissues. At 6 months-of-age, the
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Figure 2.2 Volcano plots and Gene Ontology (GO) analysis comparing the global gene
expression profile of AF and NP cells at 2.5 and 6 months-of-age. A. Volcano plots of
differentially expressed genes between AF and NP from 2.5-month-old or 6-month-old mice.
(n=2-3 mice per group; 5-6 IVDs pooled per mouse). Fold-change (x-axis) is plotted against
statistical significance (y-axis) for each gene set. Genes significantly up-regulated are located
within the green quadrants, and those significantly down-regulated are located within the red
quadrants based on a threshold of fold-change ≥2 and p<0.05 (number of significantly altered
genes is indicated in each of the quadrants). Only transcripts with annotated gene symbols were
included. The five most differentially expressed genes in each quadrant are indicated by their
gene symbols on the plots (arrows). B. The five most enriched GO terms in the comparison
between AF and NP for molecular function (blue), biological process (green), and cellular
component (red) are presented for the 2.5- and 6-month time points. The most enriched GO terms
for cellular component and biological process are consistent at both time points; however, the
most enriched GO terms for molecular function differ between 2.5 and 6 months-of-age.
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Table 2.1 Ten most up-regulated and ten most down-regulated genes between the AF and
the NP at 2.5 and 6 months-of-age.

55
five most up-regulated genes in the NP compared to the AF were Dsc3, reelin (Reln), RAS family
member Rab38, Gm14267, and the G protein-coupled receptor Gpr133 (Figure 2.2A; Table
2.1). Dsc3 and Gm14267 were in the top 5 of comparisons at both time points, while Gpr133 and
membrane integral NOTCH2 associated receptor 1 (AF529169; Minar1) were in the top 10 of
comparisons at both time points (Table 2.1).
To provide insight into the functional categories associated with the DEGs, we performed
Gene Ontology (GO) analysis at both time points. Similar to the patterns highlighted in the
analysis of individual differentially expressed genes, the five most enriched GO terms were
remarkably consistent between the time points assessed. The five most enriched GO terms
associated with cellular components and biological processes at both time points were identical
at the 2.5- and 6-month time points with only slight differences in the enrichment scores/rank
order (Figure 2.2B). Three of the five most enriched GO terms for molecular function were
consistent between time points, with the differences being “Ion Binding” and “Calcium Ion
Binding” at 2.5 months being replaced at 6 months by “Heparin Binding” and “Sulfur Compound
Binding” (Figure 2.2B). The 10 most enriched GO terms from either comparison is presented in
(Supplementary Material).
To validate a subset of DEGs identified by our analyses as well as previously reported
tissue-specific markers of the IVD39,46,62, we used quantitative RT-PCR (Figure 2.3). Given that
most DEGs were consistent across time points, we focused on the 2.5-month time point. This
analysis confirmed robust gene expression of Ibsp and Prg4 in the AF, with no detectable
expression in the NP (Figure 2.3A). Furthermore, the gene expression of carbonic anhydrase 3
(Car3), keratin 8 (Krt8), the solute carrier family member also known as Glut1 (Slc2a1), and
brachyury (T) were all confirmed to be significantly up-regulated in the NP compared to the AF
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Figure 2.3 Real-time quantitative PCR validation of differentially expressed genes in the
AF and the NP at 2.5 months-of-age. A. In keeping with our microarray analysis, transcript
levels of integrin binding sialoprotein (Ibsp) and proteoglycan 4 (megakaryocyte stimulating
factor, articular superficial zone protein) (Prg4) show significant up-regulation in the AF
compared to the NP (N.D indicates no detectable expression in the NP). B. Similarly, transcript
levels of carbonic anhydrase 3 (Car3), keratin 8 (Krt8), solute carrier family 2 (facilitated glucose
transporter), member 1 (Slc2a1; also known as Glut1), and brachyury, T-box transcription factor
T (T), show significant up-regulation in NP compared to AF tissue. Data presented as mean ±
SEM, n=4 mice per group; 5-6 IVDs pooled per mouse. Asterisk (*) indicates p-value <0.05. pvalues are denoted for statistical comparisons that did not meet the threshold for significance.
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(Figure 2.3B). Of note, although the difference in gene expression of glypican 3 (Gpc3) between
the NP and the AF was not statistically significant, there was almost no detectable expression in
the AF, making it nonetheless an intriguing candidate for a tissue-specific marker.
2.5.4 Predictive Bioinformatic Analysis of Differences in Transcription Factor Activity
Between NP and AF
To investigate the pattern of transcription factor activity associated with the DEGs
identified between the NP and AF, we used ISMARA61. Briefly, this analysis integrates gene
expression data with annotated transcription factor binding sites to computationally predict the
transcription factors driving gene expression. At 2.5 months-of-age, the transcription factors
predicted as having the most activity in the AF compared to the NP were the ETS transcription
factor (Erg) and the hitherto unnamed transcription factor with motif AGCACCA (Figure 2.4A).
The transcription factors predicted to have the most activity in the NP compared to the AF at this
time point were nuclear respiratory factor 1 (Nrf1), and zinc-finger proteins Zfx and Zfp711. At
6 months-of-age, the transcription factors predicted to have the most activity in the AF compared
to the NP were oocyte specific homeobox 5 and 6 (Obox5,6), and autoimmune regulator (Aire).
The transcription factors predicted to have the most activity in the NP compared to the AF at this
time point were Nrf1, and Y box protein 1 (Ybx1), nuclear transcription factor Y a, b and c (Nfya,
b, c), and CCAAT/enhancer binding protein zeta (Cebpz) (Figure 2.4B).
2.5.5 Gene Expression Profiles Associated with Age-induced Degeneration of the Nucleus
Pulposus
Microarray-based expression profiling was next conducted on EGFP+ NP cells isolated
from mice at 2.5, 6, and 21 months-of-age to investigate changes related to age-associated
degeneration. Gene expression was compared between each time point examined: the expression
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Figure 2.4 Integrated motif activity response analysis (ISMARA) of microarray
comparisons between the AF and the NP at 2.5 and 6 months-of-age. Transcription factor
binding motifs are ranked in order of descending Z-value quantifying the motif’s contribution to
the altered transcriptional activity of all of the motif’s associated genes. The activity of a given
motif is denoted as either increased in the AF relative to NP or vice versa. The two highest ranked
motifs in each comparison are presented for 2.5 (A) and 6 (B) months-of-age. Associated genes
are a list of target promoters for the motif ranked by target score. Consensus binding motifs show
a graphical representation of the sequence conservation of nucleotides for a given motif. “Targetspecific score” quantifies the motif’s ability to regulate transcription of each specific target gene
listed in the adjacent column.
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of 153 genes was significantly altered from 2.5 to 6 months-of-age (Supplementary Material);
the expression of 86 genes was significantly altered from 6 to 21 months-of-age (Supplementary
Material); and the expression of 324 genes was significantly altered from 2.5 to 21 months-ofage (Figure 2.5A, B; Supplementary Material). Broadly, this suggests that the NP undergoes
greater changes in gene expression from 2.5 to 6 months-of-age (a transition associated with
early stages of histopathological degeneration) than from 6 to 21 months-of-age (a transition
associated with the progression to advanced stages of histopathological degeneration).
The five most up-regulated genes in the NP at 2.5 months vs. 6 months-of-age were small
nucleolar RNAs Snord99, Snord69, Snora2b, microRNA 24-1 (Mir24-1), and predicted gene 572
(Gm572) (Figure 2.5A; Table 2.2). Conversely, the five most down-regulated genes in the NP
at 2.5 months vs. 6 months-of-age were microRNA 703 (Mir703), sonic hedgehog (Shh), secreted
frizzled-related sequence protein 5 (Sfrp5), and predicted genes 19960 and 10330 (Gm19960 and
Gm 10330) (Figure 2.5A; Table 2.2). The five most up-regulated genes in the NP at 21 months
vs. 6 months-of-age were Prg4, the peptidase inhibitor Serpina1c, the ATPase Atp2a1, the actin
Acta1, and the troponin Tnnt3 (Figure 2.5A; Table 2.2). Conversely, the five most downregulated genes in the NP at 21 months vs. 6 months-of-age were small nuclear RNAs Rnu3a and
Rnu3b1, microRNA 669h (Mir669h), sonic hedgehog (Shh), and small nucleolar RNA Snora44
(Figure 2.5A; Table 2.2). The five most up-regulated genes in the NP at 2.5 months vs. 21
months-of-age were Rnu3a, Mir669h, Rnu3b1, predicted gene 7429 (Gm7429) and Snora2b
(Figure 2.5A; Table 2.2). Conversely, the five most down-regulated genes in the NP at 2.5
months vs. 21 months-of-age were the peptidase inhibitors Serpina3n and Serpina1c, scinderin
(Scin), cytochrome P450 family member Cyp3a13, and Prg4 (Figure 2.5A; Table 2.2).
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Figure 2.5 Global gene expression and ISMARA analysis of NP-specific gene expression
over time. A. Volcano plots of differentially expressed genes between NP cells isolated at 2.5, 6
or 21 months-of-age. (n=2-3 mice per group; 5-6 IVDs pooled per mouse). Fold-change (x-axis)
is plotted against statistical significance (y-axis) for each comparison. Genes significantly upregulated are located within the green quadrants, and those significantly down-regulated are
located within the red quadrants based on a threshold of fold-change ≥2 and p<0.05 (number of
significantly altered genes is indicated in each quadrant). Only transcripts with annotated gene
symbols were included. The five most differentially expressed genes in each quadrant are
indicated by their gene symbols on the plots (arrows). B. Venn diagram depicting the association
between differentially expressed genes in the group-wise comparisons between 2.5-month-old
vs. 6-month-old (red), 21-month-old vs. 6-month-old (blue), and 2.5-month-old vs. 21-month-old
(green) NP transcriptome. The threshold for significance was set at fold-change ≥2 and p<0.05.
Only transcripts with annotated gene symbols were included. C. Integrated motif activity
response analysis (ISMARA) of NP-specific microarray comparisons. Transcription factor
binding motifs are ranked in order of descending Z-value quantifying the motif’s contribution to
the altered transcriptional activity of all of the motif’s associated genes. The activity profile of a
given motif is graphically presented over the 3 time points. The 4 highest ranked motifs are
presented for the NP at 2.5, 6, and 21 months-of-age. Associated genes are a list of target
promoters for the motif ranked by target score. Consensus binding motifs show a graphical
representation of the sequence conservation of nucleotides for a given motif. “Target-specific
score” quantifies the motif’s ability to regulate transcription of each specific target gene listed in
the adjacent column.
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Table 2.2 Five most up-regulated and five most down-regulated genes between the NP at
2.5, 6, and 21 months-of-age.
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Venn analysis identified interesting subsets of DEGs based on their degree of overlap
between time points. As expected, a subset of the DEGs identified in the NP between 6 and 21
months-of-age were also differentially expressed between 2.5 and 21 months-of-age (total 33
genes; Figure 2.5B). Of note, two genes – Snora69 and Snora75, which are small nucleolar
RNAs – showed consistent down-regulation in their expression with increased age (from 2.5 to
6 months, 2.5 to 21 months, and 6 to 21 months-of-age), suggesting that these may contribute to
progressive age-associated NP degeneration (Figure 2.5B; full list of genes by sector in the Venn
analysis are presented in Supplementary Material).
2.5.6 Predictive Bioinformatic Analysis of Transcription Factor Activity in the NP
ISMARA was used to investigate transcriptional regulators in the aging NP. The
transcription factors predicted to have the most differential activity in the NP with age are
presented in Figure 2.5C. The two groups of transcription factors with the highest Z-Score
(which quantifies the motif’s contribution to the altered transcriptional activity of all of the
motif’s associated genes) were myocyte enhancer factors Mef2a/d and Mef2c, whose activity
profiles demonstrated a consistent decrease from 2.5 to 6 months-of-age (Figure 2.5C). Of note,
a cluster of transcription factors including Arntl, Tfe3, Mlx, Mitf, Mlxipl, and Tfec was identified
which consistently showed activity profiles predicted to increase over time (Figure 2.5C, row
3). These transcription factors, as well as the gene targets they regulate such as dishevelled
segment polarity protein 2 (Dvl2) and cathepsin A (Ctsa), may provide insight into the pathways
associated with NP degeneration.
2.5.7 Gene Ontology Analysis in the NP
To investigate the potential molecular functions associated with changes in NP gene
expression over time, we used Gene Ontology (GO) analysis (data not shown). In the transition
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of the NP from 2.5 to 6 months-of-age, there was a consistent enrichment of genes associated
with ECM or cell surface receptor binding (e.g. laminin and BMP receptor binding). The
transition of the NP from 6 to 21 months-of-age was enriched for cytoskeletal component
binding. Finally, the comparison of NP at 2.5 vs. 21 months-of-age demonstrated an enrichment
of genes associated with ECM binding (e.g. glycoprotein binding), as well as carbohydrate
derivate transporter activity and ion channel activity. The 10 most enriched GO terms in
molecular function for each comparison is included in Supplementary Material.
2.5.8 qRT-PCR Confirmation of DEGs Associated with NP Aging
Quantitative RT-PCR was used to validate a subset of DEGs identified by our
bioinformatic analyses, with gene targets selected to validate specific comparisons (Figure 2.6).
Prg4 was selected since it was in the top 5 genes up-regulated at 21 months-of-age vs. 6 monthsof-age and top 5 genes down-regulated at 2.5 months-of-age vs. 21 months-of-age. Serpina3n
was in the top 5 genes down-regulated at 2.5 months-of-age vs. 21 months-of-age. Ckm was
differentially expressed in the NP in the 21 months-of-age vs. 6 months-of-age comparison (11th
most up-regulated), and was also one of the genes uniquely up-regulated in the NP at 21 monthsof-age vs. 6 months-of-age as revealed by Venn analysis (Supplementary Material). qRT-PCR
confirmed the gene expression patterns from the microarray for all three genes examined, with
significantly increased expression of creatine kinase, muscle (Ckm), Prg4, and peptidase
inhibitor Serpina3n in the NP from 2.5 to 21 months-of-age. Furthermore, there was a significant
increase in gene expression from 6 to 21 months-of-age in both Prg4 and Serpina3n. Of note,
these transcripts were not altered in the AF between 2.5 and 6 months-of-age.
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Figure 2.6 Real-time quantitative PCR validation of differentially expressed genes in the
aging NP. Transcript levels of creatine kinase, muscle (Ckm), proteoglycan 4 (megakaryocyte
stimulating factor, articular superficial zone protein) (Prg4), and serine (or cysteine) peptidase
inhibitor, clade A, member 3N (Serpina3n) show significant up-regulation in 21-month-old NP
compared to 2.5-month-old NP. Transcript levels of Prg4 and Serpina3n show significant upregulation in 21-month-old NP compared to 6-month-old NP. p-value is indicated for Ckm (21month-old vs. 6-month-old NP tissue). Data presented as mean ± SEM, n=3-5 mice per group;
5-6 IVDs pooled per mouse. Asterisk (*) indicates p-value <0.05.
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2.6 Discussion
In the current study, transcriptional profiling paired with bioinformatic analysis allowed
us to identify distinct markers of the NP and the AF as well as the molecular profile associated
with progressive age-associated degeneration in the NP in the mouse. In the field of disc biology,
it is widely acknowledged that defining the phenotype of cell types within the IVD is necessary
to understand disc physiology and function. For example, in 2014 the Spine Research Interest
Group at the Orthopaedic Research Society Meeting convened to compile a working definition
of the NP cell phenotype, based on the current state of knowledge in the field62. Although the
proposed NP markers were selected based on validation at both the mRNA and protein levels
and established physiological importance, the consensus statement did not consider NP-negative
markers nor propose specific AF markers. Furthermore, reflecting an emphasis on regenerative
medicine applications and clinical translation, the proposed phenotypic definition was based
primarily on studies of human tissue/cells. Highlighting the importance of pre-clinical animal
models in basic research, a number of studies have since called attention to issues related to
conservation of markers from human to common animal models46.
Our study therefore aimed to first identify transcriptomic signatures enriched in the
murine NP and AF prior to degeneration. Amongst the 5 most up-regulated genes identified in
the NP relative to the AF at 2.5 months-of-age (which included Dsc3, St6galnac3, Mir218-1,
Mir490, Gm14267), desmocollin 339 and microRNA 49063 have previously been suggested as
NP markers in human and rat, respectively. At 6 months-of-age the 5 most up-regulated genes
identified in the NP relative to the AF (Dsc3, Reln, Rab38, Gm14267, Gpr133) included Rab38
which has been proposed as a marker of notochord cells in chondrodystrophic dogs64, a marker
of chordoma65, and shown to be expressed in the zebrafish notochord66. Gpr133 encodes an
adhesion G-protein-coupled receptor that has been reported as up-regulated in the NP compared
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to articular cartilage (AC) in humans38. Interestingly, Dsc3 and Gm14267 were identified
amongst the most up-regulated genes in the NP compared to the AF at both time points. Gm14267
is a predicted gene, but may warrant further investigation in the NP given its consistent upregulation (~12-fold). Dsc3 belongs to the desmocollin family of cadherin proteins that, together
with desmogleins, form desmosomes to mediate cell-cell adhesions and interactions67.
Interestingly, both Dsc2 and Dsc3 have been proposed as NP markers in multiple species28,45,62.
The differential expression of these genes in the NP compared to the AF likely reflects important
differences in tissue organization and cell-cell communication.
Our analyses also allowed us to propose AF markers. AF-enriched gene expression was
remarkably consistent at 2.5 and 6 months-of-age, with Prg4, Cilp, Ibsp, Omd, Comp, Lect1,
Clec3a, and Cfh in the 10 most up-regulated genes in the AF compared to the NP. Importantly,
our qPCR analysis suggests that Ibsp and Prg4 may also be NP-negative markers in the healthy
mouse IVD, making them valuable for the analysis of heterogeneous IVD cell populations. Ibsp
has been proposed as an AF marker in both humans and cows by microarray and qPCR37, and
based on our findings, serves as a strong candidate as an AF marker across species. Our findings
of increased Prg4 expression in the AF vs. NP are in contrast with previous reports in which
immunohistochemistry68 and proteomic analysis69 of human IVD tissue showed increased
expression of lubricin (encoded by Prg4) in the NP compared to AF, with both tissues having
detectable expression. Of note, analysis of caprine tissue showed no lubricin in the NP, but
robust expression in the interlamellar space of the AF where it is thought to play a role in
interlamellar tribology. Interestingly, our study also identified Prg4 as one of the most enriched
transcripts in the NP at the 21 months-of-age. This may reflect the loss of demarcation between
the NP and AF in advanced degeneration, or a compensatory response by NP cells to the altered
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tissue microenvironment associated with degeneration. Further studies are required to investigate
inter-species differences in lubricin expression, changes associated with degeneration, and
potential differences in the localization of Prg4 expression within the IVD.
Our analysis of potential transcriptional regulators of the NP and the AF demonstrated
overall changes in transcription factor activity with age. Nrf1 was however, consistently
predicted to be the most differentially enriched NP-associated transcription factor. In the NP, our
analysis suggests that Nrf1 regulates downstream targets, including myotubularin related protein
7 (Mtmr7) and T cell leukemia translocation altered gene (Tcta). At 2.5 months-of-age, the
transcription factors predicted as having the most activity in the AF compared to the NP were the
ETS transcription factor (Erg) and a transcription factor with motif AGCACCA. The implication
of ETS transcription factor activity in the AF is intriguing, as polymorphisms in ETS binding
sites have been associated with modulation of MMP1 activity and consequently cleavage of
fibrillar collagens in IVD degeneration70. The transcription factor with binding motif AGCACCA
is a novel target that has yet to be characterized in any tissue, and thus may prove an interesting
target for study in the IVD and related tissues. We cross-referenced the AGCACCA binding
motif target genes to the most highly enriched GO terms in the AF to explore its potential function
in the IVD. This bioinformatic analysis showed that of the 250 genes differentially expressed in
the AF compared to the NP at 2.5 months associated with the cellular component GO term
“extracellular region”, 26 are predicted to be regulated by the transcription factor with binding
motif AGCACCA. Similarly, of the 1000 genes differentially expressed in the AF compared to
the NP at 2.5 months associated with the molecular function GO term “binding”, 54 are predicted
to be regulated by the binding motif AGCACCA. Our analyses have confirmed previously
reported markers of NP and AF cells in the murine IVD, and provided potential novel markers.
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Given the potential impact of variability in the degree of degeneration between individual
animals, as well as the variability in degeneration noted in this and other studies between
individual IVDs across spinal levels71, we acknowledge that our findings may be limited by the
number of biological replicates used for transcriptomic analysis. Moreover, our study is limited
by the lack of distinction between the inner and outer AF, which has recently been shown to be
biologically important35,36, or NP and endplate chondrocytes29, or notochord cells from
chondrocyte-like NP cells64. Recent studies have characterized the phenotype of notochord cells
in both human and mouse48,72; bioinformatic comparisons of this data from the mouse with the
gene expression signature established in these studies would provide interesting insight into NP
biology particularly in the context of the differential persistence of notochord cells in the human
and mouse IVD with age26.
Our study aimed to correlate the IVD transcriptional profile with histological
characteristics of the tissue at the time points analyzed. Histopathological characterization of the
IVD demonstrated progressive age-associated degeneration in both the NP and AF. In the NP,
this included the loss of notochord cells and, in some IVDs, the accumulation of large
hypertrophic cells within the degenerative NP at 21 months-of-age. The detection of hypertrophic
cells associated with degeneration in the NP is consistent with recent characterization of
degeneration following needle-puncture injury14, and the “slow-healing” SM/J mouse model of
spontaneous IVD degeneration71,73. Our study found that time points associated with the
accumulation of hypertrophic cells in the NP were associated with decreased transcription of
small nuclear (Rnu3b1, Rnu3a) and nucleolar (Snord99, Snord69, Snora2b, Snora44) RNAs.
Little is known about the role of small nucleolar RNAs (snoRNAs) and small nuclear RNAs
(snRNAs) in the context of aging and disease; however, they are detectable in the bloodstream74
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and therefore may be promising targets as biomarkers of NP degeneration. Of the small noncoding RNAs, microRNAs are the best characterized to date and are associated with senescence
and aging74,75. Our analysis also implicated multiple miRNAs with NP aging including Mir24-1,
Mir703 and Mir669h. Mir669h is an intriguing candidate for further analysis, as its transcript
levels decreased from 2.5 to 21 months and 6 to 21 months-of-age. The study of snoRNAs,
snRNAs, miRNAs and predicted genes has been limited, especially in the context of the IVD, and
therefore should be explored in future studies to characterize their function.
Bioinformatic analysis of gene ontology (GO) identified fundamental differences in
pathways associated with molecular function and biological processes for each comparison. As
expected, GO analysis revealed the highest enrichment of pathways associated with extracellular
matrix, protein binding, and developmental processes between the NP and AF – consistent with
their differences in tissue composition, structure and developmental origins76. Of note, our
predictive analysis of transcription factor activity may provide some mechanistic insight
underlying these differences. For example, the transcription factor Nrf1 was predicted to be
enriched in the NP at both the 2.5- and 6-month time points. When we cross-referenced the Nrf1
targets to the most highly enriched GO terms in the NP, we found that numerous Nrf1 targets
annotate to these GO terms. For example, of the 726 genes differentially expressed in the NP
compared to the AF at 2.5 months associated with the molecular function GO term “protein
binding”, 20 are predicted to be regulated by Nrf1. At 6 months-of-age, 30 of the 805 genes
differentially expressed in the NP associated with this GO term are predicted to be regulated by
Nrf1. Of note, Mapk8 and Slc12a2 contain Nrf1 binding sites in their promoters, and were found
to be significantly upregulated in the NP at both 2.5 and 6 months-of-age. The genes are
annotated to both the GO molecular function “protein binding” term and the GO biological
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process “developmental process” term, suggesting that Nrf1 may mediate NP-specific functions.
Similarly, the GO analysis of changes in NP gene expression over time show the
enrichment of numerous pathways associated with the extracellular matrix. Of note, between 2.5
and 6 months-of-age our analysis suggested an enrichment of genes associated with laminin
binding. This finding is consistent with previous literature suggesting the importance of laminin
in the notochord and NP77. Annotated to this pathway, our microarray analysis shows a
significant increase in the expression of non-integrin laminin-binding proteins Lgals178 and
Rpsa79 (2.2-fold increase for both at 6 months-of-age compared to 2 months-of-age). No
significant difference however was detected in the expression of the primary integrin laminin
receptors (a6, b1 or b4) in the murine NP over time, previously shown to mediate porcine NP
cell attachment to laminin80. Despite well characterized changes in NP ECM composition over
time81-83, our analysis did not show changes at the level of gene expression for laminin α, β or γ
chains in the murine NP over time. Although previous studies suggest differential expression of
laminin chains and corresponding integrin receptors in notochord cells compared to NP cells32,
the absence of detectable changes in gene expression in our study may reflect the differences in
the species and age of animals examined, and consequently in NP cell composition, between
these studies. The general enrichment of laminin-associated genes we report in the NP may be in
keeping with recent reports suggesting that culture of NP cells in laminin-rich ECM may promote
a juvenile NP phenotype and ECM regeneration84.
In addition to highlighting intriguing pathways altered over time in the NP, our analysis
also identified interesting patterns in the expression of individual genes. For example, we
identified dynamic changes in the expression of sonic hedgehog (Shh), a critical regulator of NP
development. Our analysis showed a significant up-regulation of Shh at 6 months-of-age
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compared to both 2.5 and 21 months-of-age. However, when downstream effectors of Shh (Gli1
and Ptch1) were queried in our dataset, there were no differences detected based on our threshold
for significance. Previous studies have reported Shh expression in embryonic and postnatal IVD
development. Shh gene and protein expression were shown to significantly decrease from
embryonic day 12.5 (E12.5) to post-natal day 0 (PO)72, although the authors acknowledge a
potential role for the Shh pathway in the postnatal IVD. Similar to our findings, Shh expression
was shown to decrease in the IVD of mice at 1 yr-of-age compared to expression levels at
postnatal day 485. Our findings are in keeping with these previous reports and suggest potential
dynamic regulation of Shh in the IVD, with low levels of expression in early post-natal life
compared to embryonic stages, but a relative increase in expression at 6 months-of-age that
subsequently declines at 1yr and 21 months-of-age. Taken together, these findings suggest the
need for careful analysis of the Shh pathway at multiple time points along the continuum of IVD
development and aging to further validate its dynamic regulation.
A subset of genes highlighted by our bioinformatic analyses as differentially expressed
was also validated by qPCR. Ckm expression was significantly increased from 2.5 to 21 monthsof-age. Although typically associated with muscle, CKM is involved with ATP turnover which
is likely altered as the metabolism of NP cells changes with age and/or degeneration86. Serpina3n
transcript levels were similarly increased at 21 months-of-age. Of note, Serpina3n was found to
be enriched in the sclerotome compared to the notochord in the developing IVD 48. Similar to the
pattern of Prg4 expression we show, it is possible that with advanced degeneration, cells
remaining in the NP alter gene expression to acquire functions typically carried out by the AF.
The increased expression of the Serpina3n serine protease inhibitor with degeneration is in
keeping with a study of wound healing in diabetic mice. Administration of the protein encoded
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by Serpina3n improved re-epithelialization and collagen deposition, leading to enhanced wound
healing87. The increased expression of this gene in the NP may be indicative of a similar repair
process.
Our analysis of DEGs in the NP from 2.5 to 6 months-of-age predicted decreased activity
of the transcription factors myocyte enhancer factors Mef2a/d and Mef2c. These findings are in
keeping with a previous study that implicated Mef2d in IVD degeneration in the rat. This study
showed that Mef2d expression was significantly reduced in the NP from 3 to 24 months-of-age,
corresponding to increased lysosomal-associated membrane protein 2 (LAMP-2A) levels
suggesting macro- and chaperone-mediated autophagy pathway activation88. Additionally, a
cluster of transcription factors including Arntl, Tfe3, Mlx, Mitf, Mlxipl, and Tfec showed activity
profiles predicted to increase with age. These transcription factors, as well as the gene targets
they regulate such as dishevelled segment polarity protein 2 (Dvl2) and cathepsin A (Ctsa), may
provide insight into the pathways associated with NP degeneration. Dvl2 is a component of the
Wnt signaling pathway; up-regulation of which is associated with the transition from notochord
cell-rich to chondrocyte-like cell-rich NP in the canine89. More broadly, increased Wnt activation
is associated with IVD cell senescence with age and degeneration90. Though cathepsin A has not
been investigated in the IVD, family members cathepsin D and L are localized to sites of
degeneration in human IVDs91.
The current study has provided insight into the phenotype of NP and AF cells as well as
the gene expression signature associated with progressive age-associated NP degeneration.
Further studies are required to characterize candidate effectors at the protein level as well as
examine their potential roles in the context of IVD biology. This study contributes to the
identification of novel genes and molecular pathways associated with degeneration of the NP in
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mice, which is an integral step in understanding this complex process. These molecules and
pathways provide avenues for potential new therapeutics to delay disc degeneration or activate
regeneration of the NP.
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CHAPTER THREE

LOSS OF ENT1 INCREASES CELL PROLIFERATION IN THE ANNULUS FIBROSUS OF
THE INTERVERTEBRAL DISC

_____________________
Sections of this chapter have been reproduced with permission from:
Veras M.A., Tenn N.A., Kuljanin M., Lajoie G.A., Hammond J.R., Dixon S.J., Séguin
C.A. Loss of ENT1 increases cell proliferation in the annulus fibrosus of the intervertebral
disc. J Cell Physiol. (2019) 234:13705-13719
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3.2 Chapter Summary
Mice lacking equilibrative nucleoside transporter 1 (ENT1-/-) demonstrate progressive
calcification of spinal tissues including the annulus fibrosus (AF) of the intervertebral disc (IVD).
We previously established ENT1 as the primary nucleoside transporter in the AF and
demonstrated dysregulation of biomineralization pathways. To identify cellular pathways altered
by loss of ENT1, we conducted microarray analysis of AF tissue from wild-type (WT) and ENT1/-

mice prior to calcification (2 months-of-age) and associated with calcification (6 months-of-

age). Bioinformatic analyses identified cell cycle dysregulation in ENT1-/- AF tissues and
implicated the E2f family of transcription factors as potential effectors. qPCR analysis confirmed
increased expression of multiple E2f transcription factors and E2f interacting proteins (Rb1,
Cdk2) in ENT1-/- AF cells compared to WT at 6 months-of-age. At this time point, ENT1-/- AF
tissues showed increased JNK MAPK pathway activation, CDK1, MCM5 and PCNA protein
expression, and PCNA-positive proliferating cells compared to WT controls. The current study
demonstrates that loss of ENT1-mediated adenosine transport leads to increased cell proliferation
in the annulus fibrosus of the IVD.
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3.3 Introduction
Equilibrative nucleoside transporter 1 (ENT1) is a member of the ENT family (or SLC29A
family) of equilibrative nucleoside transporters (ENT1-4), which are sodium-independent
facilitated diffusion carriers that transport nucleosides bi-directionally across the plasma
membrane1. ENT1 is localized primarily to the cell membrane and is expressed in almost every
tissue, including heart, brain, spleen, lung, liver, skeletal muscle, kidney, and testes1,2. Although
numerous purine and pyrimidine nucleosides can be transported by ENT1, it has the highest
affinity for adenosine amongst ENT family members, with a Km of 0.12 mM in humans and 0.13
mM in mice1,3. Interestingly, our group has recently shown that ENT1 is the primary adenosine
transporter in the annulus fibrosus of the murine intervertebral disc (IVD)4.
Mice lacking expression of Slc29a1, the gene encoding ENT1, exhibit significantly
elevated levels of plasma adenosine in vivo5,6. In vitro studies demonstrated that loss of ENT1mediated transport leads to increased extracellular adenosine and adenosine receptor signaling6.
Adenosine can bind to four known receptors – A1, A2A, A2B, and A37. All adenosine receptors
couple to heterotrimeric G proteins, which signal through multiple pathways. These include
phospholipase C (PLC), phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K), and protein
kinase A (PKA) via modulation of cAMP production. Ultimately, the adenosine receptors and
their associated G proteins can modulate mitogen-activated protein kinase (MAPK) signaling
cascades, which in turn regulate cell proliferation, growth and differentiation8,9.
ENT1 expression has been investigated as a biomarker for numerous diseases including
inflammatory bowel disease10, Huntington’s disease11, and cancer12, where it has been suggested
that JNK may negatively regulate ENT1 expression in response to stress induced by
chemotherapy13. Furthermore, using knockout-mouse models, ENT1 function has been studied
in the context of anxiety14, cardiovascular disease6,15, disruption of sleep-wake regulation16,
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hepatocyte function17, intestinal absorption18, and diffuse idiopathic skeletal hyperostosis
(DISH)4,5. Adenosine receptors have been investigated for use as therapeutic targets for a
plethora of diseases including cardiovascular, renal, pulmonary, inflammatory, endocrine,
nervous system disorders, and cancer 9,19. As initiators of the aforementioned signaling cascades,
dysregulation of adenosine transport and consequently of adenosine receptor activity has
potential to alter cell growth, differentiation, and proliferation thereby contributing to such a
broad range of disease pathologies.
A mouse with global deletion of ENT1 (ENT1-/-) was generated and used to investigate
central nervous system alterations related to ethanol consumption and sensitivity to the ataxic
effect of ethanol20. This group subsequently showed that ENT1-/- mice exhibit decreased anxietylike behaviour using multiple behavioural tests14. The ENT1-/- mice also exhibit a
cardioprotective phenotype, where myocardial infarct size is significantly reduced following
ischemia-reperfusion15. Using the same ENT1-/- mouse model, our lab has reported that mice
lacking ENT1 develop ectopic calcification of connective tissues in the axial spine, which
follows a remarkably reproducible spatial and temporal pattern4,5. Areas of ectopic calcification
in ENT1-/- mice are present in the paraspinal ligaments of the cervical-thoracic region as early as
2 months-of-age, and extend to the lumbar and caudal regions by 6 and 12 months-of-age,
respectively. At these later time points, amorphous, acellular calcified lesions are detected in
fibrocartilaginous tissues of the spinal ligaments, rib entheses, sternocostal articulations and the
annulus fibrosus (AF) of the IVD. Importantly, there was no evidence that ectopic calcified
lesions were associated with inflammation or increased vascularization.
The current study was designed to investigate the global transcriptional signature
associated with loss of ENT1 and altered systemic adenosine levels, both prior to and coinciding
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with ectopic calcification of the IVD. Our group previously showed that at 2 months-of-age, there
is no radiographic detection of ectopic calcification in AF tissue of the thoracic spine in ENT1-/mice; however, at 6 months-of-age, ectopic calcifications are consistently detected in this region5.
Therefore, we examined differences in gene expression in thoracic AF tissue from wild-type and
ENT1-/- mice at these time points. This allowed us to investigate the gene expression signatures:
i) associated with loss of ENT1 (2 months-of-age, ENT1-/- compared to WT); ii) coinciding with
ectopic calcifications (6 months-of-age, ENT1-/- compared to WT); and iii) associated with the
progression of tissue calcification (6-month-old ENT1-/- compared to 2-month-old ENT1-/-). We
performed bioinformatic analyses of microarray data at these time points and subsequently
validated findings by real-time quantitative PCR, western blot, immunohistochemistry, and
proteomics using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Together,
these analyses revealed differences in the regulation of cell proliferation between WT and ENT1/-

mice. Specifically, increased cell proliferation in ENT1-/- AF tissue in vivo was associated with

increased expression of cell cycle regulators Cdk2 and Rb1, E2f transcription factors, and
increased MAPK pathway activation. These findings provide novel insights into one of the
molecular pathways associated with ectopic calcification in ENT1-/- mice.

3.4 Materials and Methods
3.4.1 Animals
ENT1-/- mice generated by deletion of exons 2-4 of the gene encoding ENT1 (Slc29a1)
were generously provided by Dr. Doo-Sup Choi (Mayo Clinic College of Medicine, Rochester,
MN, USA)20. ENT1-/- mice were backcrossed with C57BL/6 mice and the colony was maintained
by breeding heterozygote mice (ENT+/-) to obtain wild-type (ENT+/+) and knock-out (ENT1-/-)
littermate mice. Genotyping was performed, as previously described5. Mice were housed in

87
standard cages and maintained on a 12 h light/dark cycle, with rodent chow and water available
ad libitum. Male and female mice were sacrificed at 2 or 6 months-of-age for spine and AF tissue
isolation. All aspects of this study were conducted in accordance with the policies and guidelines
set forth by the Canadian Council on Animal Care and were approved by the Animal Use
Subcommittee of the University of Western Ontario (protocol 2017-154; Appendix C).
3.4.2 AF Tissue Isolation and RNA Extraction
IVDs (5-6 per mouse) were microdissected from the thoracic spine of 2- or 6-month-old
wild-type and ENT1-/- mice. Intact IVDs were lacerated in phosphate-buffered saline (PBS) to
remove the gelatinous nucleus pulposus, isolating AF tissue. Following microdissection, AF
tissues were placed in RNAlater (Life Technologies) and stored at -80°C. Samples were
subsequently thawed and centrifuged for 2 min at 627 g, RNAlater was aspirated and replaced
with 1 mL of PureZOL® (Bio-Rad Laboratories). Tissues were homogenized using a Polytron®
benchtop homogenizer and RNA was extracted using the Aurum Total RNA Fatty and Fibrous
Kit (Bio-Rad Laboratories), according to the manufacturer’s protocol. RNA was quantified using
a NanoDrop 2000 spectrophotometer (Thermo Scientific). RNA quality was verified using the
Agilent 2100 Bioanalyzer (Agilent Technologies) and the RNA 6000 Nano kit (Caliper Life
Sciences). RNA samples with RNA integrity number (RIN) values greater than 7 were used for
microarray analysis.
3.4.3 Microarray Analysis
Microarray analysis was performed on thoracic AF tissues from 2- and 6-month-old WT
and ENT1-/- mice (n=2 mice of each age/genotype combination) at the London Regional
Genomics Centre (Robarts Research Institute, London, ON). Briefly, single stranded
complementary DNA (sscDNA) was prepared from 200 ng of total RNA using the Ambion WT
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Expression Kit for Affymetrix GeneChip Whole Transcript WT Expression Arrays (Applied
Biosystems) and the Affymetrix GeneChip WT Terminal Labeling kit (Affymetrix). Total RNA
was first converted to cDNA, followed by in vitro transcription to cRNA. 5.5 µg of sscDNA was
synthesized, end labeled and hybridized for 16 h at 45°C, to Mouse Gene 2.0 ST arrays. All liquid
handling steps were performed using the GeneChip Fluidics Station 450 and GeneChips were
scanned with GeneChip Scanner 3000 7G (Affymetrix) using Command Console v3.2.4. Probe
level (.CEL file) data were generated using Affymetrix Command Console v3.2.4. Probes were
summarized to gene level data in Partek Genomics Suite v6.6 using the robust multi-array
average (RMA) algorithm21. Partek was used to determine gene level ANOVA p-values and fold
changes. Genes demonstrating at least a 2.0-fold change with a p<0.05 were considered
significant and used for downstream analysis. The full data set will be deposited in NCBI’s Gene
Expression Omnibus (GEO).
3.4.4 Bioinformatic Analyses
Probes demonstrating a significant change between groups (2-month-old ENT1-/- vs 2month-old WT; 6-month-old ENT1-/- vs 6-month-old WT; 6-month-old ENT1-/- vs 2-month-old
ENT1-/-) were used for functional categorization and pathway analysis. Database categories were
generated based on the Mus musculus annotations for Gene ontology (GO) analysis
(geneontology.org) and Kyoto encyclopedia of genes and genomes (KEGG) pathway analysis
(genome.jp/kegg/). GO and KEGG pathway analyses were performed using a Fisher’s exact test
and the data are presented as enrichment scores. The Integrated System for Motif Activity
Response Analysis (ISMARA)22 was used to predict transcription factors responsible for gene
expression changes. Microarray CEL files were uploaded to the ISMARA online tool to
computationally predict regulatory sites for transcription factors associated with differentially
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expressed genes between WT and ENT1-/- mice. Data are presented in ranked order by Z-value.
Based on genes identified by Partek and ISMARA analyses, genes of interest were selected for
subsequent validation.
3.4.5 qRT-PCR Analysis
Real-time PCR analysis was performed on thoracic AF tissues (5-6 IVDs pooled per
mouse) from 2- and 6-month-old wild-type and ENT1-/- mice (n=6 mice each age/genotype).
RNA was extracted (as described above) and quantified using a NanoDrop 2000
spectrophotometer. cDNA was synthesized using the iScript cDNA kit (Bio-Rad, Philadelphia,
PA) from 500 ng RNA/sample. Gene expression was determined by SYBR-based real-time PCR
using the Bio-Rad CFX384 system. PCR reactions were run in triplicate using 310 nM forward
and

reverse

primers

(sequences

provided

in

Supplementary

Material:

https://onlinelibrary.wiley.com/doi/abs/10.1002/jcp.28051) with 2X SsoFast™ EvaGreen®
Supermix (Bio-Rad). The PCR program consisted of the following: initial 3 min denaturation at
95°C; 10 s at 95°C denaturing; and 30 s annealing/elongation at 60°C, for a total of 40 cycles.
Gene transcript levels were calculated using the ∆∆Ct method, normalized for input based on
ribosomal protein 29 (Rps29) expression, and expressed relative to WT controls at each time
point.
3.4.6 Western Blotting
AF tissue was isolated from thoracic IVDs (8 IVDs pooled per mouse) of WT and ENT1/-

mice (n=4 for each genotype) at 6 months-of-age. AF tissues were placed in 300 µL of

radioimmunoprecipitation assay (RIPA) buffer in RINO® screw-cap tubes (Next Advance) and
homogenized using the Bullet Blender® Storm (Next Advance). Samples were centrifuged at
14,000 g for 15 min at 4°C. The supernatant was collected and protein concentration was
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determined using the BCA Protein Assay Kit (Pierce Biotechnology, Rockford, IL) according to
the manufacturer’s protocol. Either 30 µg of protein (for p38 and ERK) or 32 µg of protein (for
JNK) was loaded and resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE), followed by transfer onto an Immobilon®-P (Sigma) polyvinylidene difluoride
(PVDF) membrane using the Trans-Blot® Turbo™ Blotting System (Bio-Rad). Membranes were
then blocked in Tris-buffered saline-tween with 5% skim milk powder (5% milk-TBST), and
incubated with primary antibodies against phospho-p38 MAPK Thr180/Tyr182 (1:1000; mAb
4511, RRID:AB_2139682), p38 MAPK (1:1000; mAb 8690, RRID:AB_10999090), phosphop44/42 MAPK Erk1/2 Thr202/Tyr204 (1:2000; mAb 4370, RRID:AB_2315112), p44/42 MAPK
Erk1/2 (1:1000; mAb 4695, RRID:AB_390779), phospho-SAPK/JNK Thr183/Tyr185 (1:750;
mAb 4668, RRID:AB_2307320), or SAPK/JNK (1:1000; Antibody 9252, RRID:AB_2250373)
in TBST with either 5% milk (for p38 and ERK) or bovine serum albumin (for JNK). All
antibodies were purchased from Cell Signaling Technology (Danvers, MA). After washing in
TBST, the membranes were incubated with goat anti-rabbit immunoglobulin G-horseradish
peroxidase-conjugated secondary antibody (Antibody 7074, Cell Signaling Technology,
RRID:AB_2099233). Signal visualization was performed using the Clarity Western ECL
Substrate (Bio-Rad) and the Bio-Rad ChemiDoc MP Imaging System. Levels of phosphoproteins were quantified and presented normalized to corresponding total protein levels.
3.4.7 Histology & Immunohistochemistry
Formalin-fixed tissue samples from the intact thoracic spine were decalcified, processed
and paraffin-embedded as previously described5. 5 µm-thick coronal tissue sections were
deparaffinised in xylene and rehydrated by successive immersion in descending concentrations
of ethanol. Histological sections were stained with hematoxylin and eosin (H&E). Mid-coronal
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sections of the T2/T3 IVDs from 3 mice per genotype and age were used to determine cell counts
in the right lateral aspect of the AF (defined by the NP/AF and CEP/AF boundaries; excluding
rib entheses when in field of view). For immunohistochemistry, antigen retrieval was performed
with 0.1% Triton X-100 (Sigma) for 25 min at RT. Tissue sections were blocked with 5% fetal
bovine serum (FBS) in phosphate buffered for 45 min at RT then incubated with a mouse
monoclonal primary antibody against proliferating cell nuclear antigen (PCNA) (mAb 2586; Cell
Signaling Technology, RRID:AB_2160343) overnight at 4°C in a humidified chamber. Slides
were washed with dH20 followed by incubation with mouse immunoglobulin G! light chain
binding protein-horseradish peroxidase conjugated secondary antibody (SC-516102; Santa Cruz,
RRID:AB_2687626) for 1 h at room temperature. Following incubation with DAB+ chromogen
(Dako; Carpinteria, CA), sections were counterstained with methyl green (1% methyl green in
0.1 M sodium acetate buffer, pH 4.2, for 3 min). Sections were dehydrated by successive
immersion in ascending concentrations of ethanol, followed by 100% xylene and mounted using
xylene-based mounting media. Images corresponding to n=3 animals per genotype and age were
acquired using a Leica DFC295 digital camera and Leica DM1000 microscope with Leica
Application Suite (Leica Microsystems).
3.4.8 Liquid Chromatography-tandem Mass Spectrometry and Proteomic Data Analyses
AF tissue was microdissected from upper thoracic IVDs of WT and ENT1-/- mice at 2 and
6 months-of-age (n=2 mice per group; 4 IVDs pooled per mouse) and immediately snap frozen
in liquid nitrogen. For protein extraction, AF tissues were sonicated in buffer containing 8 M
urea, 50 mM ammonium bicarbonate (ABC), 10 mM dithiothreitol, and 2% SDS. Lysates were
clarified by centrifugation and protein concentration in the supernatants were measured using the
Pierce 660 nm protein assay (ThermoFisher Scientific) with a CLARIOstar plate reader (BMG
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Labtech). Protein extracts were alkylated with 10 mM iodoacetamide for 30 min at room
temperature in the dark. 25µg of protein per sample was precipitated using chloroform/methanol,
as described previously23. Peptides were digested overnight in 50 mM ABC containing lysyl
endopeptidase (Lys-C) (Wako) at a 1:100 enzyme to protein ratio and trypsin/Lys-C (Promega)
at a 1:50 ratio. A subsequent on-pellet digestion was performed with trypsin/Lys-C for 4 h.
Protein concentration was measured using the Pierce bicinchoninic acid (BCA) protein assay
(ThermoFisher Scientific) and ~20 µg of tryptic peptides were fractionated by basic reverse phase
fractionation using in-house made StageTips. Prepared fractions were injected and separated
using a nanoAcquity system (Waters, Milford, MA) on a 25-cm long x 75 µm inner diameter
C18 column maintained at 35˚C. All samples were trapped for 5 min at 99% H20, 1% acetonitrile,
and separated using a 5.0% to 32.5% acetonitrile gradient over 74 min, followed by 60%
acetonitrile over 6 min, at a flow rate of 300 nL/min. Fractions were quantified using the BCA
assay (ThermoFisher Scientific) and 1 µg of material was injected per fraction. Data analysis was
performed with MaxQuant version 1.5.0.30 using the Andromeda search engine. MS/MS spectra
were searched against the Uniprot database with trypsin specificity. Bioinformatic analysis was
performed using Perseus version 1.5.0.8. Datasets were filtered for proteins containing a
minimum of one unique peptide.
3.4.9 Statistical Analyses
Statistical analyses were performed with GraphPad Prism 6 Software.

3.5 Results
3.5.1 Global Transcriptome Analysis
To investigate gene expression changes associated with the loss of ENT1, we performed
microarray analysis of annulus fibrosus (AF) tissues isolated from the thoracic IVDs of mice in
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the following four groups: 2-month-old WT, 6-month-old WT, 2-month-old ENT1-/-, and 6month-old ENT1-/-. Using the total gene expression signature, we first assessed the degree of
similarity between samples using principal component analysis (Supplementary Material). As
expected, samples within the same group (biological replicates for genotype and age) were the
most closely related. Although the gene expression signatures of AF tissues isolated from 2month-old ENT1-/- mice appeared to be the least similar group in terms of the second principle
component, they grouped close together in the first principle component which accounts for more
variability within the dataset (34.8% vs. 16.5%). This suggested that biological replicates were
indeed valid. Of note, samples corresponding to the 6-month-old ENT1-/- mice showed the
highest degree of similarity. Transcripts with an annotated gene symbol (hereby referred to as
genes) were then examined in volcano plots to determine the extent of changes in gene expression
between groups: AF tissues from 2-month-old ENT1-/- compared to 2-month-old WT, 6-monthold ENT1-/- compared to 6-month-old WT and 6-month-old ENT1-/- compared to 2-month-old
ENT1-/- (Figure 3.1). Based on a threshold of fold-change ≥2 and p<0.05, the vast majority of
genes were unchanged in each comparison (black points); however, of the genes that were
significantly altered, more were up-regulated than down-regulated in ENT1-/- AF tissues
compared to WT.
3.5.2 Gene Expression Profiles Associated with Loss of ENT1 and AF Calcification
Gene expression was further investigated to decipher changes associated specifically with
loss of ENT1 function, the presence of ectopic calcification, and age in the ENT1-/- AF. This
analysis enabled us to identify gene subsets significantly altered in AF tissues associated with: i)
loss of ENT1 prior to ectopic AF calcification (2-month-old ENT1-/- vs. 2-month-old WT;
Supplementary Material); ii) loss of ENT1 associated with ectopic AF calcification (6-month-
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Figure 3.1 Volcano plots of microarray data. Volcano plots of transcripts differing between
AF tissues from 2-month-old ENT1-/- compared to 2-month-old WT, 6-month-old ENT1-/compared to 6-month-old WT and 6-month-old ENT1-/- compared to 2-month-old ENT1-/- (n=2
mice per group; 5-6 IVDs/mouse). Fold-change (x-axis) is plotted against statistical significance
(y-axis) for each gene set. Genes significantly up-regulated are depicted in green, and those
down-regulated are depicted in red based on a threshold of fold-change ≥2 and p<0.05
(percentage indicates genes significantly altered out of all 29727 genes on the microarray). Black
represents genes that did not differ significantly for a given comparison. Only transcripts with
annotated gene symbols were included.
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old ENT1-/- vs. 6-month-old WT; Supplementary Material); iii) change in ENT1-/- tissues over
time (6-month-old ENT1-/- vs. 2-month-old ENT1-/-; Supplementary Material), and ageassociated changes in WT AF (6-month-old WT vs. 2-month-old WT; Supplementary
Material) (data summarized in Figure 3.2). Interestingly, in all comparisons, most of the
significant changes were associated with the up-regulation of gene expression based on threshold
of >2-fold change (Figure 3.2A). The age-dependent changes in AF gene expression (6-monthold WT vs. 2-month-old WT) demonstrated the lowest number of genes differentially regulated
(total of 61 genes altered). Conversely, the largest amount of change in gene expression was
detected when comparing AF tissues isolated from WT and ENT1-/- mice at 6 months-of-age
(total of 1727 genes altered, 4.49% of all genes detected) (Figure 3.2A). Notably, there were
fewer differentially expressed genes in ENT1-/- AF tissues at 2 months-of-age compared to WT
(261 genes) preceding the detection of AF calcification.
The association between genes up-regulated and down-regulated in the group-wise
comparisons was assessed by Venn analysis (Figure 3.2B; gene lists provided in
Supplementary Material). This analysis identified unique gene subsets. For example, 20 genes
altered in ENT1-/- AF tissue at 2 months-of-age compared to WT (8 up-regulated and 12 downregulated) were not altered in ENT1-/- AF tissue at 6 months-of-age; 234 genes (214 up-regulated
and 20 down-regulated) were altered in ENT1-/- AF tissue at both 2 and 6 months-of-age
compared to each respective WT; and 1386 probes were altered in ENT1-/- AF cells at 6 monthsof-age compared to WT, but not altered in ENT1-/- AF cells at 2 months-of-age. Interestingly,
most of the genes differentially regulated in ENT1-/- AF tissues at 2 months-of-age were also
differentially regulated in ENT1-/- AF tissues at 6 months-of age, compared to age-matched WT.
These specific gene expression signatures may contain intriguing candidates for genes associated
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Figure 3.2 Overview of genes altered with age and loss of ENT1 in annulus fibrosus (AF)
tissues. (A) Table showing total number of up- and down-regulated genes in each group-wise
comparison. (B) Venn diagram depicting the association between genes up-regulated (left) and
down-regulated (right) in the group-wise comparisons between 2-month-old ENT1-/- vs 2-monthold WT tissues (red), 6-month-old ENT1-/- vs 6-month-old WT tissues (blue) and 6-month-old
ENT1-/- vs 2-month-old ENT1-/- tissues (yellow). The threshold for significance was set at >2fold change, p<0.05. Only transcripts with annotated gene symbols were included.
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with the loss of ENT1, response of AF cells to ectopic calcification, and the progression of
ectopic calcification.
3.5.3 Functional Annotation Clustering by GO and KEGG Pathway Analyses
To provide insight into the biological processes and pathways associated with loss of
ENT1 in the AF and ectopic calcification in ENT1-/- mice, the gene expression profiles were
assessed using Gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG)
bioinformatic functional analyses (Supplementary Material). When GO terms containing
“bone” or “mineral” were specifically queried, no terms were significantly enriched in the 2month-old ENT1-/- vs. WT (Supplementary Material). Furthermore, based on our threshold for
significance (≥2.0-fold change, p<0.05), only three genes mapped to these GO terms were
differentially expressed: carbonic anhydrase 2 (Car2; 4.37-fold increase in ENT1-/- vs. WT), zinc
finger protein, multitype 1 (Zfpm1; 2.02-fold increase in ENT1-/- vs. WT), and cathepsin S (Ctss;
2.01-fold increase in ENT1-/- vs. WT). In contrast, at 6 months-of-age when calcification is
detected in the AF, analysis of GO terms demonstrated a significant enrichment of pathways
including “regulation of bone mineralization” (enrichment score of 8.20), “regulation of bone
resorption” (enrichment score of 8.18), “regulation of biomineral tissue development”
(enrichment score of 7.68), “regulation of bone remodeling” (enrichment score of 7.48), and
“negative regulation of bone mineralization” (enrichment score of 6.55) in ENT1-/- vs. WT AF
tissues (Figure 3.3A). The 3 most upregulated genes mapped to these GO terms were Car2 (4.38fold increase in ENT1-/- vs. WT), a disintegrin and metallopeptidase domain 8 (Adam8; 4.38-fold
increase in ENT1-/- vs. WT), and inositol polyphosphate-5-phosphatase D (Inpp5d; 4.24-fold
increase in ENT1-/- vs. WT). The 3 most downregulated genes mapped to these GO terms were
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Figure 3.3 Functional analyses for enriched biological processes and pathways in ENT1-/vs WT AF tissues. The five most enriched Gene Ontology (GO) biological processes are
presented for each comparison (A&B). (A) Five most enriched GO terms containing “bone” or
“mineral” in 6-month-old ENT1-/- compared to 6-month-old WT AF tissues. (B) Five most
enriched GO terms overall in 2-month-old ENT1-/- compared to 2-month-old WT, 6-month-old
ENT1-/- compared to 2-month-old ENT1-/-, and 6-month-old ENT1-/- compared to 6-month-old
WT AF tissues. The length of each column represents the enrichment score for each pathway.
Values for the KEGG “cell cycle” pathway are presented in (C) which is the most enriched
pathway in all group-wise comparisons.
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bone morphogenetic protein 6 (Bmp6; down 2.81-fold in ENT1-/- vs. WT), osteomodulin (Omd;
down 2.67-fold in ENT1-/- vs. WT), and odd-skipped related transcription factor 1 (Osr1; down
2.30-fold in ENT1-/- vs. WT). Lastly, in the 6-month-old ENT1-/- vs. 2-month-old ENT1-/comparison, there was a significant enrichment of a single GO term containing “bone” or
“mineral” – “bone cell development” (enrichment score of 4.33). The dysregulated genes in this
comparison were Zfpm1 (2.24-fold increase in 6-month-old vs. 2-month-old ENT1-/-), protein
tyrosine phosphatase, non-receptor type 6 (Ptpn6; 2.12-fold increase in 6-month-old vs. 2-monthold ENT1-/-), and KIT proto-oncogene receptor tyrosine kinase (Kit; 2.06-fold increase in 6month-old vs. 2-month-old ENT1-/-).
We next queried for GO terms based on enrichment scores for each group-wise
comparison (Figure 3.3B). When comparing 2-month-old ENT1-/- tissues to age-matched WT
(Figure 3.3B), the most enriched GO terms were those associated with cell cycle progression
such as “cell division”, “nuclear division”, and “cell cycle”. Unexpectedly, when comparing 6month-old ENT1-/- tissues to WT controls (Figure 3.3B), the most enriched GO term was that of
“immune system process”, although cell cycle GO terms are also heavily enriched with terms
such as “single-organism cellular process” and “cell cycle process” (enrichment score of 88.6)
amongst the 5 most enriched terms for this comparison. Finally, GO analysis of ENT1-/- tissues
6 months-of-age compared to 2 months-of-age (Figure 3.3B) revealed an increase in enrichment
score of cell cycle GO terms such as “cell cycle” (enrichment score of 56.5), “cell cycle process”
(enrichment score of 50), and “mitotic nuclear division” (enrichment score of 46.5) with age and
concomitantly, AF calcification.
KEGG pathway analysis supports the GO analysis, with the “cell cycle” pathway being
the most enriched in all comparisons (Figure 3.3C). Notably, the enrichment score for the KEGG
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“cell cycle” pathway increased from the 2-month-old ENT1-/- vs. WT comparison (enrichment
score of 14.47) to the 6-month-old ENT1-/- vs. WT comparison (enrichment score of 31.89). In
the 6-month-old ENT1-/- vs. WT comparison, 40 genes dysregulated in our dataset mapped to the
KEGG “cell cycle” pathway – 32% of all genes annotated to this pathway (Supplementary
Material). Of the genes with the largest associated fold change, many up-regulated genes such
as cyclin-dependent kinase 1 (Cdk1; increase of 6.3-fold), E2f8 (increase of 6-fold), and E2f2
(increase of 5.5-fold) were identified as part of the common cell cycle pathways.
3.5.4 Predictive Bioinformatic Analysis of Differences in Transcription Factor Activity
To investigate if a common pattern of altered transcription factor activity may be
associated with the changes in gene expression identified, we used ISMARA (Integrated Motif
Activity Response Analysis)22. Briefly, this analysis integrates gene expression data from
microarray .CEL files with annotated transcription factor binding sites to computationally predict
which transcription factors may be driving gene expression changes. Comparing the
transcriptional profiles of ENT1-/- AF tissues at 2 and 6 months-of-age to their respective WT
controls using ISMARA, the top ranked motifs by Z-value (which quantifies a motif’s
contribution to explaining altered transcriptional activity of associated genes22) were associated
with the E2f transcription factor family (specifically E2f1-5; Table 3.1). ISMARA predicted that
the E2f1-5 motif was up-regulated at both 2 and 6-months-of-age in ENT1-/- AF tissues with Zvalues of 8.74 and 11.24 respectively. Examples of E2f-associated genes up-regulated in our
dataset at both 2 and 6 months-of-age in ENT1-/- mice include Cdk1, E2f8, and E2f2 along with
Rrm2

(ribonucleotide

reductase

regulatory

subunit

M2;

increased

6-fold),

Mcm5

(minichromosome maintenance complex component 5; increased 4.6-fold), and H2afx (H2A
histone family member x; increased 4.6-fold). Interestingly, the Z-value for E2f1-5
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Table 3.1. Integrated motif activity response analysis (ISMARA) of microarray
comparisons between ENT1-/- and WT AF tissues at 2 and 6 months-of-age.
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increased from 2 to 6 months-of-age corresponding with the increased severity of the ENT1-/phenotype. The Spi1 motif was also ranked in the top 5 in both comparisons, predicted to be upregulated with a Z-value of 4.15 at 2 months-of-age and 6.77 at 6 months-of-age.
3.5.5 qRT-PCR Confirmation of Changes in E2f Transcription Factor and E2f-related
Protein Gene Expression in ENT1-/- Tissues
To validate the transcriptional alterations identified by our bioinformatic analyses, we
used quantitative RT-PCR to analyze the expression of E2f transcription factor family members
and cell cycle-related genes that are potential upstream regulators of E2f transcription factor
activity altered in our microarray analysis. At 2 months-of-age, transcript levels of E2f1, 3, 4, 5
and 6 were all significantly down-regulated in ENT1-/- AF tissues compared to WT controls
(Figure 3.4A). In contrast, at 6 months-of-age, transcript levels of E2f1, 3, 5, 6, and 7 were
significantly up-regulated in ENT1-/- AF tissues compared to WT controls (Figure 3.4B). We
then analyzed the expression of cyclin-dependent kinases known to regulate the activity of E2f
transcription factors, of which 3 were found to be up-regulated in our microarray comparison of
AF tissues at 6-months-of-age (Cdk1, 2 and 6; Supplementary Material). Cdk genes
demonstrated a pattern of expression similar to that of the E2f transcription factors. At 2 monthsof-age, transcript levels of Cdk1, 2, 4 and 6 were down-regulated in ENT1-/- AF tissues compared
to WT controls (Figure 3.5A). In contrast, transcript levels of Cdk2 were significantly upregulated by over 5-fold in ENT1-/- AF tissues compared to WT controls at 6 months-of-age
(Figure 3.5A). We analyzed the gene expression of retinoblastoma protein (Rb1) and
retinoblastoma-like protein (Rbl1) which directly interact with E2f transcription factors and were
up-regulated in our 6-months-of-age microarray comparison (Supplementary Material).
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Figure 3.4 Real-time quantitative PCR analysis of E2f transcription factor gene expression
in AF tissue of WT and ENT1-/- mice at 2 and 6 months-of-age. Expression of E2f family
transcription factor genes (E2f1-8). (A) Transcript levels of E2f1, 3, 4, 5, and 6 show significant
down-regulation in ENT1-/- mice at 2 months-of-age compared to WT controls. (B) Transcript
levels of E2f1, 3, 5, 6, and 7 show significant up-regulation in ENT1-/- mice at 6 months-of-age
compared to WT controls. Gene transcript levels were calculated using ∆∆Ct, normalized for
input based on ribosomal protein 29 (Rps29) expression, and expressed relative to age-matched
WT controls. Data presented as mean ± SEM, n=4-6 mice per group (5-6 thoracic IVDs pooled
per mouse). Asterisk (*) indicates p-value <0.05
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Figure 3.5. Real-time quantitative PCR analysis of cell cycle-related gene expression in AF
tissue of WT and ENT1-/- mice at 2 and 6 months-of-age. (A) Transcript levels of Cdk1, 2, 4,
and 6 show significant down-regulation in ENT1-/- mice at 2 months-of-age. Transcript levels of
Cdk2 show significant up-regulation in ENT1-/- mice at 6 months-of-age. (B) Expression of E2f
transcription factor-associated proteins Rb1 and Rbl1. Transcript levels of Rb1 show significant
down-regulation in ENT1-/- mice at 2 months-of-age. Transcript levels of Rb1 show significant
up-regulation in ENT1-/- mice at 6 months-of-age. (C) Expression of G proteins associated with
adenosine receptor signaling Gnas and Gnaq. Transcript levels of Gnas show significant upregulation in ENT1-/- mice at 6 months-of-age. Gene transcript levels were calculated using ∆∆Ct,
normalized for input based on ribosomal protein 29 (Rps29) expression, and expressed relative
to age-matched WT controls. Data presented as mean ± SEM, n=4-6 mice per group (5-6 thoracic
IVDs pooled per mouse). Asterisk (*) indicates p-value <0.05.
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Transcript levels of Rb1 were significantly down-regulated at 2 months-of-age, but significantly
up-regulated at 6 months-of-age in ENT1-/- AF tissues compared to WT controls (Figure 3.5B).
It is possible that G proteins are involved in signaling from adenosine receptors to
effectors of cell cycle progression, therefore we analyzed the expression of Gαs and Gαq subunits
which are directly coupled to adenosine receptors. Interestingly, levels of Gnas transcript
(encodes Gαs) were significantly up-regulated at only 6 months-of-age in ENT1-/- AF tissues
compared to WT controls (Figure 3.5C).
3.5.6 Loss of ENT1 Alters Cell Proliferation in vivo
To determine if candidate cell signaling pathways were altered by loss of ENT1, we
performed western blot analysis on total protein extracted from AF tissues from 6-month-old WT
and ENT1-/- mice, to coincide with the gene expression signature suggesting increased cell cycle
progression. . The MAPK pathways were of particular interest since they are known regulators
of cell growth and proliferation, and have been shown to be differentially activated in response
to adenosine receptor stimulation8. In AF tissues isolated from mice at 6 months-of-age, our
analysis demonstrated a significant increase in JNK pathway activation (phosphorylation at
threonine 183 and tyrosine 185) in ENT1-/- AF tissue compared to WT control (Figure 3.6A &
B).
To validate the apparent enrichment in pathways associated with cell cycle identified by
molecular analysis of ENT1-/- AF tissues, we examined cell proliferation in situ using
immunohistochemistry (Figure 3.7A). Thoracic spine tissue sections from WT and ENT1-/- mice
at 2 months-of-age showed similar PCNA staining patterns. At this time point, a similar
proportion of PCNA-positive cells were detected in the AF of ENT1-/- and WT mice. However,
at 6 months-of-age there was a striking difference in the number of proliferating cells with almost
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Figure 3.6 MAPK pathway activation in AF tissue from ENT1-/- mice compared to wildtype controls at 6 months-of-age. (A) Western blot analysis of total AF tissue extracts isolated
from 6-month-old WT and ENT1-/- mice. 30 µg of protein (p38 and ERK) or 32 µg of protein
(JNK) was resolved on 7.5% SDS-PAGE and immunoblotted using antibodies reactive for the
phosphorylated forms (upper panels) or total (lower panels) p38, ERK1/2, and JNK (n=4 mice
per genotype; 8 thoracic IVDs pooled per mouse). (B) Quantification was performed by
measurement of average relative density of bands corresponding to phospho-proteins,
normalized to total protein. Data presented as mean ± SEM (n=4 mice per group; 8 thoracic IVDs
pooled per mouse). Asterisk (*) indicates p-value <0.05.

107

Figure 3.7 Proliferation and cell number in AF tissues from ENT1-/- mice compared to wildtype controls. (A) Representative images of PCNA immunolocalization in AF tissue in thoracic
IVDs of WT and ENT1-/- mice at 2 and 6 months-of-age. ENT1-/- and WT mice display similar
patterns of PCNA staining in the AF at 2 months-of-age (brown stain, PCNA-positive cells
indicated by arrows). At 6 months-of-age ENT1-/- mice show a greater number of PCNA-positive
cells in the AF compared to WT controls, with WT sections containing almost no PCNA-positive
cells (images representative of n=3 mice per group). Scale bar = 100 µm. (B) Heat map of
proteomics-based quantification of the abundance of cell proliferation-associated proteins
PCNA, MCM5, and CDK1 in thoracic AF tissue from 2- and 6-month-old WT and ENT1-/- mice
(n=2 mice per group; 4 thoracic IVDs pooled per mouse). The Z score represents the deviation
from the mean of all protein expression values by standard deviation units. Blue represents high
expression values, red represents low expression values. At 2 months-of-age both WT and ENT1/expression values of all proteins depicted are close to the mean. At 6 months-of-age WT
expression values are low compared to the mean and ENT1-/- expression values are high
compared to the mean for PCNA, MCM5, and CDK1. (C) Quantification of PCNA, MCM5, and
CDK1 protein expression in thoracic AF tissue from ENT1-/- mice at 2 and 6 months-of-age,
presented relative to age matched WT mice (n=2 mice per group; 4 thoracic IVDs pooled per
mouse). At 2 months-of-age there is no significant difference in expression of any of the proteins.
At 6 months-of-age there is a significant increase in the expression of PCNA, MCM5, and CDK1
in thoracic AF tissue of ENT1-/- mice compared to WT. Data presented as mean ± SEM. Double
asterisk (**) indicates p-value <0.01 and triple asterisk (***) indicates p-value <0.001. (D) Midcoronal sections of T2/T3 IVDs from 2- and 6-month-old WT and ENT1-/- stained with
hematoxylin & eosin. IVD tissues from ENT1-/- mice at 2 and 6 months-of-age show disruptions
in the organization of AF tissue compared to age matched controls, whereby AF cells do not
appear to be arranged along the concentric collagen lamellae. Furthermore, a larger proportion
of AF cells, particularly in the inner AF, appear as large rounded cells in ENT1-/- IVDs compared
to WT control at both 2 and 6 months-of-age (arrows denote examples). (E) Number of AF cells
in the right lateral aspect of the T2/T3 intervertebral disc in WT and ENT1-/- mice at 2 and 6
months-of-age. No significant difference was detected in the number of AF cells between WT
and ENT1-/- at either time point. Data presented as mean ± SEM (n=3 mice per group).
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no detection of proliferating cells in the intervertebral disc of 6-month-old WT mice compared
to robust detection of PCNA-positive cells in the annulus fibrosus of ENT1-/- mice (Figure 3.7A).
To confirm upregulation of PCNA, we performed proteomic analysis on AF tissues isolated from
the same time points and genotypes used for gene expression analysis. When a heat map of
protein expression values was generated according to Z score, we found that the expression of
PCNA, MCM5, and CDK1 at 2 months-of-age in both WT and ENT1-/- mice showed unchanged
protein expression values (black). This suggests that there is no difference in the expression of
these proteins following loss of ENT1 (Figure 3.7B). However, at 6 months-of-age the
expression of these cell cycle-associated proteins was clearly near the lowest-end (red) of
expression in WT and the higher end (blue) of expression in ENT1-/- mice (Figure 3.7B). This
suggests that there was likely a large difference in expression between genotypes at this time
point. Indeed, we found no significant difference in relative PCNA protein expression between
ENT1-/- mice and WT at 2 months-of-age but a drastic increase of 8.51-fold PCNA expression in
ENT1-/- mice compared to WT at 6 months-of-age (Figure 3.7C). Moreover, proteomic analysis
showed a similar pattern of expression of CDK1 and MCM5 – proteins downstream of PCNA in
cell-cycle checkpoint between G1 and S phase. There was no significant difference in either
CDK1 or MCM5 protein expression at 2 months-of-age in ENT1-/- mice compared to WT control
(Figure 3.7C). However, at 6 months-of-age CDK1 protein expression was significantly
increased by 6.49-fold and MCM5 by 21.04-fold in ENT1-/- mice compared to WT control
(Figure 3.7C).
Since the gene and protein expression signatures suggested alterations in AF cell
proliferation, we assessed the number of AF cells in ENT1-/- AF tissues compared to WT controls
at each time point within a specific tissue compartment (Figure 3.7D). To standardize for

110
anatomical location and region within the IVD, we quantified the number of cells in the right
lateral aspect of the T2/T3 IVD and found no significant difference in the number of AF cells at
either timepoint in ENT1-/- AF tissues compared to WT control. The mean number of AF cells in
this compartment of 2-month-old ENT1-/- AF tissues was 113 vs. 123 in 2-month-old WT AF
tissues (Figure 3.7E). Similarly, the mean number of AF cells in 6-month-old ENT1-/- AF tissues
was 93 vs. 108 in 6-month-old WT tissues (Figure 3.7E). Examination of H&E stained sections
highlighted alterations in AF tissue structure at 2 months-of-age in ENT1-/- mice, marked by the
presence of large rounded AF cells in ENT1-/- mice compare to WT control and an apparent loss
in the alignment of AF cells with the concentric AF lamellae (Figure 3.7D).

3.6 Discussion
Our previous studies demonstrated that loss of ENT1 function in mice leads to ectopic
calcification of fibrocartilaginous paraspinal tissues and sternocostal articulations 5. Importantly,
the mechanism(s) underlying ectopic calcification following loss of ENT1 function are not
understood, with only a limited subset of candidate pathways investigated in IVD tissues of
ENT1-/- mice 4. To better understand the cellular changes associated with loss of ENT1 in the
intervertebral disc, the current study employed transcriptional profiling paired with bioinformatic
analyses to identify changes both preceding and associated with ectopic calcification of AF
tissues in ENT1-/- mice. Using targets identified by bioinformatic analyses, we show increased
cell proliferation in the annulus fibrosus of the intervertebral disc associated with increased JNK
MAPK activation and deregulated gene expression of E2f transcription factors, cyclin dependent
kinases, and the Rb and Rbl E2f-associated proteins.
The bioinformatic analyses conducted on the global gene expression data highlighted
several interesting aspects. First, principal component analysis showed that while all biological
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replicates grouped most closely together than to other samples, the 6-month-old ENT1-/- mice
showed the highest degree of similarity. This suggests consistencies in the cellular pathways
associated with ectopic AF calcification in ENT1-/- mice, supporting further use of this model to
study the biological processes of aberrant calcification. Interestingly, all comparisons of changes
based on age and genotype showed drastically more genes up-regulated than down-regulated. Of
note, compared to age-matched WT controls 261 genes were found to be dysregulated in AF
tissues from ENT1-/- mice at 2 months-of-age while 1727 genes were dysregulated in AF tissues
from ENT1-/- mice at 6 months-of-age. This greater than 6-fold increase in total gene
dysregulation between time points establishes that gene expression becomes increasingly
aberrant coincident with ectopic calcification of the AF in ENT1-/- mice. Moreover, our analysis
identified subsets of genes either common in ENT1-/- mice at each time point, or unique to AF
tissues demonstrating ectopic calcification. These genes warrant further investigation to identify
pathways responsible for the induction of ectopic calcification in ENT1-/- mice.
Previous studies by our group suggest that decreased expression of inhibitors of soft tissue
mineralization (Mgp, Enpp1, Spp1, Ank) contribute to ectopic calcification of AF tissues in
ENT1-/- mice 4. Although changes in the expression of these genes in our microarray analysis did
not meet the parameters set by this study for significance (>2-fold change), we observed slight
decreases in the expression of Mgp (1.2-fold change), Enpp1 (1.8-fold change), and Spp1 (1.1fold change) in AF tissues from 6-month-old ENT1-/- mice compared to WT controls. To further
investigate changes in gene expression related to mineralization, we queried the GO functional
analyses for terms containing either “bone” or “mineral”. Surprisingly, these terms were far from
the most enriched terms in our dataset. At 2 months-of-age no GO terms were significantly
enriched between genotypes, with only three differentially expressed genes mapping to these
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terms between ENT1-/- and WT AF tissues. Of these, Car2 has been shown to negatively regulate
mineral formation in osteocyte-like cells 24, and it has been suggested that Ctss promotes bone
resorption, as deficiency leads to increased cortical bone mineralized matrix in vivo

25

. Since

Car2 and Ctss are upregulated in ENT1-/- AF tissues compared to WT at 2 months-of-age, this
may reflect a response of AF cells attempting to prevent the early formation of mineral. At 6
months-of-age, multiple “bone” or “mineral” GO terms were significantly enriched in ENT1-/AF tissues compared to WT. The most upregulated genes mapped to the term “bone cell
development”, including Car2, Adam8 and Inpp5d. Although global knockout of Adam8 does
not result in a skeletal phenotype 26, Adam8 stimulates osteoclastogenesis in vitro 27, and when
deleted from osteoclastic lineage cells, results in osteopenia

26

. Also amongst the three most

upregulated genes in this GO term in ENT1-/- AF cells compared to WT was Inpp5d; an inositol
phosphatase that regulates osteoclast and osteoblast activity

28

. Specifically, Inpp5d knockout

mice exhibit osteoporosis, attributed to hyper-resorptive osteoclasts and low alkaline
phosphatase activity in osteoblasts

29

. Increased Inpp5d expression in ENT1-/- AF cells may

therefore be in keeping with our previous finding of increased alkaline phosphatase activity in
these cells compared to WT 4. Thus, Inpp5d is an intriguing target for subsequent study in this
model.
Although there is a small signature of genes related to bone/mineralization in our dataset,
unexpectedly these genes were not identified by bioinformatic analyses as the most significant
changes. Of note, the most up-regulated genes in ENT1-/- AF tissues compared to WT at both 2
and 6-months-of-age included numerous immunoglobulin heavy chain or kappa variable region
transcripts. In the context of the current study, we do not have an explanation for the large foldchanges in these genes; however, they may reflect cellular processes not directly annotated to
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tissue calcification. Of note, although the ectopic calcification of spinal tissues in the ENT1-/mouse was not associated with signs of local tissue inflammation 5, adenosine and adenosine
receptor activation have been shown to regulate the inflammatory and immune response in
inflammatory arthritis affecting T and B cells 19. Further investigation of these cellular pathways
in the ENT1-/- mouse are required to better understand the signature of gene expression detected.
The bioinformatic analyses of gene expression and subsequent immunohistochemical,
and proteomic analyses demonstrated a dysregulation of cell cycle in ENT1-/- AF cells, associated
with altered expression of E2f transcription factors. The E2f family of transcription factors (E2f18) work in concert to regulate cell cycle progression, with activators (E2f1-3) driving cells to
progress from G1 to S phase, and repressors (E2f4-8) inhibiting cell cycle progression

30,31

.

Importantly, the activity of E2f family members is directly modulated by complex formation
with retinoblastoma protein family members (Rb1, Rbl1, and p130)

31

. To initiate cell cycle

progression, activated cyclins (A, D, and E) and their associated cyclin-dependent kinases (2, 4,
and 6) phosphorylate Rb family members

30,31

thereby triggering a conformational change that

releases E2fs from the complex to bind their target genes

31

. We demonstrated, by both

microarray analysis and real-time PCR, a significant up-regulation of E2f1, 3, 4, 5, and 7 as well
as Cdk2 and Rb1 in ENT1-/- compared to WT controls at 6 months-of-age. It is interesting to note
that at 2 months-of-age, transcript levels of these genes, save E2f7, were significantly downregulated in ENT1-/- compared to WT controls. It is tempting to speculate that this finding may
be a result of isolating a snapshot of a signaling cascade in transition, given the complex network
of feedback loops amongst the Rb/E2f pathways

30,31

. Further analysis of AF tissues at

intermediary time points are required to better understand this temporal relationship.
We also aimed to assess whether these molecular changes in cell cycle pathways were

114
associated with increased cell number by histological analysis of AF tissues. Despite the
dysregulation of cell cycle-associated markers, no difference in AF cell number in situ was
detected between genotypes at the time points assessed. It is possible that the cellular changes
associated with loss of ENT1 function in AF cells promote increased entry into the cell cycle,
but cells either do not progress through to the end of the cell cycle or become senescent. However,
analysis of our gene expression data showed changes in effectors mapping to all stages of the
cell cycle (Supplementary Material) and preliminary analysis of senescence-associated genes
showed no change in ENT1-/- AF cells compared to WT controls. We therefore postulate that the
lack of increase in cell density in the ENT1-/- AF may result from increased cell apoptosis. If so,
it is possible that apoptosis contributes to nucleation of mineral in AF tissue. A role for apoptosis
in mineralization has been documented in osteoarthritic cartilage, where phosphatidylserine on
apoptotic bodies is exposed to the extracellular space, allowing for the accumulation of calcium
and inorganic phosphate 32. A similar mineralization mechanism has been reported to occur in
both human mesenchymal stem cell and vascular smooth muscle cell culture 33-35. Although our
previous studies did not detect an increase in apoptosis in areas of ectopic calcification localized
to the paraspinal ligaments in the ENT1-/- mouse 5, this analysis was limited to regions associated
with advanced calcification and may not have captured the cellular events associated with early
pathological changes.
The dramatic alterations we detected in cell cycle pathways in ENT1-/- AF cells were
unexpected; however, we postulate that this finding is linked to alterations in adenosine levels in
ENT1-/- mice. Consistent with the loss of ENT1, plasma adenosine was significantly increased in
ENT1-/- mice compared to WT controls at 2 months-of-age 5. Moreover, extracellular adenosine
levels are increased in ENT1-/- cardiomyocytes compared to WT controls associated with
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increased cAMP levels suggesting an increase in activity of adenosine receptors A2A and A2B 6.
The addition of extracellular adenosine has been shown to increase the proliferation of
endothelial cells, osteoblast-like cells, mouse fibroblasts, and rat arterial smooth muscle cells 3638

. Furthermore, adenosine A2A receptor stimulation has been shown to increase the expression

of numerous cell cycle-associated proteins including CCNE, CCND1, CDK2, and CDK6 in
mouse skin tissue

39

. Stimulation of adenosine A1, A2A, and A2B receptors has been shown to

increase alkaline phosphatase activity and cell proliferation in human and rat mesenchymal stem
cells 40-42. This is in keeping with the characteristics we previously reported in ENT1-/- mice, as
AF cells isolated from ENT1-/- mouse IVDs demonstrated greater alkaline phosphatase activity
4

. Altered localization of alkaline phosphatase activity was also detected in vivo in the AF of

ENT1-/- mice 4.
Given the reported link between adenosine dysregulation, adenosine receptor stimulation,
altered cell cycle processes, and altered biomineralization, we examined the potential start of this
cascade – G protein gene expression in ENT1-/- AF cells. Adenosine receptors are coupled to the
G proteins Gαs (Gnas gene) and Gαq (Gnaq gene), therefore we postulate that altered stimulation
of A2A and A2B receptors results in the increased Gnas expression we observed in ENT1-/- AF
tissue. Though G protein signaling affects numerous intracellular pathways, we investigated the
MAPK family since their activity is known to be immediately upstream of cyclin, E2f, and cell
cycle alterations. Western blot analysis showed activation of the JNK pathway in ENT1-/- AF
tissues. MAPK pathways are known to affect cell proliferation 8. Interestingly, they can act in
concert; ERK can induce the activation of JNK which ultimately can influence cell proliferation
43

. Subsequent studies will capitalize on a previously described in vitro culture model
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(Supplementary Material) to further explore the association between adenosine receptor
activation, and MAPK-mediated G protein signaling in the regulation of AF cell proliferation.
The current study reports global transcriptome changes associated with loss of ENT1 and
pathological calcification of AF tissues using the ENT1-/- mouse model. Taken together, the
results of this analysis and subsequent validation led us to suggest a potential mechanism by
which increased adenosine levels resulting from loss of ENT1 alters cell cycle processes. We
propose that G protein signaling may activate MAPK signaling and cell cycle progression,
potentially via modulation of PI3K, PLC or PKA activity. Further studies are however required
to assess the role of PI3K, PLC or PKA signaling in the ENT1-/- mouse model

8,9

. The

identification of novel molecular pathways associated with loss of ENT1 and induction of
paraspinal calcification may provide new insight into the mechanisms controlling the initiation
or progression of human diseases, particularly related to proliferation and calcification. These
analyses provide avenues and potential targets for future studies aimed at elucidating the
mechanism causing ectopic calcification in ENT1-/- mice. Importantly, to our knowledge, we
present for the first time an association between ENT1 and cell cycle proliferation via adenosine
signaling, providing an intriguing area of study in the future.
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CHAPTER FOUR

PROTOCOL FOR PARALLEL PROTEOMIC AND METABOLOMIC ANALYSIS OF
MOUSE INTERVERTEBRAL DISC TISSUES
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4.1 Co-Authorship Statement
Experiments were performed by M.A. Veras in the laboratory of C.A. Séguin, M.
Kuljanin in the laboratory of G.A. Lajoie, and Y.J. Lim in the laboratory of B.L. Urquhart. The
majority of the manuscript was written by M.A. Veras with suggestions from Y.J. Lim, M.
Kuljanin, B.L. Urquhart, G.A. Lajoie and C.A. Séguin. All authors were involved in study
conception and design, and analysis and interpretation of the data.
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4.2 Chapter Summary
The comprehensiveness of data collected by “omics” modalities has demonstrated the
ability to drastically transform our understanding of the molecular mechanisms of chronic,
complex diseases such as MSK pathologies, how biomarkers are identified, and how therapeutic
targets are developed. Standardization of protocols will enable comparisons between findings
reported by multiple research groups and move the application of these technologies forward.
Herein, we describe a protocol for parallel proteomic and metabolomic analysis of mouse
intervertebral disc (IVD) tissues, building from the combined expertise of our collaborative team.
This protocol covers dissection of murine IVD tissues, sample isolation, and data analysis for
both proteomics and metabolomics applications. The protocol presented below was optimized
to maximize the utility of a mouse model for “omics” applications, accounting for the challenges
associated with the small starting quantity of sample due to small tissue size as well as the
extracellular matrix-rich nature of the tissue.
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4.3 Introduction
The advent of “omics” technologies has transformed how biological systems are
investigated, and consequently how diseases are diagnosed and treated1. These approaches are
particularly well suited to chronic, complex diseases such as musculoskeletal (MSK)
pathologies2. In recent years, next-generation sequencing-based “omics” methodologies such as
genomics and RNA-Seq have seen a drastic increase in use due in part to standardization,
including library preparation, instrumentation, and data analysis. Over time, and with increased
use of these methodologies has resulted in a substantial reduction in cost, making them even
more accessible for use by the scientific community-at-large3.
Mass spectrometry-based “omics” methodologies such as proteomics and metabolomics
are more nascent, with metabolomics being the most recent, therefore there is a lack of consensus
on methodologies for sample preparation and bioinformatic analysis4. Proteomics can
quantitatively assess the relative abundance of thousands of proteins in a tissue or circulating in
plasma with the sensitivity and dynamic range to allow for high-throughput biological insights
and biomarker discovery5. For instance, proteomics has been used to identify biomarkers of
mortality in older men6, characterize the effects of sustained weight-loss7, determine the
composition of cartilage8, and how cartilage responds to injury and inflammation9. Metabolomics
allows for the comprehensive analysis of all small molecule metabolites in a diseased tissue or
in circulation to develop a functional readout of the pathological state of an organism1. This
technology has been used to develop biomarkers and therapeutic targets for numerous disorders
including diabetic nephropathy, renal failure, cardiovascular disease, and prostate cancer2. Since
mass spectrometry-based proteomic and metabolomic techniques can be used for many sample
types, it can be difficult to standardize instrument parameters, therefore optimization must be
done on a sample-by-sample basis. Moreover, metabolomic techniques have been difficult to
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standardize due to differences in physicochemical properties of metabolites. The differences in
metabolite properties may necessitate the use of several techniques (e.g. LC-MS, GC-MS, NMR)
to be fully comprehensive. However, the comprehensive data collected by these “omics”
modalities has demonstrated the ability to drastically transform our understanding of the
molecular mechanisms of disease, how biomarkers are identified, and how therapeutic targets
are developed. Therefore, it is essential that standardized protocols be developed within specific
fields of research to enable comparisons between findings reported by multiple research groups
and move the application of these technologies forward.
One such field of research is intervertebral disc (IVD) biology, which lacks
standardization of disease models and model organisms. Numerous models of common spine
pathologies such as IVD degeneration have been reported, induced by aging10, mechanical
loading (i.e. compression11 or tail-loop12), surgical injury13-15, or genetic manipulation16-19. Many
of these models have been validated in multiple model organisms including cow, pig, sheep, goat,
dog, rat, and mouse, for which each has advantages and disadvantages20. The lack of
standardization in IVD biology can also be exemplified by recent efforts to determine a
standardized set of cell type-specific phenotypic markers. Cell type-specific markers have been
proposed either by focusing on specific candidate genes or classes in human primary cells21-25
and animal models25-29, or by using unbiased whole transcriptome approaches30-39. Although
these studies have identified a common subset of markers that have helped to define IVD cell
phenotypes, their findings also highlight differences across species34,39-41. This heterogeneity in
model systems and methodologies is not ideal for exploring disease mechanisms at the molecular
level that can then be translated to the clinic.
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For experimental strategies exploring the molecular mechanisms of disease, or seeking
to identify disease biomarkers or therapeutic targets, a key model organism is the mouse. This is
due to the relatively short gestation period and lifespan, ease of genetic manipulation, and
robustness of bioinformatic databases compared to those of other organisms. Work by our group
and others have established the strength of mouse models to study IVD biology and common
spine disorders. We have explored the effect of mechanical loading on the IVD in mice42-44 and
used transgenic mice to study IVD development45, disc degeneration16,46, and diffuse idiopathic
skeletal hyperostosis (DISH)47-50. Important insights have likewise been provided by others using
mouse models to study disc development51-53, inflammation54, IVD degeneration10,13,55-58,
calcification59,60, and scoliosis61-63. The multitude of available mouse models of spine pathologies
allows for global molecular comparisons to uncover novel biological insights. The use of
unbiased “omics” approaches increases the likelihood of uncovering novel pathways implicated
in spine pathologies, and therefore candidate targets for therapeutic interventions and novel
biomarkers.
Transcriptomics technologies have been applied extensively to study the IVD, identifying
numerous genes associated with IVD degeneration in model organisms37,39,46,64,65 as well as
humans66-69. In comparison, the use of proteomics has been limited, with a few studies of IVD
degeneration in humans70-72, although access to tissues at various stages of diseases is limited.
Proteomics has also been used in mice for global characterization of the healthy IVD73, to
examine the response to mechanical loading42, to characterize different mouse strains74, and to
investigate ectopic calcification in the IVD48. To date, there have been no metabolomic studies
of murine IVD tissues, and the analysis of human IVD tissues is limited to a single unbiased
metabolite screen using high-resolution magic angle spinning (HR-MAS) nuclear magnetic
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resonance (NMR)75, which is much less sensitive than mass spectrometry (MS) based
metabolomics76. Despite the limitations to the starting quantity of sample associated with the
small size of the mouse, it should be possible to gain novel insights into mechanisms, biomarkers
and therapeutic targets of IVD pathologies using optimized protocols for proteomic and
metabolomic analyses.
Herein, we describe a protocol for parallel proteomic and metabolomic analysis of mouse
IVD tissues, building from the combined expertise of our collaborative team (Figure 4.1). Our
group has lead technical development in proteomics77-81 and applied these methodologies to
develop biomarker panels to improve classifications of ovarian carcinomas82, evaluate the
potential of multi-potent stromal cells for pancreas regeneration83, and developed optimized
protocols to characterize extracellular matrices84-86, or increase the detection of low-abundant
proteins in extracellular matrix-rich samples87. These studies led to the development of the
current protocol for label-free quantitative proteomics of murine IVD tissue48. Our group has
also used metabolomics to develop biomarkers of chronic kidney disease88, muscle response to
exercise in diabetes89, kidney function90, and characterize the association of the microbiome to
atherosclerosis91. The metabolomics methods used previously to assess kidney and muscle
tissues required minimal adaptation for use with murine IVD tissue.
The protocol presented below was optimized to maximize the utility of a mouse model
for “omics” applications, accounting for the challenges of minimal starting quantity of sample
due to small tissue size as well as the extracellular matrix-rich nature of the tissue. The protocol
was developed to investigate proteomic and metabolomic changes in annulus fibrosus tissue from
the thoracic spine of a transgenic mouse model of diffuse idiopathic skeletal hyperostosis

127

Cervical

Thoracic

Lumbar

top 4 (proteomics)

bottom 8 (metabolomics) + plasma

Protein Extraction

Metabolite Isolation

Enzymatic Digest

MS Analysis

Fractionation

Target ID

MS Analysis

Validation Run

Figure 4.1 Schematic overview of protocol for simultaneous assessment of proteomic and
metabolomic changes.
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(DISH). For these analyses, the methods are expected to be robust and reproducible. While
sensitive methods, a primary limitation is obtaining enough tissue from each sample (discs will
have to be pooled) and ensuring complete homogenization. Incomplete homogenization will
result in a lower number of features and ultimately less peptides and metabolites identified.
Importantly, for metabolomics, prior to experimentation, ensure the detector, lockspray and
calibration setups have been performed and the sample cone has been cleaned by sonication in
formic acid. In addition, our method will detect molecules with m/z between 50-1200. Features
greater than 1200 m/z will not be captured.
For our specific experimental question, the protocol was designed to isolate protein and
metabolites from the annulus fibrosus of IVDs within a specific anatomical region from each
mouse; sample isolation should therefore be more straightforward for experiments that allow for
pooling of IVDs from multiple anatomical regions or those focused only on one type of analysis.
This protocol is not limited to a particular genetic background of mouse as IVD size is generally
consistent across strains. Furthermore, this protocol is not limited to thoracic IVDs as lumbar and
tail IVDs would be even larger, and thus easier to isolate samples, though cervical IVDs would
be challenging. Theoretically, this protocol could be used for NP tissue as well, however, there
are typically substantially less NP cells compared to AF cells in an IVD, so tissue yield by weight
(or total protein for proteomics) would need to be equivalent to AF, requiring the use of more
IVDs. However, using a whole IVD should not present any challenges compared to use of AF
alone. Furthermore, these methodologies should be applicable to other small rodent models such
as the rat, as tissue composition is very similar, and tissues are even larger.
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4.4 Materials
4.4.1 Reagents
Proteomics
Ammonium acetate (Sigma-Aldrich, cat. no. 73594)
Ammonium bicarbonate solution
Prepare 50 mM ammonium bicarbonate solution by dissolving ammonium bicarbonate (SigmaAldrich, cat. no. 09830) in HPLC-grade water. This solution can be made ahead of time and
stored up to 2 months at room temperature.
8M urea protein extraction buffer
Prepare protein extraction buffer by mixing 50 mM ammonium bicarbonate, 2% sodium dodecyl
sulfate (SDS; Sigma-Aldrich, cat. no. L6026) and 8 M urea (Sigma-Aldrich, cat. no. 05378) at
pH 8.0. The buffer should be freshly prepared.
DTT reducing solution
Prepare 100 mM dithiothreitol (DTT) solution by dissolving DTT (Sigma-Aldrich, cat. no.
D9779) in HPLC-grade water. This solution should be made fresh to prevent self-quenching of
DTT after solubilization.
IAA alkylating solution
Prepare 100 mM iodoacetamide (IAA) solution by dissolving IAA (Sigma-Aldrich, cat. no.
I1149) in HPLC-grade water. This solution should be made fresh and protected from light.
LC solvent A
LC solvent A is 99% (vol/vol) mass spectrometry-grade water, 1% (vol/vol) mass spectrometrygrade acetonitrile (EMD Millipore, cat. no. AX1056-1) and 0.1% (vol/vol) mass spectrometrygrade formic acid (FA; EMD Millipore, cat. no. 1002641000). This solution can be stored at
room temperature for up to 1 yr.
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LC solvent B
LC solvent B is 99% (vol/vol) mass spectrometry-grade acetonitrile, 1% (vol/vol) mass
spectrometry-grade water and 0.1% (vol/vol) mass spectrometry-grade formic acid (FA). This
solution can be stored at room temperature for up to 1 yr.
Lys-C Aliquot (FUJIFILM Wako Pure Chemical Corporation, cat. no. 121-05063, 20 µg
quantity)
Prepare Lys-C aliquot at a concentration of 0.04 µg/µL in 50 mM ammonium bicarbonate (ABC)
by dissolving 20 µg of enzyme in 500 µL ABC. This can be stored at -20ºC for up to 1 yr.
Trypsin/Lys-C Aliquot (Promega, cat. no. V5071, 20 µg quantity)
Prepare Trypsin/Lys-C aliquot at a concentration of 0.04 µg/µL in 50 mM ammonium
bicarbonate (ABC) by dissolving 20 µg of enzyme in 500 µL ABC. This can be stored at -20ºC
for up to 1 yr.

Metabolomics
Atenolol-d7 (Toronto Research Chemicals, cat. no. A790077, 10 mg quantity)
Prepare a stock solution at a concentration of 1 mg/mL in 50:50 methanol:water (vol/vol, LCMS grade). This can be stored at -20ºC for up to 1 yr.
Chlorpropamide (Sigma Aldrich, cat. no. C1290, 25 g quantity)
Prepare a stock solution at a concentration of 1.38 mg/mL in 50:50 methanol:water (vol/vol, LCMS grade). This can be stored at -20ºC for up to 1 yr.
DL-2-aminoheptanedioic acid (Bachem, cat. no. 4014992, 5 g quantity)
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Prepare a stock solution at a concentration of 8.75 mg/mL in LC-MS grade water. This can be
stored at -20ºC for up to 1 yr.
Flurazepam (Cerilliant, cat. no. F003, 1 mL at 1.0 mg/mL)
Formic acid (EMD Millipore, cat. no. 1002641000, 1 L bottle)
LC-MS grade acetonitrile (EMD Millipore, cat. no. AX1056-1)
Milli-Q water (or other LC-MS grade water)
UPLC Solvents:
Solvent A: Water + 0.1% Formic Acid
To prepare solvent A, fill a 4 L HPLC bottle with 4 L of LC-MS grade water then add 4
mL of formic acid. Cap the bottle and mix by rotating and inverting the bottle. This can
be stored for up to 1 yr at RT.
Solvent B: Acetonitrile + 0.1 % Formic Acid
To prepare solvent B, add 4 mL of formic acid to a 4 L bottle of LC-MS grade acetonitrile.
Cap the bottle and mix by rotating and inverting the bottle. This can be stored for up to 1
yr at RT.
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4.4.2 Equipment
Proteomics
UPLC System: Waters nanoACQUITY UPLC M-Class
Mass Spectrometer: ThermoScientific Q Exactive Plus
Software: MaxQuant 1.5.0.30 and Perseus 1.5.0.8 software packages used for data analysis
Columns:
Trapping column: Waters ACQUITY UPLC M-Class Symmetry C18 Trap Column (100 Å pore
size, 1.7 µm particle size, 25 cm x 75 µm; SKU: 186007496).
Analytical column: Waters ACQUITY UPLC Peptide BEH C18 column (130 Å pore size, 1.7
µm particle size, 25 cm x 75 µm; SKU: 186003556), set column temperature to be maintained
at 35°C.

Metabolomics
UPLC System: Waters ACQUITY UPLC I-Class
Mass Spectrometer: Waters Xevo G2-S QTof
Software: Waters MassLynx 4.1.1 software package used for data acquisition and control of
UPLC and MS parameters
Umetrics EZinfo 2.0 software package (must be purchased) for statistical analysis of
metabolomics data.
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Column: Waters ACQUITY UPLC HSS T3 (100 Å pore size, 1.8 µm particle size, 100 mm x
2.1 mm; SKU: 186003539) reverse-phase C18 column, set column temperature to be maintained
at 45 °C.
4.4.3 Equipment setup/conditions
Proteomics
Liquid chromatography
Use the following LC gradient at a flow rate of 0.3 mL/min for whole proteome analysis (Data
acquisition and analysis section: Proteomics, step 2)
NOTE: Gradients should be optimized for each specific column type, LC, and solvent setups.
Time interval (min)

LC solvent A (%)

LC solvent B (%)

0

95

5

74

67.5

32.5

80

40

60

81

5

95

90

5

95

Mass spectrometry analysis
Settings for whole proteome analysis on a Q Exactive Plus MS instrument are described in the
following table.
NOTE: Instrument parameters may need to be adjusted slightly due to variability in performance
between MS instruments.
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Method Parameter

Value

Polarity

Positive

Mass range (m/z)

400-1500

Micro scans

1

Resolution

70, 000 @ 200 m/z

AGC target

3E6

Maximum injection time (ms)

250

dd-MS2
Micro scans

1

Resolution

17, 500 @ 200 m/z

AGC targets

2E5

Maximum ion time (ms)

64

Loop count

1

Isolation window (m/z)

2

Isolation offset (m/z)

0

Fixed first mass

100

Normalized collision energy

25

Data dependent acquisition

Top12

Threshold (counts)

2E3

Minimum AGC target

3.1E4

Peptide match

Preferred

Exclude isotopes

Enabled

Fragmentation Type

HCD
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Charge state rejection

Unassigned, +1, 7, >8

Lock Mass (445.120025 m/z)

best

Dynamic exclusion (s)

30

Metabolomics
For the Waters ACQUITY system, set injection volume of 2 µL for plasma metabolomics, 5 µL
for disc tissue metabolomics. Randomize the sample injection order for both plasma and disc
runs.
Gradient conditions are as follows:
Gradient Conditions
Time (min)

%B

Flow rate (mL/min)

0.0

1

0.45

2.0

60

0.45

6.0

85

0.45

8.0

99

0.45

10.0

1

0.45

11.0

1

0.45

MS parameters and data acquisition:
NOTE: Instrument parameters may need to be adjusted slightly due to variability in performance
between MS instruments.
Measure metabolites in both positive and negative electrospray ionization (ESI) modes with the
following MS instrument conditions:
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Capillary voltage: 2.00 kV
Cone voltage: 40 V
Source temperature: 150°C
Desolvation gas flow: 1000 L/h
Desolvation gas temperature: 500 °C
Cone gas flow: 50 L/h
Set MS acquisition settings to acquire data in centroid, using the MSE method in resolution mode.
The MSE method allows for the simultaneous generation of precursor (function 1 of MSE method)
and fragment ions (function 2 of MSE method) in a single run. The acquisition period is 11 min,
with 0.05 s scan time and a mass range of 50 – 1200 Da. Set collision energy as 0 V for function
1 and ramp the collision energy from 15 – 50 V for function 2. Use leucine-enkephalin (500
ng/mL) as the lockspray solution to ensure mass accuracy. Infuse the lockspray solution at a flow
rate of 10 µL/min. Set the lockmass to be acquired at intervals of 10 s and averaged over 3 scans.

4.5 Procedure
All aspects of this study were conducted in accordance with the policies and guidelines set forth
by the Canadian Council on Animal Care and were approved by the Animal Use Subcommittee
of the University of Western Ontario (protocol 2017-154; Appendix C).
4.5.1 Blood Plasma Collection
(Timing: ~5 min per mouse)
1. Pre-cool micro-centrifuge to 4ºC.
2. Weigh mice and prepare sodium pentobarbital at a concentration of 270 mg/mL to be
used at a 540 mg/kg dosage.
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3. Prepare 25-gauge blood drawing needles with heparin (Sandoz, cat. no. 10750) coating.
4. Administer sodium pentobarbital (Bimeda-MTC, cat. no. 8EUT002) by intraperitoneal
injection.
5. Once the breathing of the mouse is slowed, perform cardiac puncture and withdraw blood,
aiming to collect 500 µL - 1 mL for an adult mouse.
6. Immediately transfer blood to 1.5 mL microcentrifuge tube and centrifuge at 4 000 RPM
for 10 min at 4ºC to separate plasma from other phases.
7. Immediately transfer plasma supernatant (taking care to avoid the interphase) to a new
1.5 mL microcentrifuge tube. Immediately freeze at -80ºC.
4.5.2 Intervertebral Disc Microdissection
(Timing: 30-45 min per mouse)
1. Fill dewar with liquid nitrogen and prepare aluminum foil pouches for each mouse sample
(1 for metabolomics, 1 for proteomics). Label aluminum foil directly with permanent
marker (adhesive tape will fall off in liquid nitrogen).
2. Following cardiac puncture, rotate mouse to expose the dorsal side and douse fur with
70% ethanol in H20 (vol/vol). Make an incision with scissors (length: 11.5 cm; cutting
edge: 25 mm) just above the tail, taking care to cut only through the skin, and continue
incision up to the skull (Fig. 4.2A, B).
3. Gently peel back skin to expose the spinal column and then make incisions on either side
of the lumbar spine with scissors (through musculature and surrounding tissues) and cut
along each side of the spine to the base of the skull (Fig. 4.2C, D).
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Figure 4.2 Intervertebral disc (IVD)
microdissection. (A-G) Removal of spinal
column. (H-K) Isolation of thoracic spine.
(L-O) Dissection of anterior thoracic spine.
(P-U) IVD microdissection and AF
isolation. (V, W) Snap freezing in liquid
nitrogen. (X, Y) Repetition of previous
steps for entire thoracic spine.
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4. Holding at the base of the tail, lift spine from the body of the mouse (Fig. 4.2E) to make
a transverse cut through the spinal column at the base of the skull (Fig. 4.2F) to remove
the intact spinal column and rinse in PBS (Fig. 4.2G, H).
5. Make transverse cuts within the sacral region (Fig. 4.2I) below the bottom rib (Fig. 4.2J)
and above the top rib to isolate the cervical, thoracic, and lumbar spines (Fig. 4.2K).
Note: The remaining protocol focuses on the annulus fibrosus of the thoracic region, but
techniques should be applicable to NP or intact IVD from any anatomical region.
Furthermore, the caudal region can be used as well in the same manner as long as the skin
and ligaments are removed. However, at least 3 mg of disc tissue is needed to detect
metabolites. Proteomics would require a minimum of 1.5 mg of disc tissue (yielding 4080 µg of protein).
6. Isolate the anterior aspect of the thoracic spine (vertebrae + IVDs) by inserting scissors
into the vertebral foramen (Fig. 4.2L) and cutting along the length of the spinal column
directly adjacent to intervertebral disc bilaterally to remove all musculature, connective
tissue and spinous processes (Fig. 4.2M, N).
7. Use scalpel to scrape off as much soft tissue as possible surrounding the vertebrae and
IVDs (Fig. 4.2O).
8. Use stereoscope to microdissect each individual IVD by using transverse cuts where the
vertebral body meets the IVD on the inferior (Fig. 4.2P) and superior (Fig. 4.2Q) side to
isolate the intact IVD.
9. Once an IVD is isolated, use a scalpel to scrape away the hard, cartilaginous endplate
from both surfaces (Fig. 4.2R) and then lacerate the AF on one side (Fig. 4.2S) and place
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IVD briefly into PBS to allow the NP to leak out (Fig. 4.2T; as previously reported (M.
A. Veras et al., 2020)). Scrape along inner AF to remove any remaining NP tissue.
10. Quickly transfer the AF to aluminum foil pouch (Fig. 4.2U, V) and immediately snap
freeze in liquid nitrogen (Fig. 4.2W). Repeat to collect a total of 4 thoracic AFs adding
each to a single pouch for proteomics. Repeat to collect an additional 8 thoracic AFs into
a single pouch for metabolomics (Fig 4.2X, Y).
CRITICAL STEP: Leave AF tissue in PBS for as little time as possible, only to allow
NP to leak out, as PBS can contaminate mass spectrometer at high concentrations and
metabolites can diffuse out from the tissue into PBS.
11. Once all tissues are snap frozen, remove from liquid nitrogen and weigh to ensure a
minimum of 1.8 mg of tissue for metabolomics and 1 mg for proteomics (corresponding
to ~40-80 µg of protein).
12. Immediately transfer tissue to 1.5 mL low-retention microcentrifuge tubes and store at 80ºC until sample preparation (up to 6 mo).
4.5.3 Proteomics – Protein Extraction
(Summarized in Figure 4.3A; Timing: ~2h)
1. Prepare protein extraction buffer (8 M urea, 50 mM ammonium bicarbonate, 10 mM
dithiothreitol, and 2% SDS). This should be prepared fresh.
2. Mince IVDs into approximately 8 pieces prior to homogenization.
3. Add 100 µL of extraction buffer to each sample and sonicate to homogenize at an
intensity of 1 (Sonic Dismembrator Model 100, Fisher Scientific) using 25 pulses spaced
1 second apart.

141

Proteomics

A

add
enzymes

plastic
insert

homogenate

+ chloroform
+ methanol

IVDs
Homogenize
(Protein extraction
Steps 1-7)

Isolate protein
(Sample preparation
Steps 1-10)

B
Metabolomics

white
protein
disk

protein
pellet

C18
material

Digest protein
(Sample preparation
Steps 11-15)

Load MS
instrument
(Data acquisition
Steps 1-2)

Fractionate
using
StageTips
(Sample preparation
Steps 16-28)

add
internal
standards

metal
beads
magnet
IVDs
metal
beads
Homogenize
in Bullet
Blender
(Metabolite
extraction
Steps 1-2)

homogenate

Remove
Beads
(Metabolite
extraction
Steps 3-7)

Data analysis and
Identification of
Metabolites
Sample
preparation
(Steps 1-10)

Load MS
instrument
(LC-MS/MS acquisition
Steps 1-3)

Validation
run
(Metabolite validation
Steps 1-7)

Figure 4.3 Schematic overview of workflow for proteomics and metabolomics. (A)
Proteomic workflow including homogenization (protein extraction steps 1-7), protein isolation
(sample preparation steps 1-10), protein digestion (sample preparation steps 11-15), fractionation
(sample preparation steps 16-28), and the mass spectrometry instrument. (B) Metabolomic
workflow including homogenization (metabolite extraction steps 1-2), metal bead removal
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validation run (metabolite validation steps 1-7), and the mass spectrometry instrument.
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CAUTION: Always wear protective ear equipment while sonicating. Also, be careful to
sonicate in bursts to avoid melting the sample tube. Excessive heating of the samples in
8 M urea extraction buffer will results in peptide carbamylation. Alternatively, sonication
can be done in a cold room or on ice to minimize heating.
4. Clarify lysates by centrifugation at 16 000 RCF for 5 min at RT and transfer supernatant
to new 1.5mL low-retention microcentrifuge tubes (Fisher Scientific, cat. no. 02-681320).
CRITICAL STEP: Always use low-retention tubes to ensure complete recovery and
minimize loss of peptide or proteins during mass spectrometry sample preparation.
5. Measure protein concentration (in triplicate) using the Pierce 660 nm protein assay
(ThermoFisher Scientific, cat. no. 22662) with a CLARIOstar Plus plate reader (BMG
Labtech).
CRITICAL STEP: Pierce 660 nm assay must be used since DTT will interfere with
quantification of protein concentrations when using the BCA assay.
PAUSE POINT: Samples may be stored at -80ºC indefinitely for future use.
6. Reduce protein extracts using 10 mM DTT for 30 min at RT with thorough vortexing.
7. Alkylate protein extracts with 20 mM iodoacetamide for 30 min at RT in the dark with
thorough vortexing.
PAUSE POINT: Samples can be stored at -80ºC for up to 1 year.
4.5.4 Proteomics – Sample Preparation
(Timing: 24-48 hrs)
1. Transfer 25 µg of protein per sample into new 1.5mL low-retention microcentrifuge tubes
for precipitation according to the Wessel and Flügge protocol92.

143
CRITICAL STEP: It is imperative to keep all reagents cold for precipitation. Refrigerate
methanol and chloroform until use.
2. Dilute samples with HPLC-grade H2O to total volume of 150 µL.
3. Add 150 µL cold chloroform (BioShop, cat. no. CCL4027) and 650 µL methanol (Fisher
Scientific, cat. no. A412) and vortex vigorously.
4. Fill remaining volume in 1.5mL low-retention microcentrifuge tubes with H2O and vortex
vigorously.
CRITICAL STEP: Protein precipitate should be visible as an opaque or white solid. If
proteins are not visible, the ratios of solvents need to be adjusted by adding more HPLCgrade water.
5. Centrifuge at 14 000 RCF for 5 min at RT.
6. Preheat ThermoMixer® to 37ºC.
7. Remove the top aqueous layer from samples and discard.
CRITICAL STEP: A white protein ‘disk’ should be visible near the interface between
the chloroform and methanol-water layer.
8. Wash the protein pellet by filling sample tubes with methanol and vortexing vigorously.
9. Centrifuge at 14 000 RCF for 5 min at RT.
10. Remove the top aqueous layer from samples and discard (white protein ‘disk’ should still
be visible). Leave sample tubes open on benchtop for 5 min to evaporate all excess
methanol.
CRITICAL STEP: The protein pellet can be weakly attached to the walls of the
centrifuge tube. Take care in removing the final chloroform-methanol solution. If a
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protein pellet is not firmly formed against the walls of the centrifuge tube, centrifuge
again at 14 000 RCF for 5 min.
11. Add 100 µL 50 mM ABC to each sample containing 6.25 µL Lys-C (1:100 enzyme to
protein ratio vol/vol) and 12.5 µL Trypsin/Lys-C (1:50 enzyme to protein ratio vol/vol).
CRITICAL STEP: Do not touch protein pellet at this step as it will stick to the pipette
tip and significant sample loss will occur. Ensure the pellet is removed from the side of
the tube by a short vortex to ensure maximum surface area exposure to enzymes.
12. Place samples in ThermoMixer® at 37ºC overnight (approximately 18 h) at 700 RPM.
13. Add an additional aliquot of 6.25 µL Trypsin/Lys-C (1:100 enzyme to protein ratio
vol/vol) to each sample and continue mixing in ThermoMixer® at 37ºC at 700 RPM for
an additional 4 h.
14. Acidify samples with 10% formic acid (pH 3-4) and centrifuge at 14 000 RCF for 2 min.
Remove supernatant and transfer to new 1.5mL low-retention microcentrifuge tubes.
CRITICAL STEP: Centrifugation must be done following acidification to remove
insoluble material that will interfere with injection into the mass spectrometer.
15. Quantify peptide concentrations with the Pierce BCA assay (ThermoFisher Scientific,
cat. no. 23250).
PAUSE POINT: Samples can be stored at -80ºC for up to 1 yr.
16. Transfer approximately 20 µg of tryptic peptides to a new 1.5 mL low-retention
microcentrifuge tube for basic reversed-phase (RP) fractionation (bRP).
CRITICAL STEP: Due to the low starting quantity of sample material, to maximize the
number of quantifiable peptides, basic reversed-phase fractionation (bRP) must be
performed. This helps reduce bias of increased detection of matrix proteins in an
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extracellular matrix-rich tissue and allow detection of proteins from all cell
compartments.
17. Prepare StageTips by punching 12 discs of C18 using an 18-gauge needle and packing a
200 µL StageTip.
18. Place tips into centrifuge and add 50 µL ACN to each tip and centrifuge at 10 000 RCF
at RT for 2 min. Discard flow through.
CRITICAL STEP: Flow through may vary, so be sure not to dry out C18 completely.
A dry C18 will not retain peptides properly. Adjust speeds and time according to
centrifuge.
19. Prepare elution buffers containing 25 mM ammonium acetate (pH 10) and increasing the
% of ACN for each of 7 fractions as follows: 1) 5% 2) 7.5% 3) 10% 4) 12.5% 5) 15% 6)
17.5% 7) 50%. These solutions can be stored for up to 1 yr at RT.
20. Add ammonium acetate in 50% ACN to tips and centrifuge at 1 000 RCF until all liquid
flows through (approximately 2-3 min). Discard flow through.
21. Add 100% ammonium acetate to tips to equilibrate and centrifuge at 1 000 RCF until all
liquid flows through (approximately 2-3 min). Discard flow through.
22. Turn on condenser SpeedVac (ThermoFisher Scientific) to cool (minimum 30 min prior
to use). Preheat centrifuge attached to condenser to 60ºC to be ready when fractionation
is complete.
23. Resuspend peptide sample in 100 µL of ammonium acetate to ensure the pH is ~10. Load
samples onto the stage tips for centrifugation and to prepare for elution.
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CRITICAL STEP: pH at least 1 sample at this step to ensure it is ~pH 10. Our samples
were around pH 2 to begin, and pH 10 afterward. Determine pH by adding 1 µL sample
to pH strip (Hydrion DRJ pH 1-12, Micro Essential Laboratory cat. no. DJ-910).
24. Centrifuge at 1 000 RCF for 5 min. Collect flow through and reload on to StageTip.
25. Transfer the stage tips that contains bounds peptides into a new collection tube for elution
of peptides using the above-mentioned elution buffers (containing 25 mM ammonium
acetate and varying % of ACN). Centrifuge for 1 000 RCF for 2-5 min until all liquid has
flowed through.
26. Transfer the stage tips to the next collection tube and add the next elution buffer. Repeat
this step 7 times until all the peptides have been eluted. Centrifuge at 1 000 RCF for
approximately 5 min until all liquid has flowed through. Aim for ~20 µL/min flow rate.
The final flow through is fraction 8.
27. To decrease total instrument time needed for peptide analysis, fractions 1, 7 and 8 were
concatenated, leaving 6 total fractions.
CRITICAL STEP: Samples were combined to increase total mass spectrometry time
availability and to ensure each fraction had approximately the same amount of material.
Concatenation strategies will be sample dependent.
PAUSE POINT: Samples can be stored at -80ºC for 1 yr.
28. Quantify fractions using the BCA assay (ThermoFisher Scientific) and calculate volume
needed for 1 µg for sample injection.
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4.5.5 Proteomics – Data Acquisition and Analysis
(Timing: 90min per fraction, 9 h per sample plus additional time for data analysis)
1. Resuspend fractionated peptide samples in 0.1% (vol/vol) formic acid and place into
deactivated glass vials designed for proteomics analysis (TruView LCMS Certified Clear
Glass, Waters SKU: 186005668CV).
2. Inject up to 1 µg of peptides per sample using a nanoAcquity system (Waters, Milford,
MA) and separate peptides on the analytical column maintained at 35˚C. Desalt all
peptide samples using a trapping column (ACQUITY UPLC M-Class Symmetry C18
Trap Column, 100Å, 5 µm, 180 µm x 20 mm) for 5 min using Buffer A (99% H20, 1%
acetonitrile), and separate peptides using an analytical column (ACQUITY UPLC
Peptide BEH C18 column, 130Å, 1.7 µm, 75 µm x 250mm) using Buffer B (5.0% to
32.5% acetonitrile gradient over 74 min), followed by Buffer B 60% acetonitrile over 6
min, at a flow rate of 300 nL/min.
3. Proteomics data acquisition files (Raw files) are analyzed using the Andromeda search
engine in MaxQuant with the Mouse Uniprot Database. For all database searches, set
missed cleavages to 3, set cysteine carbamidomethylation as a fixed modification and
oxidation of methionine residues, N-terminal acetylation (protein) and deamidation (NQ)
were as variable modifications, with a maximum number of modifications per peptide set
to 5 and peptide length specified as ≥6. Precursor mass deviation set to 20 ppm and 4.5
ppm for the first and main searches, respectively. Fragment mass deviation set to 20 ppm.
For filtering, assign protein and peptide level false discover rate (FDR) to 0.01 (1%, for
each) and decoy databases to revert. Finally, enable the match between runs algorithm
and leave all remaining parameters as default.
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4. Bioinformatics analyses can be performed using multiple software packages and we
recommend using the packages that accompanied MaxQuant called Perseus. Load in
protein lists, generated from MaxQuant as text files, in Perseus. Remove proteins that
were identified only by site, reverse sequences and contaminants using the filter function.
To further filter the proteomics dataset, remove quantified proteins that were only found
in one replicate using the valid value filter in Perseus. Categorically annotate each
replicate sample a unique name to identify each sample type using the categorical row
annotator. Perform a two-sample t-test to determine if the mean of each group is
significantly different, generating a list of proteins, their fold changes and p-values for
further downstream analysis.
5. Export list of proteins from Perseus using the export matrix function or by copy and
pasting the matrix in a text or Excel document for further downstream analysis.
4.5.6 Metabolomics – Metabolite Extraction
(Summarized in Figure 4.3B; Timing: ~45 min)
1. For metabolite extraction, transfer tissue to Navy RINO® screw-cap tubes (Next
Advance, cat. no. NAVYR1) and add 300µL cold acetonitrile to each sample tube.
2. Homogenize using the Bullet Blender® Storm (Next Advance, cat. no. BBY24M) set to
Time: 5, and Power: 12, two times.
Note: We found that using the proprietary Bullet Blender was the most efficient method
for multiple samples. However, this step is for simple tissue homogenization which could
be done using a mortar and pestle with liquid nitrogen to freeze the tissue or a tissue
homogenizer.
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3. Remove the metal beads from RINO® tubes using a strong magnet slid upwards slowly
along the outside of the tube.
4. Immediately place tubes into -20ºC freezer for 20 min to allow precipitation of proteins.
5. Cool microcentrifuge to 4ºC while samples are in freezer.
6. Centrifuge samples at 4ºC for 5 min at 14 000 RCF.
7. Remove supernatant and transfer samples to new 1.5 mL microcentrifuge tubes.
PAUSE POINT: Samples can be stored at -80ºC for up to 6 mo.
4.5.7 Metabolomics – Sample preparation
(Timing: ~5 h)
Total volume of solvent required for protein precipitation will depend on number of samples to
be analyzed. Acetonitrile (ACN) is the organic solvent used in this protocol for protein
precipitation. 150 µL of acetonitrile solvent containing internal standards will be added to 50 µL
of each sample for protein precipitation. We recommend making 1.2 times the required amount
of precipitation solvent.
1. To prepare the precipitation solvent, add chlorpropamide, atenolol-d7, flurazepam, and
DL-2-aminoheptanedioic acid to the appropriate volume of LC-MS grade acetonitrile to
achieve concentrations of 1.1 µg/mL, 500 ng/mL, 50 ng/mL, and 17.5 µg/mL,
respectively. This solution should be prepared fresh.
NOTE: Chlorpropamide, atenolol-d7, flurazepam, and DL-2-aminoheptanedioic acid
will serve as the internal standards in the experiment. In our experience, using these
internal standards allows analysis of positive and negative ionization for reverse phase
chromatography.
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2. Thaw samples on ice. Identical sample preparation was done for both AF and plasma
samples.
3. Aliquot 50 µL from each sample into 1.5 mL microcentrifuge tubes.
4. Add 150 µL of ice-cold acetonitrile solvent containing internal standards into each plasma
aliquot tube for protein precipitation (3:1 acetonitrile:plasma vol/vol).
5. Vortex tubes for 30 s, then incubate at −20 °C for 20 min.
6. Centrifuge at 14 000 RCF for 10 min.
7. Remove and transfer 150 µL supernatant from samples into new 1.5 mL microcentrifuge
tubes, being careful not to disturb the pellet/residue at the bottom.
8. Prepare a new set of 1.5 mL microcentrifuge tubes (one for each sample) and add 80 µL
of LC-MS grade water to each.
9. Transfer 20 µL of supernatant into corresponding tubes containing water (1 in 5 (vol/vol)
dilution in water).
10. Vortex the dilution for 10 s.
11. Pool a small volume from each water dilution tube (see note below) into a separate 1.5
mL microcentrifuge tube. This pooled sample will be used for quality control and will be
injected at regular intervals throughout the metabolomics run.
CRITICAL STEP: The amount taken from each diluted sample will depend on the
number of samples. As large metabolomics runs take a long time and the pooled sample
will be injected frequently, you must ensure there is adequate volume to last the entire
analytical run. We recommend pooling enough from each sample to reach a total volume
of 300 µL or more.
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12. Transfer the remaining contents of the water dilution tubes and the pooled sample into
vials designed for mass spectrometry (Deactivated Clear Glass 12 x 32 mm Screw Neck
Total Recovery Vials, Waters SKU: 186000384DV) and cap the vials.
13. Ensure there are no air bubbles in the total recovery vials. If any air bubbles are present,
gently tap the bottom of vials on the benchtop to remove the bubbles.
14. Place sample vials and pooled sample vial in 48-well plates and place the plates into the
UPLC sample manager for injection.
4.5.8 Metabolomics - LC-MS/MS Acquisition
(Timing: ~11 min per sample plus controls)
1. Set injection volume of 2 µL for plasma metabolomics, 5 µL for AF tissue metabolomics.
2. Randomize the sample injection order for both plasma and disc runs but keep it identical
between ionization modes (i.e. negative ionization mode for plasma is the same order as
positive ionization mode).
3. Inject pooled sample 5 times at the very beginning of the run, and then after every 5
sample injections.
CRITICAL STEP: Assign group numbers (G1, G2, G3, etc.) for each of your
experimental groups, taking note of how you’ve assigned them. When making your
sample list for the analysis, include the date of analysis and assigned group numbers in
the file names for each sample (i.e. Aug23_2019_6MonthKO1_Disc_G3_Pos).
4.5.9 Metabolomics – Data Analysis
1. Copy the project folder from run, which contains the “Data” folder (Waters .raw data
files), to the computer where analysis will be completed.
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NOTE: We use a separate computer to analyze the data so other samples can be analyzed
by LC-MS while data analysis is occurring. Data analysis can be performed on the same
computer as acquisition if desired.
2. Open the script “Convert Waters MSe file to mzData file” (Supplementary Material) in
RStudio. This script uses the convert.waters.raw package (which will need to be installed)
to convert .raw data files to .mzData files. Set the input folder to the full file path name
of the “Data” folder and set the output folder to the same file path name of the “Data”
folder, but with “/converted” at the end. This will create a subfolder within “Data” called
“converted” and put all the converted files into it.
CRITICAL STEP: If using Windows and copying the file path name into RStudio, make
sure the slashes separating the directories are forward slashes (“/”) and not backslashes
(“\”). R uses forward slashes to denote separate directories, whereas Windows uses
backslashes.
3. Run the script.
4. Once the script is finished, create a subfolder in “converted” called “Neg”. Move all
.mzData files from the negative ionization mode into the “Neg” subfolder. Within the
“Neg” subfolder, create subfolders for each experimental group, including the pooled run
(i.e. G1, G2, G3, Pool). Place all data files into their appropriate subfolders according to
sample group.
CRITICAL STEP: Ensure that each file has been put into the correct group folder. The
script will not run as intended if this is not the case.
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IPO script
The IPO script (Supplementary Material) is used to optimize parameters for XCMS data
processing for peak picking.
1. In your project folder create another subfolder called “IPO”. Inside “IPO”, create two
folders: “IPO RPLC Neg” and “IPO RPLC Pos”.
2. Copy the .mzData data files of all pooled injections from negative ionization mode, minus
the first 5 pooled injections, into the “IPO RPLC Neg” folder created in the step above.
Repeat for positive ionization mode pooled files into “IPO RPLC Pos”.
3. Change the “setwd” and “save.image” parameters in the IPO script to the appropriate
target folders.
4. Run IPO script.
5. Copy the parameters generated by IPO into a word document.
XCMS Script
XCMS is designed to provide automated processing of LC-MS metabolomics data.
1. In your project folder, create another subfolder called “XCMS”. Inside “XCMS”, create
two folders: “XCMS RPLC Neg” and “XCMS RPLC Pos”.
2. Copy the contents of (project)/Data/converted/Neg (i.e. G1, G2, G3, and Pool folders) to
“XCMS RPLC Neg” and the contents of (project)/Data/converted/Pos to “XCMS RPLC
Pos”.
3. Open XCMS script in R (Supplementary Material), load the XCMS package, and set
working directory to the “XCMS RPLC Neg” folder.
4. Paste over the existing “xset” parameters in the script with the new parameters from IPO.
5. Change xset names to xsetP, xsetR, xsetG, xsetF ensuring that each xset command draws
from the previous (i.e. xsetR draws from xsetP, xsetG draws form xsetR etc.).
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6. Run XCMS lines between markers labeled “here”.
7. Load the CAMERA package.
8. Use the next lines of the XCMS script to make an annotated diffreport
(annotateDiffreport() function, part of the CAMERA package).
9. Continue with the script to generated box plots and extracted ion chromatograms (EICs)
for all detected metabolites with the diffreport() function. Before you do this, you will
need to denote the column numbers of the annotated diffreport that contain your sample
groups. The groups will always start at column 13 (i.e. G1, G2, G3, and Pool are columns
13-16).
10. Repeat steps 3 – 9 for the positive ionization (Supplementary Material) mode files.
11. Create combined positive- and negative-ion diffreport using the combine XCMS script
(Supplementary Material). The first part of this script loads in files that were saved in
the previous scripts for negative and positive ionization modes (saved just before the
CAMERA package was loaded).
12. Follow the rest of the script, and you will generate the files “camAnotNeg.csv” and
“camAnotPos.csv”
13. Use the last script (for combined annotated diffreport) to prepare a final output file for
EZInfo (Supplementary Material). This script will take your annotated diffreport for
negative (camAnotNeg.csv) and positive ionization (camAnotPos.csv), normalize each
mode to an internal standard, combine both modes, evaluate the quality control (pooled
samples) variability, and reorganize/tidy up the data for upload into EZInfo. The steps for
all of these processes are outlined in detail in the script itself.
Note: This step can be done outside of R if desired.
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EZInfo Analysis
1. Proceed to EZInfo analysis to identify potential metabolites-of-interest by uploading the
EZInfo final sheet from the XCMS scripts to a new EZInfo sheet.
2. Click “View” and change the 2nd row (Pos or Neg) to secondary variable by clicking on
drop down arrow, then click “done” at the bottom of the window.
3. Change scaling to “Pareto scaling” by clicking on the “View and change the selected
template” hyperlink and changing the “Scale type for x-variables” to “Pareto”. Ensure
that file location and name are correct at the bottom of the window, then click “finish”.
4. Click refresh and scroll down to find principal component analysis (PCA) plot.
5. On the right side of the window, select “color by” and change to “sample group”.
6. Ensure all “pooled” samples are in the center of the plot, if so, delete pooled samples
from EZInfo final sheet and repeat above EZInfo analysis steps.
7. Generate Orthogonal Projections to Latent Structures Discriminant Analysis (OPLS-DA)
plot by clicking the box of the groups in the legend that you want to compare. Check off
OPLS-DA box at the bottom of the window and click “done”.
8. Create S-plot from OPLS-DA data by clicking “S-plot” at the top of the window. Change
x-axis to p(loadings).
9. Open a new Excel spreadsheet to copy over important columns for identification of
potential metabolites-of-interest.
10. Within EZInfo, click on “Tools” tab, click “List” to retrieve p(corr) values, click on the
top corner to select all and copy to Excel.
11. Within the S-plot window in EZInfo select VIP (Variable Importance in Projection), then
click “Tools”, then “List” to retrieve VIP values and copy to Excel.
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12. Sort the p(corr) and VIP lists by primary ID so that they are in the same order, then cut
the VIP column and past next to p(corr). Dleete remaining two columns from VIP list to
leave 5 columns: Primary ID, PosOrNeg, p(1)P, p(corr), VIP.
13. Filter spreadsheet for p(corr) values greater than 0.4 or lesser than -0.4.
14. Then sort by VIP value. VIP values >0.8 are worth attempting to identify.
Identification of Metabolites
1. For each metabolite-of-interest use the human metabolome database (HMDB) at
hmdb.ca. Specifically, within the “search” tab select “LC-MS Search”. This window will
allow you to enter the m/z of each metabolite-of-interest. Select the correct ion mode
from the drop down menu and select “Unknown” for the Adduct Type. Use a molecular
weight tolerance of 0.01 to generate a stringent list of potential metabolite IDs.
2. From the HMDB list, choose potential metabolite IDs by having a low “Delta” score
(meaning the actual m/z is close to theoretical m/z; 0 means exactly the same), a
potentially relevant biological function and an adduct that is possible in your sample
preparation. (i.e. most likely adducts are multiples of hydrogen ions M+H, M-H or M+2H
etc. adducts adding H20, or ACN makes sense, sodiated ions i.e. M+Na are also common,
potassium or methyl group adducts are extremely unlikely given the ionization energy in
our mass spectrometry method).
3. To better predict the correct metabolite ID from multiple potential options, download the
.MOL file from each respective metabolite page on HMDB and compare the
fragmentation patterns using Mass Fragment in MassLynx as follows.
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4. For each metabolite-of-interest, click on it in the S-plot in EZInfo and select “Variable
Trend Plot” to generate a trace at the bottom of the window. Note the sample that has the
highest value, which will be used to investigate the peak from the chromatogram.
5. Open sample list in the correct mode (Pos or Neg) in MassLynx and select the sample
with the highest value for the metabolite-of-interest. Click on “Display” then select
“Mass” and type in the accurate mass of the metabolite of interest (from the Excel
spreadsheet) into the 1st and 2nd function in the pop-up window and hit Enter.
6. Click “Tools” and select “Mass Fragment”, in the pop-up window, select the .MOL file
saved from HMDB, then click “OK”.
7. A new tab will open, select the correct ionization mode and click “Submit”.
8. View the possible fragments between the different candidate IDs using this strategy. The
lower the number beside a fragment, the more likely it is your metabolite-of-interest.
9. Once you have determined some metabolites-of-interest, you will need to order analytical
standards to validate the metabolite ID using the steps below.
4.5.10 Metabolomics – Metabolite Validation
To confirm the identity of metabolites of interest, analytical standards must be purchased and run
in tandem with experimental samples. If the purchased standard has the same retention time, m/z,
and fragmentation spectrum as the unidentified target analyte in the experimental samples, it is
considered a “level 1” (highest level possible) identification according to a previously defined
categorization system of metabolite identification (Sumner et al., 2007).
Steps of metabolite validation for one metabolite of interest are as follows:
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1. Create a stock solution of your analytical standard. The concentration of stock solution
and the solvent used will depend on the quantity of standard purchased and chemical
properties of the compound, respectively.
2. For your metabolite of interest, determine which experimental group yielded the highest
average signal intensity from the metabolomics run.
3. Pool plasma and/or AF samples from the experimental group with highest average signal
intensity. The amount taken from each sample will depend on the number of samples you
have in that experimental group. We recommend a total pooled volume of 100 µL.
4. Add your stock standard solution to LC-MS grade water and plasma/disc pooled samples
to achieve a concentration of 100 µM and a total volume of 50 µL, creating a “spiked”
water sample, and a “spiked” plasma/disc pooled sample. Prepare a separate aliquot of
50 µL of plasma/disc pooled samples with no standard added (“non-spiked”)
CRITICAL STEP: Use a minimal amount of stock standard solution to avoid drastically
altering the composition of biological matrices. We recommend no more than 1% stock
(v/v).
NOTE: 100 µM is a recommended starting point that typically results in a strong signal
for most metabolites.
5. Continue with sample preparation for “spiked” water, “spiked” plasma/disc pooled
sample, and “non-spiked” plasma/disc pooled sample. Sample preparation from this point
forward is identical to steps 3 – 13 in the metabolomics sample preparation section,
excluding step 10.
6. Analyze prepared samples with the same UPLC and MS parameters as described
previously.
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7. Compare retention time, m/z, and fragmentation spectrum between the various “spiked”
samples and the “non-spiked” sample. If all three categories are match, you have level 1
metabolite identification (Figure 4.4).

4.6 Anticipated Results & Discussion
Proteomics: Based on our experiments using 2- or 6-month-old C57/Bl6 mice, AF tissues
isolated from 4 thoracic IVDs should yield at least 1.5 mg of tissue (wet weight). This should
lead to a total protein yield between 40-80 µg per sample, of which 25 µg is needed per run. With
fractionation, this proteomics protocol consistently quantified >5000 unique proteins per sample
(98% of identified proteins were quantified), a greater than 2-fold increase in detection compared
to our previous method that did not use fractionation and used a different MS instrument73 (Table
4.1). Importantly, proteins are detected from all cell compartments (cytoplasm, nucleus,
mitochondrion, plasma membrane, extracellular matrix) (Figure 4.5), suggesting this protocol
reduces potential bias of high-abundant extracellular matrix proteins in IVD tissue that could
obscure low-abundant intracellular proteins.
Metabolomics: Due to the low concentration of metabolites in the intervertebral disc
compared to plasma, the 300 µL of disc metabolite preparation (generated from 8 thoracic AFs;
~ 3 mg of tissue) will allow for 2-3 metabolomics runs, if samples are pooled for a validation run
with analytical standards. The disc metabolite preparation will not yield high-quality results after
6 months of being stored at -80ºC (loss of signal intensity due to low starting quantity), but
plasma samples will last over 1 year (retaining the same signal intensity). Based on this protocol,
detection of >300 features should be expected in both plasma and IVD samples (Table 4.2).
However, it is important to carefully consider sample size for metabolomics studies, as
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1st function

2nd function

2nd function fragmentation pattern

Figure 4.4 Example validation run for metabolomics using phenyl sulfate identified as a
Level 1 metabolite.
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Table 4.1 Number of unique proteins identified and quantified by proteomics.

Sample

# Unique
proteins
identified

# Unique
proteins
quantified

5527
5418
5418

5404
5340
5340

97.8

5408

98.3

2 month WT 1
2 month WT 2

% Quantified

98.6

2 month WT 3

5501
5501

2 month KO 1

5390

5306

98.4

2 month KO 2

5164

5095

98.7

2 month KO 3

5294

5224

98.7

6 month WT 1

4725

4669

98.8

6 month WT 2

5314

5216

98.2

6 month WT 3

4334

4216

97.3

6 month KO 1

4825

4709

97.6

6 month KO 2

5077

4970

97.9

6 month KO 3

5188

5060

97.5

Average

5146

5051

98.2

Method

# Unique proteins identified

McCann et al., 2016

1940

Veras et al., 2020

5146

Fold-increase in coverage

2.65-fold
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Integral component of plasma membrane

Total proteins annotated to GO term
Proteins in dataset

Extracellular matrix
Nucleolus
Plasma membrane region
Mitochondrion
Cytosol
Nucleus
Membrane
Cytoplasm
Cellular component
0

5000

10000

15000

20000

25000

# of Proteins

Figure 4.5 Gene ontology (GO) cellular component enrichment for proteomics. Proteins
quantified in this study’s datasets in all experimental groups (black bars) are overlaid on the total
proteins annotated to a given GO term (grey bars) for various cellular components. n=3
mice/genotype and age combination (2 mo WT, 2 mo KO, 6 mo WT, 6 mo KO).
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Table 4.2 Number of features detected by metabolomics and number meeting threshold
values (Fold-change ³2 or £-2, p<0.05).

Sample

# Unique metabolites
identified

Plasma

314

IVD

714

Comparison

# Unique metabolites meeting
VIP and pcorr thresholds

6 month WT vs. 6 month KO Plasma

29

6 month WT vs. 6 month KO IVD

29

2 month WT vs. 2 month KO Plasma

24

2 month WT vs. 2 month KO IVD

42

2 month KO vs. 6 month KO Plasma

28

2 month KO vs. 6 month KO IVD

41

2 month WT vs. 6 month WT Plasma

22

2 month WT vs. 6 month WT IVD

88
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abundance of metabolites is often highly variable even within sample groups. We suggest a
minimum of 10 biological replicates stratified by sex to reduce sex-related differences in
metabolite abundance. Metabolomics validation is also critical, whereby one should aim for
Level 1 validation by analytical standard of at least 5 metabolites-of-interest based on criteria
developed in the field93.
Overall, the use of this protocol should be expected to provide additional biological
insights into molecular mechanisms of spine pathologies, biomarker development, and
therapeutic targets beyond the use of genomics or transcriptomics alone. Furthermore, the
acquisition of data by multiple “omics” modalities in the same animal leaves room to integrate
multi-omics datasets in the future when more powerful bioinformatic tools are developed.
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4.7 Supplementary Material
Convert Waters Raw Files Script
## This file contains the code to convert waters .raw files to .mzdata files
## The function to convert files is called convert.waters which is part of the convert.waters.raw
package##
## Use the “convert.waters” function which works as follows
## convert.waters(indir,outdir)
##
##Make sure slashes for directory are "/" and not "\"
##
## indir = the input directory
## outdir = the output directory
library(convert.waters.raw)
convert.waters("E:/Good/Urquharts Projects/James Mouse Plasma Metabolomics day14.PRO/Data","E:/Good/Urquharts Projects/James Mouse Plasma Metabolomics day14.PRO/Data/converted")
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Isotopologue Parameter Optimization Script
##Isotopologue Parameter Optimization (IPO) optimizes XCMS peak picking parameters by
using natural, stable 13C isotopic peaks to calculate a peak picking score. Retention time
correction is optimized by minimizing relative retention time differences within peak groups.
Grouping parameters are optimized by maximizing the number of peak groups that show one
peak from each injection of a pooled sample. The different parameter settings are achieved by
design of experiments, and the resulting scores are evaluated using response surface models.
See https://github.com/glibiseller/IPO/blob/master/vignettes/IPO.Rmd for more info##
##To use this package. Set the working directory to the folder containing only pooled files in
positive or negative mode for your metabolomics run, then paste the code into R##
## Do not include the first 5 pool injections, if the run is long then choose at least 15 pool
injections spread out over the run##
###BEFORE RUNNING THIS####
###Change working directory and "save.image" file name##
library(IPO)
setwd("F:/MassLynx/James ABLE Plasma Metabolomics
RPLC.PRO/IPO/2018_05_18_Plasma RPLC Neg 1of4")
peakpickingParameters<-getDefaultXcmsSetStartingParams('centWave')
#setting levels for min_peakwidth to 2 and 5 (hence 3.5 is the center point)
peakpickingParameters$min_peakwidth<-c(2,5)
peakpickingParameters$max_peakwidth<-c(10,20)
#setting only one value for ppm therefore this parameter is not optimized
peakpickingParameters$ppm<-15
#srl <- SerialParam()
resultPeakpicking<-optimizeXcmsSet(params=peakpickingParameters, subdir='rsmDirectory',
nSlaves=1, BPPARAM = bpparam("SerialParam"))
optimizedXcmsSetObject<-resultPeakpicking$best_settings$xset
retcorGroupParameters<-getDefaultRetGroupStartingParams()
retcorGroupParameters$profStep <- 1
resultRetcorGroup<-optimizeRetGroup(xset=optimizedXcmsSetObject,
params=retcorGroupParameters, subdir="rsmDirectory2")
save.image(file="IPO Parameters for James ABLE Plasma Neg Vials.RData")
writeRScript(resultPeakpicking$best_settings$parameters, resultRetcorGroup$best_settings,
nSlaves = 0)
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Negative Mode Metabolomics XCMS Script
####XCMS Script#####
###For further information outside of this script see XCMS Reference Manual##
##Copy settings from IPO optimization, do not overwrite xset by changing object name on
each line##
##set xsetF as an object you can use later. In this case "xsetRPLCNeg" at end with correct file
name###
setwd("F:/MassLynx/James ABLE Plasma Metabolomics RPLC.PRO/XCMS/Plasma RPLC
Neg 1of4")
##Run all at once FROM HERE##
library(xcms)
xsetP <- xcmsSet(
method = "centWave",
peakwidth
= c(5.252, 32),
ppm
= 25,
noise
= 0,
snthresh
= 10,
mzdiff
= 0.01275,
prefilter
= c(3, 100),
mzCenterFun = "wMean",
integrate
= 1,
fitgauss
= FALSE,
verbose.columns = FALSE,
BPPARAM = bpparam("SerialParam"))
xsetR <- retcor(
xsetP,
method
= "obiwarp",
plottype
= "none",
distFunc
= "cor_opt",
profStep
= 1,
center
= 13,
response
= 1,
gapInit
= 0.8,
gapExtend = 2.688,
factorDiag = 2,
factorGap = 1,
localAlignment = 0)
xsetG <- group(
xsetR,
method = "density",
bw = 0.879999999999999,
mzwid = 0.035,
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minfrac = 1,
minsamp = 1,
max = 50)
xsetF <- fillPeaks(xsetG, BPPARAM = bpparam("SerialParam"))
##TO HERE##
xsetRPLCNeg<-xsetF
save(xsetRPLCNeg,file="RPLC_Plasma_Neg_Mode_XCMS.RData")
#Make a diffreport with CAMERA result to annotate isotopes and adducts. Choose polarity##
##This will only be used if you do not combine polarities##
library(CAMERA)
anN <- annotateDiffreport(xsetRPLCNeg, perfwhm=0.6, polarity = 'negative')
write.csv(anN, "RPLC_Plasma_Neg_annotated_diffreport_1.csv")
##Open up the diffreport created above and take the column names for each group (including
Pool) from the diffreport##
names<-colnames(anN[,13:17])
##"diffreport" function is meant for two groups, so you must specify two groups to get the
function to run.
##However, it will generate EICs and boxplots for all groups##
reporttab<-diffreport(xsetRPLCNeg, "G1", "G2",filebase="All_Samples", eicmax=5000,
eicwidth=60,classeic=names,value="into")
##Use the "All_Samples.csv" to view the Box Plots and EICs of interest...NOT THE
ANNOTATED DIFFREPORT##
##set an R image file name and save the workspace so that you can go back to this if you have
to##
save.image(file="RPLC_Plasma_Neg_Workspace.RData")
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Positive Mode Metabolomics XCMS Script
####XCMS Script#####
###For further information outside of this script see XCMS Reference Manual##
##Copy settings from IPO optimization, do not overight xset by changing object name on each
line##
##set xsetF as an object you can use later. In this case "xsetRPLCPos" at end with correct file
name###
setwd("E:/Good/Urquharts Projects/James Mouse Plasma RPLC
Metabolomics.PRO/XCMS/Pos test")
##Run all at once FROM HERE##
library(xcms)
xsetP <- xcmsSet(
method = "centWave",
peakwidth
= c(5.1656, 39.9),
ppm
= 15,
noise
= 0,
snthresh
= 10,
mzdiff
= -0.01585,
prefilter
= c(3, 100),
mzCenterFun = "wMean",
integrate
= 1,
fitgauss
= FALSE,
verbose.columns = FALSE,
BPPARAM = bpparam("SerialParam"))
xsetR <- retcor(
xsetP,
method
= "obiwarp",
plottype
= "none",
distFunc
= "cor_opt",
profStep
= 1,
center
= 6,
response
= 1,
gapInit
= 0.78,
gapExtend = 2.688,
factorDiag = 2,
factorGap = 1,
localAlignment = 0)
xsetG <- group(
xsetR,
method = "density",
bw = 0.879999999999999,
mzwid = 0.0042,
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minfrac = 1,
minsamp = 1,
max = 50)
xsetF <- fillPeaks.chrom(xsetG, BPPARAM = bpparam("SerialParam"))
##TO HERE##
xsetRPLCPos<-xsetF
save(xsetRPLCPos,file="RPLC_Plasma_Pos_Mode_XCMS.RData")
#Make a diffreport with CAMERA result to annotate isotopes and adducts. Choose polarity##
library(CAMERA)
anP <- annotateDiffreport(xsetRPLCPos, perfwhm=0.6, polarity = 'positive')
write.csv(anP, "RPLC_Plasma_Pos_annotated_diffreport_1.csv")
## take the column names for each group column from the diffreport##
names<-colnames(anP[,13:17])
##"diffreport" function is meant for two groups, so you must specify two groups to get the
function to run.
##However, it will generate EICs and boxplots for all groups##
reporttab<-diffreport(xsetRPLCPos, "G1", "G2",filebase="All_Samples", eicmax=5000,
eicwidth=60,classeic=names,value="into")
##Use the "All_Samples.csv" to view the Box Plots and EICs of interest...NOT THE
ANNOTATED DIFFREPORT##
##set an R image file name and save the workspace so that you can go back to this if you have
to##
save.image(file="RPLC_Plasma_Pos_Workspace.RData")

171
Positive and Negative Combined CAMERA Script
##Integrating Pos and Neg Mode##
setwd("E:/Good/Urquharts Projects/James Mouse Plasma RPLC
Metabolomics.PRO/XCMS/Neg test")
load(file="RPLC_Plasma_Neg_Mode_XCMS.RData") # From the Negative XCMS Script
(i.e."RPLC_Plasma_Neg_Mode_XCMS.RData")
setwd("E:/Good/Urquharts Projects/James Mouse Plasma RPLC
Metabolomics.PRO/XCMS/Pos test")
load(file="RPLC_Plasma_Pos_Mode_XCMS.RData") # From the Positive XCMS Script
(i.e."RPLC_Plasma_Pos_Mode_XCMS.RData")
setwd("E:/Good/Urquharts Projects/James Mouse Plasma RPLC
Metabolomics.PRO/XCMS/Plasma RPLC Combined test")
# load required libraries
library(xcms)
library(CAMERA)
an <- xsAnnotate(xsetRPLCPos)
an <- groupFWHM(an, perfwhm = 0.6)
an <- findIsotopes(an, mzabs = 0.01)
an <- groupCorr(an, cor_eic_th = 0.75)
anP <- findAdducts(an, polarity="positive")
an <- xsAnnotate(xsetRPLCNeg)
an <- groupFWHM(an, perfwhm = 0.6)
an <- findIsotopes(an, mzabs = 0.01)
an <- groupCorr(an, cor_eic_th = 0.75)
anN <- findAdducts(an, polarity="negative")
# combine positive and negative acquisition modes, keeping track of individual modes. # It is
possible to combine the acquisition modes setting positive or negative
# as reference input table.
# comb 1
camAnotNeg <- combinexsAnnos(anP, anN, pos=FALSE, tol=2)
write.csv(camAnot,"camAnotNeg.csv")
camAnotPos <- combinexsAnnos(anP, anN, pos=TRUE, tol = 2)
write.csv(camAnot,"camAnotPos.csv")
library(ProbMetab)
camAnotNeg <- combineMolIon(peaklist=camAnot, cameraobj=anN, polarity="neg")
write.csv(camAnotNeg$molIon, "Overlapping Ions from camAnot Neg.csv")
camAnotPos <- combineMolIon(peaklist=camAnot, cameraobj=anP, polarity="pos")
write.csv(camAnotPos$molIon, "Overlapping Ions from camAnot POS.csv")
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Generate Combined Annotated Diffreport R Script
##Code for annotated diffreport once it is made##
####Step 1####
##Add Pos mz to Neg annotated diffreport and Neg mz to Pos annotated diffreport
setwd("C:/Users/James Lim/Documents/School and Work/Mouse Plasma RPLC
Metabolomics/Day 1- 4 Metabolomics Aug 2019")
Neg<-read.csv("camAnotNeg.csv") ##Read Neg annotated diffreport with Pos annotations
Pos<-read.csv("camAnotPos.csv") ##Read Pos annotated diffreport with Neg annotations
NegIonBoth<-Neg[grep("*Found*", Neg$pos..Mode),] ##subset by ions found in both Neg/Pos
PosIonBoth<-Pos[grep("*Found*", Pos$neg..Mode),] ##subset by ions found in both Neg/Pos
NegPosCombine<-data.frame(NegIonBoth$mz, PosIonBoth$mz) ##combine mz found in both
rownames(NegPosCombine)<-NegPosCombine$NegIonBoth.mz ##set row names to first
column
rownames(Neg)<-Neg[,2] ##set row names to mz column so same as row names of
"NegPosCombine"
NegCombine<-merge(Neg, NegPosCombine, by="row.names", all.x = TRUE) ##merge Neg
with NegPosCombine keeping all Neg rows
NegCombine[is.na(NegCombine)] <- "" ##remove NAs from NegCombine
NegCombine$Row.names<-NULL ##delete Row.names column
NegCombine<-NegCombine[order(NegCombine$X),] ##put Neg back in original order
rownames(NegCombine)<-NegCombine[,1]; NegCombine<-NegCombine[,-1] ##put row
names back in Neg
write.csv(NegCombine,"camAnotNeg_addPos.csv") ##export Neg annotated diffreport with
Pos mz added
write.csv(NegCombine,"NegCombine.csv")
rownames(NegPosCombine)<-NegPosCombine$PosIonBoth.mz ##repeat for Pos mode
rownames(Pos)<-Pos[,2]
PosCombine<-merge(Pos, NegPosCombine, by="row.names", all.x = TRUE)
PosCombine[is.na(PosCombine)] <- ""
PosCombine$Row.names<-NULL
PosCombine<-PosCombine[order(PosCombine$X),]
rownames(PosCombine)<-PosCombine[,1]; PosCombine<-PosCombine[,-1]
write.csv(PosCombine,"camAnotPos_addNeg.csv")
##Stop HERE and proceed to Step 2 and 3 for Neg then do 2 and 3 for Pos##
############################################################################
##########################
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################### NEGATIVE MODE#####################
####Step 2: Normalize to Internal Standard (ISTD)####
##Start with Neg Mode##
##Create "Neg" folder and set it as working directoy
dir.create("Neg")
setwd("Neg")
##For NegCombine, Concatenate the mz column and rt column into first column called "mzrt"
to read as mz_rt and divide rt by 60 to convert to minutes
mzrt<-paste(NegCombine$mz,NegCombine$rt/60,sep = "_")
NegCombine<-data.frame(mzrt,NegCombine)
##Create a subset object of integrated peaks and "mzrt" column using date as a column name
pattern#
NegCombineRaw<data.frame(NegCombine[,"mzrt"],NegCombine[,grep("*Aug23*",colnames(NegCombine))]);
names(NegCombineRaw)[1]<-"mzrt"
##Check column names of all pooled samples are in order
colnames(NegCombineRaw[,grep("*Pooled_Plasma_Neg", colnames(NegCombineRaw))])
##Determine Column Numbers of first 5 pool samples and remove
poolNumbers<-grep("*Pooled_Plasma_Neg", colnames(NegCombineRaw))
NegCombineRaw<-NegCombineRaw[,-poolNumbers[14:16]] #For removing Pool 3-5
NegCombineRaw<-NegCombineRaw[,-poolNumbers[12]] #For removing Pool 2
NegCombineRaw<-NegCombineRaw[,-poolNumbers[1]] #For removing Pool 1
##Check column names of to make sure the first 5 pool are gone
colnames(NegCombineRaw)
##Create a subset of annotations before peaks and annotations after peaks#
NegCombineAnnot<-NegCombine[,-grep("*Aug23*",colnames(NegCombine))] ##subset
without integrated peaks
NegCombineAnnot1<-NegCombineAnnot[,1:(ncol(NegCombineAnnot)-6)]##subset before
peaks
NegCombineAnnot2<-NegCombineAnnot[,(ncol(NegCombineAnnot)5):ncol(NegCombineAnnot)]##subset after peaks
##Make the first column the row names then delete first column
rownames(NegCombineRaw)<-NegCombineRaw[,1]; NegCombineRaw<-NegCombineRaw[,1]
##Find ISTD row based on m/z and retention time of ISTD##
rownames(NegCombineRaw)
##and rename to "ISTD"##
ISTDrow<-grep("275.025418227833_2.50791666666667", rownames(NegCombineRaw))
rownames(NegCombineRaw)[ISTDrow]<-"ISTD"
##Check rownames to confirm
rownames(NegCombineRaw)
##Note if the number of metabolites is too long, just open the "NegCombineRaw" object
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## as a new tab to look for and copy the ISTD number, go back to check replacement with
"ISTD"
##convert to data matrix##
df1 = as.matrix(NegCombineRaw)
##Divide all rows by ISTD Row (Must find ISTD Row Number)##
ISTDMean<-mean(df1["ISTD",], dims = 1) ##calculate mean of all internal standard areas
df1["ISTD",]<-sapply(df1["ISTD",],function(x) x/ISTDMean) ##divide each ISTD by mean
ISTD
ISTD<-t(t(df1)/df1["ISTD",])
##Set base file name for Neg Mode Data
NegFileName<-"Mouse_Plasma_RPLC_camAnotNeg_addPos_"
##export ISTD normalized data for records
write.csv(ISTD,paste0(NegFileName,"ISTD.csv"))
####Step 3:Evaluate QC Variability####
QC<-t(ISTD) ##tranpose ISTD dataframe
QCtb <- QC[grep("*Pooled*",rownames(QC)),] ##subset only Pool injections
QCtb<-t(QCtb) ##transpose again
QCsd<-data.frame(apply(QCtb, 1, sd)); names(QCsd)[1] <- "SD" ##calculate SD for each ion
QCmean<-data.frame(rowMeans(QCtb, dims = 1)) ##calculate mean for each ion
QCrsd<-QCsd/QCmean; names(QCrsd)[1] <- "RSD" ##calculate RSD
QCFinal<-cbind(QCtb,QCrsd) ##add RSD to QCtb dataframe
write.csv(QCFinal,paste0(NegFileName,"QC.csv")) ##export QCFinal for records
##combine annotations with ISTD normalized data for rsd filtering##
##Add RSD values at end of each row##
rsd<-data.frame(NegCombineAnnot1,ISTD,NegCombineAnnot2, QCrsd, row.names = 1)
##keep peaks with RSD<0.3 or 30%##
threshold <- 0.3 ##set threshold
##Trim data by the RSD column which is the last column##
ISTDTrimmed<-subset(rsd, rsd[,ncol(rsd)] < threshold)
ISTDTrimmed = ISTDTrimmed[, -ncol(ISTDTrimmed)] ##remove RSD column
ISTDTrimmed[is.na(ISTDTrimmed)] <- "" ##remove NAs
##Determine max peak intensity in each row##
maxint<-apply(ISTDTrimmed[, grep("*Aug23*",colnames(ISTDTrimmed))], 1, max)
ISTDTrimmed<-data.frame(rownames(ISTDTrimmed),ISTDTrimmed,maxint);
colnames(ISTDTrimmed)[1]<-"mzrt"
##Sort by pcgroup then maxint##
ISTDTrimmed<-ISTDTrimmed[order(ISTDTrimmed$pcgroup,ISTDTrimmed$maxint),]
##Determine maxint for each group using aggregate
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ISTDTrimmedMAX<-aggregate(ISTDTrimmed$maxint, list(pcgroup =
ISTDTrimmed$pcgroup), max); colnames(ISTDTrimmedMAX)[2]<-"maxint"
##merge the Max intensity with ISTDTrimmed by pcgroup (peak clusters)##
ISTDTrimmedMERGE<-merge(ISTDTrimmed,ISTDTrimmedMAX,by = "pcgroup", all.x =
TRUE)
##order by pcgroup then maxint
ISTDTrimmedMERGE<ISTDTrimmedMERGE[order(ISTDTrimmedMERGE$pcgroup,ISTDTrimmedMERGE$maxin
t.x),]
##movepcgroup to end of dataframe##
ISTDTrimmedMERGE<-data.frame(ISTDTrimmedMERGE[,-1],ISTDTrimmedMERGE[,1]);
colnames(ISTDTrimmedMERGE)[ncol(ISTDTrimmedMERGE)]<-"pcgroup"
write.csv(ISTDTrimmedMERGE,paste0(NegFileName,"ISTD_QCTrimmed.csv")) ##export
for records
NegData<-ISTDTrimmedMERGE ##save as NegData object for later
#######Positive MODE########
#####NOTE SOME OBJECTS ARE REUSED AND THEREFORE OVERWRITTEN FROM
NEG ANALYSIS#######
####Step 2: Normalize to Internal Standard####
setwd("..")
##Create "Pos" folder and set it as working directoy
dir.create("Pos")
setwd("Pos")
##For PosCombine, Concatenate the mz column and rt column into first column called "mzrt"
to read as mz_rt and divide rt by 60 to convert to minutes
mzrt<-paste(PosCombine$mz,PosCombine$rt/60,sep = "_")
PosCombine<-data.frame(mzrt,PosCombine)
##Create a subset object of integrated peaks and "mzrt" column using date as a column name
pattern#
PosCombineRaw<data.frame(PosCombine[,"mzrt"],PosCombine[,grep("*Aug23*",colnames(PosCombine))]);
names(PosCombineRaw)[1]<-"mzrt"
##Check column names of all pooled samples are in order
colnames(PosCombineRaw[,grep("*Pooled_Plasma_Pos*", colnames(PosCombineRaw))])
##Determine Column Numbers of first 5 pool samples and remove
poolNumbers<-grep("*Pooled_Plasma_Pos", colnames(PosCombineRaw))
PosCombineRaw<-PosCombineRaw[,-poolNumbers[14:16]] #For removing Pool 3-5
PosCombineRaw<-PosCombineRaw[,-poolNumbers[12]] #For removing Pool 2
PosCombineRaw<-PosCombineRaw[,-poolNumbers[1]] #For removing Pool 1
##Check column names of to make sure the first 5 pool are gone
colnames(PosCombineRaw)
##Create a subset of annotations before peaks and annotations after peaks#
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PosCombineAnnot<-PosCombine[,-grep("*Aug23*",colnames(PosCombine))] ##subset
without integrated peaks
PosCombineAnnot1<-PosCombineAnnot[,1:(ncol(PosCombineAnnot)-6)]##subset before
peaks
PosCombineAnnot2<-PosCombineAnnot[,(ncol(PosCombineAnnot)5):ncol(PosCombineAnnot)]##subset after peaks
##Make the first column the row names then delete first column
rownames(PosCombineRaw)<-PosCombineRaw[,1]; PosCombineRaw<-PosCombineRaw[,-1]
##Find ISTD row##
rownames(PosCombineRaw)
##and rename to "ISTD"##
ISTDrow<-grep("274.21438724246_1.19658333333333", rownames(PosCombineRaw))
rownames(PosCombineRaw)[ISTDrow]<-"ISTD"
##Check rownames to confirm
rownames(PosCombineRaw)
##convert to data matrix##
df1 = as.matrix(PosCombineRaw)
##Divide all rows by ISTD Row (Must find ISTD Row Number)##
ISTDMean<-mean(df1["ISTD",], dims = 1)
df1["ISTD",]<-sapply(df1["ISTD",],function(x) x/ISTDMean)
ISTD<-t(t(df1)/df1["ISTD",])
##Set base file name for Pos Mode Data
PosFileName<-"Mouse_Plasma_RPLC_camAnotPos_addNeg_"
##export ISTD normalized data for records
write.csv(ISTD,paste0(PosFileName,"ISTD.csv"))
####Step 3:Evaluate QC Variability####
QC<-t(ISTD) ##tranpose ISTD dataframe
QCtb <- QC[grep("*Pooled*",rownames(QC)),] ##subset only Pool injections
QCtb<-t(QCtb) ##transpose again
QCsd<-data.frame(apply(QCtb, 1, sd)); names(QCsd)[1] <- "SD" ##calculate SD for each ion
QCmean<-data.frame(rowMeans(QCtb, dims = 1)) ##calculate mean for each ion
QCrsd<-QCsd/QCmean; names(QCrsd)[1] <- "RSD" ##calculate RSD
QCFinal<-cbind(QCtb,QCrsd) ##add RSD to QCtb dataframe
write.csv(QCFinal,paste0(PosFileName,"QC.csv")) ##export QCFinal for records
##combine annotations with ISTD normalized data for rsd filtering##
##Add RSD values at end of each row##
rsd<-data.frame(PosCombineAnnot1,ISTD,PosCombineAnnot2, QCrsd, row.names = 1)
##keep peaks with RSD<0.3 or 30%##
threshold <- 0.3 ##set threshold
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##Trim data by the RSD column which is the last column##
ISTDTrimmed<-subset(rsd, rsd[,ncol(rsd)] < threshold)
ISTDTrimmed = ISTDTrimmed[, -ncol(ISTDTrimmed)] ##remove RSD column
ISTDTrimmed[is.na(ISTDTrimmed)] <- "" ##remove NAs
##Determine max peak intensity in each row##
maxint<-apply(ISTDTrimmed[, grep("*Aug23*",colnames(ISTDTrimmed))], 1, max)
ISTDTrimmed<-data.frame(rownames(ISTDTrimmed),ISTDTrimmed,maxint);
colnames(ISTDTrimmed)[1]<-"mzrt"
##Sort by pcgroup then maxint##
ISTDTrimmed<-ISTDTrimmed[order(ISTDTrimmed$pcgroup,ISTDTrimmed$maxint),]
##Determine maxint for each group using aggregate
ISTDTrimmedMAX<-aggregate(ISTDTrimmed$maxint, list(pcgroup =
ISTDTrimmed$pcgroup), max); colnames(ISTDTrimmedMAX)[2]<-"maxint"
##merge the Max intensity with ISTDTrimmed by pcgroup##
ISTDTrimmedMERGE<-merge(ISTDTrimmed,ISTDTrimmedMAX,by = "pcgroup", all.x =
TRUE)
##order by pcgroup then maxint
ISTDTrimmedMERGE<ISTDTrimmedMERGE[order(ISTDTrimmedMERGE$pcgroup,ISTDTrimmedMERGE$maxin
t.x),]
##movepcgroup to end of dataframe##
ISTDTrimmedMERGE<-data.frame(ISTDTrimmedMERGE[,-1],ISTDTrimmedMERGE[,1]);
colnames(ISTDTrimmedMERGE)[ncol(ISTDTrimmedMERGE)]<-"pcgroup"
write.csv(ISTDTrimmedMERGE,paste0(PosFileName,"ISTD_QCTrimmed.csv")) ##export for
records
PosData<-ISTDTrimmedMERGE ##save as PosData object for later
####Step 4: Combine Mode and Filter Adducts####
###If you want to 1. Filter for Adducts and/or 2. Filter metabolites that ionize in pos and neg,
keeping the more sensitive mode##
setwd("..") ##setwd up one folder
##make dataframe of NegIonBoth, maxint.y and pcgroup for NegData
NegToMergePos<-data.frame(NegData$NegIonBoth.mz,NegData$maxint.y,
NegData$pcgroup); names(NegToMergePos)[1]<-"IonInBoth"
NegToMergePos[NegToMergePos==""]<-NA ##set blank spaces to NA
NegToMergePos<-subset(NegToMergePos,!is.na(IonInBoth)) ##remove NA in
"IonInBoth"Column
##make dataframe of NegIonBoth (used to merge with NegData above), PosIonBoth, maxint.y
and pcgroup for PosData
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PosToMergeNeg<-data.frame(PosData$NegIonBoth.mz,
PosData$PosIonBoth.mz,PosData$maxint.y, PosData$pcgroup); names(PosToMergeNeg)[1]<"IonInBoth"
PosToMergeNeg[PosToMergeNeg==""]<-NA
PosToMergeNeg<-subset(PosToMergeNeg,!is.na(IonInBoth))
NegPosMerge<-merge(NegToMergePos,PosToMergeNeg, by = "IonInBoth", all = TRUE)
##merge Neg and Pos together by IonInBoth
##Determine Neg ions that are lower than Pos ions to be removed
theMaxNegtoRemove<-data.frame(subset(NegPosMerge,
NegPosMerge$NegData.maxint.y<NegPosMerge$PosData.maxint.y))
names(theMaxNegtoRemove)[1]<-"NegIonBoth.mz"
##Combine NegData and Neg Ions to remove then export to neg folder for records##
NegRemoveRaw<-merge(NegData,theMaxNegtoRemove, by="NegIonBoth.mz", all.x =
TRUE) ##merge Neg and the ions to remove sheets
NegRemoveRaw[is.na(NegRemoveRaw)] <- "" ##replace NAs with space
NegRemoveRaw<-as.data.frame(append(NegRemoveRaw, NegRemoveRaw[1], after =
ncol(NegRemoveRaw)-4)) ##move column merged (column 1) to end of data sheet
NegRemoveRaw<-NegRemoveRaw[,-1] ## delete first column
write.csv(NegRemoveRaw,"Neg/NegRemoveRaw.csv", row.names = FALSE)
##You can use this exported spreasheet to check if the correct ions were removed for the
pos/neg merge because it contains all of them
NegFinal<-NegData[!NegData$pcgroup %in% theMaxNegtoRemove$NegData.pcgroup,]
##remove pcgroups in MaxNegtoRemove from Neg
##Determine Pos ions that are lower than Neg ions to be removed
theMaxPostoRemove<-data.frame(subset(NegPosMerge,
NegPosMerge$NegData.maxint.y>NegPosMerge$PosData.maxint.y))
names(theMaxPostoRemove)[3]<-"PosIonBoth.mz"
##Combine PosDataFiltered and Pos Ions to remove then export to Pos folder for records##
PosRemoveRaw<-merge(PosData,theMaxPostoRemove, by="PosIonBoth.mz", all.x = TRUE)
PosRemoveRaw[is.na(PosRemoveRaw)] <- "" ##replace NAs with space
PosRemoveRaw<-as.data.frame(append(PosRemoveRaw, PosRemoveRaw[1], after =
ncol(PosRemoveRaw)-1))
PosRemoveRaw<-PosRemoveRaw[,-1]
write.csv(PosRemoveRaw,"Pos/PosRemoveRaw.csv", row.names = FALSE)
PosFinal<-PosData[!PosData$pcgroup %in% theMaxPostoRemove$PosData.pcgroup,]
PosFinal[is.na(PosFinal)] <- ""
##Export Pos/Neg Trimmed data for records
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write.csv(NegFinal, paste0("Neg/",NegFileName,"PosTrim.csv"), row.names = FALSE)
write.csv(PosFinal, paste0("Pos/",PosFileName,"NegTrim.csv"),row.names = FALSE)
##Filter Trimmed Data for Adducts (Emily Note: A LOT of metabolites are lost here)
NegFinalFiltered<-subset(NegFinal, NegFinal$maxint.x == NegFinal$maxint.y)
PosFinalFiltered<-subset(PosFinal, PosFinal$maxint.x == PosFinal$maxint.y)
##Export Pos/Neg ADDUCT Trimmed data for records
write.csv(NegFinalFiltered, paste0("Neg/",NegFileName,"PosTrim_AdductFiltered.csv"),
row.names = FALSE)
write.csv(PosFinalFiltered,
paste0("Pos/",PosFileName,"NegTrim_AdductFiltered.csv"),row.names = FALSE)
####Step 5: Create EZInfo sheet for Pos and Neg Combined#####
NegEZInfo<-t(data.frame(NegFinalFiltered$mzrt,
NegFinalFiltered[,grep("*Aug23",colnames(NegFinalFiltered))]))
colnames(NegEZInfo)<-NegEZInfo[1,] ##make first row the column names
NegEZInfo<-NegEZInfo[-1,]##delete first row
PosORNeg<-rep("Neg",ncol(NegEZInfo))
NegEZInfo<-rbind(PosORNeg,NegEZInfo)
NegEZInfo<-data.frame(rownames(NegEZInfo),NegEZInfo); rownames(NegEZInfo)<-NULL;
colnames(NegEZInfo)[1]<-"SampleName"
PosEZInfo<-t(data.frame(PosFinalFiltered$mzrt,
PosFinalFiltered[,grep("*Aug23*",colnames(PosFinalFiltered))]))
colnames(PosEZInfo)<-PosEZInfo[1,] ##make first row the column names
PosEZInfo<-PosEZInfo[-1,]##delete first row
PosORNeg<-rep("Pos",ncol(PosEZInfo))
PosEZInfo<-rbind(PosORNeg,PosEZInfo)
PosEZInfo<-data.frame(rownames(PosEZInfo),PosEZInfo); rownames(PosEZInfo)<-NULL;
colnames(PosEZInfo)[1]<-"SampleName"
##Check that samples are in same order for Pos and Neg Mode
data.frame(NegEZInfo$SampleName,PosEZInfo$SampleName)
##Delete Pos mode SampleName columna and combine Neg and Pose dataframes
PosEZInfo$SampleName<-NULL
NegPosCombineEZInfo<-data.frame(NegEZInfo,PosEZInfo)
##String split to obtain group labels
EZInfoGroups<-strsplit(as.character(NegPosCombineEZInfo$SampleName),"_")##string split
EZInfoGroups[1]<-NULL##remove PosORNeg
EZInfoGroups<-as.factor(sapply(EZInfoGroups, "[[",3)) ##obtain group labels, note that the
column number for group labels will depending on your file naming system
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EZInfoGroups<-gsub("Neg","Pooled",EZInfoGroups) ##replace Neg with Pool
EZInfoGroups<-append("",EZInfoGroups)##insert blank cell in list for PosOrNeg
##Add SampleGroup labels##
NegPosCombineEZInfo<-data.frame(append(NegPosCombineEZInfo,
list(SampleGroups=EZInfoGroups), after = 1)); rownames(NegPosCombineEZInfo)<-NULL
##Remove date and Mode from SampleName Column
NegPosCombineEZInfo$SampleName<gsub("Aug23_2019_","",NegPosCombineEZInfo$SampleName)
NegPosCombineEZInfo$SampleName<gsub("_Neg","",NegPosCombineEZInfo$SampleName)
##Export EZinfo csv
write.csv(NegPosCombineEZInfo,
"Mouse_Plasma_RPLC_CombinedMode_EZinfo_NoAdductFilter_Final.csv", row.names =
FALSE)
save.image(file="RPLC Combined Annotated Diffreport R Environment.RData")
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CHAPTER FIVE

MULTI-OMICS APPROACH IMPLICATES LYSOPC METABOLISM AND PI3K/AKT
SIGNALING AXIS IN MURINE DIFFUSE IDIOPATHIC SKELETAL HYPEROSTOSIS
(DISH) PATHOGENESIS
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5.2 Chapter Summary
Mice lacking equilibrative nucleoside transporter 1 (ENT1-/-) demonstrate progressive
calcification of spinal tissues including the annulus fibrosus (AF) of the intervertebral disc (IVD)
that resemble diffuse idiopathic skeletal hyperostosis (DISH) in humans. We previously
investigated the gene expression signature associated with loss of ENT1 using microarray
analyses of AF tissue from wild-type (WT) and ENT1-/- mice prior to calcification (2 months-ofage) and associated with calcification (6 months-of-age). This identified that loss of ENT1mediated adenosine transport leads to increased cell proliferation in the annulus fibrosus of the
IVD. However, transcriptomic changes do not necessarily correlate to changes at the protein
level, nor do they provide indication of the activity of enzymes and thus metabolite abundance
that may likewise contribute to the formation of ectopic calcification in ENT1-/- mice. The current
study was therefore designed to investigate the global proteomic and metabolomic signature
associated with loss of ENT1 and altered systemic adenosine levels, both prior to and coinciding
with ectopic calcification of the IVD. Proteomics confirmed our previous findings of increased
cell proliferation in the AF of ENT1-/- with protein-level changes in cell cycle-related proteins
and MAPK dysregulation. Moreover, we confirmed previous findings of matrix gla protein
downregulation, associating decreases in protein levels with ectopic calcification suggesting that
this protein may play a central role in limiting calcification in the AF in normal circumstances.
Metabolomics revealed that numerous LysoPCs are elevated in both the plasma and AF tissue of
ENT1-/- mice by 6 months-of-age, implicating fatty acid metabolism in DISH pathology.
Integration of proteomic and metabolomic data allowed us to propose a model whereby
dysregulation of phagocytic signaling and cell apoptosis downstream of PI3K/Akt signaling
serve to nucleate mineral formation in the AF of ENT1-/- mice.
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5.3 Introduction
Diffuse

idiopathic

skeletal

hyperostosis

(DISH)

is

a

non-inflammatory

spondyloarthropathy and the second most common form of arthritis characterized by formation
of ectopic mineral along the spine1-3. Pathological findings in DISH include regional calcification
of the anterior longitudinal ligament, paraspinal connective tissues, and annulus fibrosus (AF) of
the intervertebral disc4. Clinical symptoms of DISH include increased spine stiffness, decreased
spinal range of motion5,6, and postural changes (e.g., kyphosis)7,8. Notably, advanced DISH can
result in severe symptoms, such as: dysphagia9, spinal cord/nerve root compression10-12, or
increased risk of vertebral fracture13. Multiple co-morbidities have been associated with DISH
including obesity, dyslipidemia, hypertension, and type 2 diabetes2. However, the molecular
pathways responsible for DISH have not been delineated and it is unclear whether DISH results
in these co-morbid conditions or vice versa. As such, there are no disease-modifying treatments
for people living with DISH; clinical treatment is limited to surgical resection of mineralized
tissue often requiring revision surgery14.
Interestingly, although few familial cases of DISH have been reported, a null mutation in
the gene encoding the equilibrative nucleoside transporter 1 (ENT1/SLC29A1) reported in a
French family results in ectopic calcification of periarticular and spinal tissues resembling
DISH15. Our group has previously reported that deletion of the gene encoding ENT1 (Slc29a1)
results in a phenotype that resembles DISH in humans16. Mice lacking ENT1 (ENT1-/-) develop
calcified lesions associated with paraspinal tissues in the cervical-thoracic region of spine as
early as 2 months-of-age, extending to the lumbar and caudal regions at 6 and 12 months,
respectively16. Histological examination revealed large, irregular accumulations of eosinophilic
material in spinal fibrocartilaginous tissues including ligaments, entheses and the AF of the
intervertebral disc16. Systemic adenosine transport in ENT1-/- mice is also dysregulated with
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increased plasma adenosine levels detected in ENT1-/- mice compared to WT controls16. We also
reported that intracellular adenosine levels are increased in AF cells from ENT1-/- mice compared
to WT controls17. Transcriptomic analysis of ENT1-/- mice revealed increased cell proliferation
in the AF without concomitant increase in tissue cellularity, leading to the theory that increased
proliferation of AF cells may lead to increased apoptosis which could result in phosphatidylserine
being exposed at the cell surface, serving to nucleate mineral formation and initiating the process
of ectopic calcification18. However, transcriptomic changes do not necessarily correlate to
changes at the protein level, nor do they provide indication of the activity of enzymes and thus
metabolite abundance that may likewise contribute to the formation of ectopic calcification in
ENT1-/- mice.
The current study was therefore designed to investigate the global proteomic and
metabolomic signature associated with loss of ENT1 and altered systemic adenosine levels, both
prior to and coinciding with ectopic calcification of the IVD. Our group previously showed that
at 2 months-of-age, ectopic calcification is not detected in the IVDs of the thoracic spine in ENT1/-

mice; however, at 6 months-of-age, ectopic calcifications are consistently detected in the AF in

this region16. Therefore, we simultaneously examined differences in protein expression and
metabolite abundance in thoracic AF tissue from wild-type and ENT1-/- mice at these time points.
Furthermore, we performed metabolomics on plasma isolated from the same mice to correlate
systemic changes with changes in the AF tissue. This allowed us to investigate the proteomic and
metabolomic signatures: i) associated with loss of ENT1 (2 months-of-age, ENT1-/- compared to
WT); ii) coinciding with ectopic AF calcification (6 months-of-age, ENT1-/- compared to WT);
and iii) associated with the progression of tissue calcification (6-month-old ENT1-/- compared to
2-month-old ENT1-/-). We performed bioinformatic analyses of proteome and metabolome data
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at these time points and subsequently validated the metabolomic dataset with internal standards.
Together, these analyses provided a comprehensive overview of cellular changes associated with
ectopic calcification of the AF, and suggest that dysregulation of phagocytic signaling and cell
apoptosis downstream of PI3K/Akt signaling may serve to nucleate mineral formation in the AF
of ENT1-/- mice.

5.4 Materials and Methods
For detailed methodology please refer to Chapter 4, below the methodology is
described briefly.
5.4.1 Animals
ENT1-/- mice (B6.129X1-Slc29a1tm1Msg), generated by deletion of exons 2-4 of the gene
encoding ENT1 (Slc29a1), were generously provided by Dr. Doo-Sup Choi (Mayo Clinic
College of Medicine, Rochester, MN, USA)19. ENT1-/- mice were backcrossed with C57BL/6N
mice (Charles River: Wilmington, MA) and the colony was maintained by breeding heterozygote
mice (ENT+/-) to obtain wild-type (ENT+/+) and knock-out (ENT1-/-) littermates. Genotyping was
performed, as previously described16. Mice were housed in standard cages and maintained on a
12 h light/dark cycle, with rodent chow and water available ad libitum. Male and female mice
were sacrificed at 2 or 6 months-of-age for tissue isolation. All aspects of this study were
conducted in accordance with the policies and guidelines set forth by the Canadian Council on
Animal Care and were approved by the Animal Use Subcommittee of the University of Western
Ontario (protocol 2017-154, Appendix C).
5.4.2 AF Tissue Isolation
IVDs (4 per mouse for proteomics, 8 per mouse for metabolomics) were isolated from
the thoracic spine of 2- or 6-month-old wild-type and ENT1-/- mice. Using a stereomicroscope,
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the AF of intact IVDs were lacerated in phosphate-buffered saline (PBS) to remove the gelatinous
nucleus pulposus. Following microdissection, AF tissues were placed in aluminum foil pouches,
flash frozen in liquid nitrogen and stored at -80°C.
5.4.3 Liquid Chromatography-tandem Mass Spectrometry and Proteomic Data Analyses
For protein extraction, AF tissues (4 thoracic IVDs/mouse) were thawed and sonicated in
buffer containing 8 M urea, 50 mM ammonium bicarbonate (ABC), 10 mM dithiothreitol, and
2% SDS (all from Sigma Aldrich: St. Louis, MO, USA). Lysates were clarified by centrifugation
and protein concentration in the supernatants were measured using the Pierce 660 nm protein
assay (ThermoFisher Scientific: Mississauga, ON, CAN) with a CLARIOstar plate reader (BMG
Labtech: Ortenberg, Germany). Protein extracts were alkylated with 10 mM iodoacetamide
(Sigma Aldrich: St. Louis, MO, USA) for 30 min at room temperature in the dark. Twenty-five
µg of protein per sample was precipitated using chloroform/methanol, as described previously
20

. Peptides were digested overnight in 50 mM ABC containing lysyl endopeptidase (Lys-C)

(Wako: Osaka, Japan; 1:100 enzyme to protein ratio) and trypsin/Lys-C (Promega: Madison, WI,
USA); 1:50 enzyme to protein ratio). A subsequent on-pellet digestion was performed with
trypsin/Lys-C for 4 h. Protein concentration was measured using the Pierce bicinchoninic acid
(BCA) protein assay (ThermoFisher Scientific: Mississauga, ON, CAN) and ~20 µg of tryptic
peptides were fractionated by basic reverse phase fractionation using in-house made StageTips.
Prepared fractions were injected and separated using a nanoAcquity system (Waters: Milford,
MA, USA) on a 25-cm long x 75 µm inner diameter C18 column maintained at 35˚C. All samples
were trapped for 5 min at 99% H20, 1% acetonitrile, and separated using a 5.0% to 32.5%
acetonitrile gradient over 74 min, followed by 60% acetonitrile over 6 min, at a flow rate of 300
nL/min. Fractions were quantified using the BCA assay (ThermoFisher Scientific: Mississauga,
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ON, CAN) and 1 µg of material was injected per fraction. Data analysis was performed with
MaxQuant version 1.5.0.30 using the Andromeda search engine. MS/MS spectra were searched
against the Uniprot database with trypsin specificity. Bioinformatic analysis was performed using
Perseus version 1.5.0.8. Datasets were filtered for proteins containing a minimum of one unique
peptide.
5.4.4 Liquid Chromatography-tandem Mass Spectrometry and Metabolomic Data
Analyses
For metabolite extraction, AF tissues were transferred to Navy RINO® screw-cap tubes
(Next Advance: Troy, NY, USA) and homogenized using a Bullet Blender® Storm (Next
Advance: Troy, NY, USA) in 300 µL cold acetonitrile per sample tube. Metal beads were
removed from RINO® tubes and samples were placed immediately at -20ºC for 20 min to allow
precipitation of proteins. At euthanasia, blood was isolated by cardiac puncture using 25-gauge
blood drawing needles with heparin coating (Sandoz: Boucherville, QC, CAN). Samples were
centrifuged to separate blood fractions, and plasma supernatant was transferred to new tubes
containing 150 µL of acetonitrile solvent with internal standards per 50 µL of each sample.
Samples were placed immediately at -20ºC for 20 min to allow precipitation of proteins,
supernatant was then transferred to new sample tubes. Both plasma and IVD samples were
diluted 1 in 5 with LC/MS grade H20; 2 µL was set for the plasma sample injection volume while
5 µL was set for the AF sample injection volume. Data acquisition and control of UPLC and MS
parameters was done using Waters MassLynx version 4.1.1. Umetrics EZinfo version 2.0 was
used for statistical analysis of metabolomics data. MS features were queried against the human
metabolome database (HMDB) to develop preliminary metabolite IDs. Metabolites-of-interest
were validated using MS-grade standards with a subsequent MS run.
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5.4.5 Bioinformatic Analyses
Proteins and metabolites demonstrating a significant change between groups (2-monthold ENT1-/- vs 2-month-old WT; 6-month-old ENT1-/- vs 6-month-old WT; 6-month-old ENT1-/vs 2-month-old ENT1-/-) were used for functional categorization and pathway analysis. Database
categories were generated based on the Mus musculus annotations for Gene ontology (GO)
analysis (geneontology.org) and Kyoto encyclopedia of genes and genomes (KEGG) pathway
analysis (genome.jp/kegg/). GO and KEGG pathway analyses were performed using a Fisher’s
exact test and the data are presented as enrichment scores.
5.4.6 Statistical Analyses
Statistical analyses were performed with GraphPad Prism 8 Software.

5.5 Results
5.5.1 Overview of Proteomic and Metabolomic Data
Global protein expression in the AF was investigated to decipher changes associated
specifically with loss of ENT1 function, the presence of ectopic calcification, and age in the
ENT1-/- mouse model of DISH. This analysis enabled us to identify proteins significantly altered
in AF tissues associated with: i) loss of ENT1 prior to ectopic AF calcification (2-month-old
ENT1-/- vs. 2-month-old WT; Supplementary Table 5.1); ii) loss of ENT1 associated with
ectopic AF calcification (6-month-old ENT1-/- vs. 6-month-old WT; Supplementary Table 5.2);
iii) change in ENT1-/- tissues over time (6-month-old ENT1-/- vs. 2-month-old ENT1-/-;
Supplementary Table 5.3) (data summarized in Figure 5.1A). Interestingly, in all comparisons,
the majority of proteins were unchanged and the number of proteins whose expression were
significantly changed in each comparison based on threshold of >2-fold change was similar
(Figure 5.1A). The largest change in protein expression was detected when comparing AF tissues
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Aim 1B: Volcano plots of proteomic data
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Figure 5.1 Overview of proteomic and metabolomic data. A. Volcano plots highlighting
differentially expressed proteins in AF tissues from 2-month-old ENT1-/- compared to 2-monthold WT, 6-month-old ENT1-/-compared to 6-month-old WT, and 6-month-old ENT1-/-compared
to 2-month-old ENT1-/- (n=3 mice per group; 4 thoracic IVDs/mouse). Fold-change (x-axis) is
plotted against statistical significance (y-axis) for each comparison. Proteins significantly upregulated are indicated in the top right quadrant of each graph with corresponding total number
of proteins identified, and those down-regulated are indicated in the top left quadrant of each
graph using thresholds of fold-change ≥2 and p<0.05. Proteins that did not differ significantly
for a given comparison are located in the center of the two vertical blue dotted lines. Only proteins
with annotated gene symbols using the UniProt database were included. B. S-plot projections
comparing metabolic features in plasma or AF tissues from 2-month-old ENT1-/- compared to 2month-old WT, 6-month-old ENT1-/- compared to 6-month-old WT, and 6-month-old ENT1-/compared to 2-month-old ENT1-/- (n=10 mice per group; 8 thoracic IVDs/mouse).
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isolated from ENT1-/- mice at 2 and 6 months-of-age (total of 348 proteins altered) (Figure 5.1A).
Global metabolite expression in the AF was similarly investigated to decipher the same
changes as detailed above at the metabolite level. Additionally, circulating metabolite levels in
plasma were compared to metabolite levels in the annulus fibrosus to elucidate changes that are
consistent in both that could be relevant to disease pathology and to identify potential biomarkers
of ectopic calcification. An overview of global metabolomics changes is presented in Figure
5.1B as S-plots. Metabolomics S-plots show that the vast majority of metabolite features are
likely unchanged (near a p[1]P (loadings) value of 0.0) in each comparison, with a small
proportion of metabolite features showing high variable importance in projection (VIP) values
on the fringes of each axis that are predicted to change between comparators. However, S-plots
do not provide information on directionality or magnitude of differences.
5.5.2 Quantification of Protein Expression in the AF
Using label-free quantitative proteomics we characterized total protein expression in the
murine AF and quantified changes associated with aging and loss of ENT1. Table 5.1 presents
the 10 most abundant proteins in each experimental group. The majority of the most highly
abundant proteins were similar between experimental groups, including numerous histones,
actin, hemoglobin subunits, and various extracellular matrix (ECM) proteins. Notably, vimentin
was amongst the 10 most abundant proteins in each experimental group, with the exception of 2month-old ENT1-/- AF tissue. Moreover, matrix gla protein, a regulator of biomineralization, was
detected as the fifth most abundant protein in AF tissue isolated from 6-month-old ENT1-/- mice.
Finally, AF tissues isolated from 6-month-old WT mice abundantly expressed cartilageassociated ECM proteins including cartilage oligomeric matrix protein (COMP) and
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Table 5.1. Ten most abundant proteins quantified in thoracic annulus fibrosus tissue by
intensity-based absolute quantification (iBAQ) value.
2 month WT

2 month ENT1-/-

Protein Name

Gene Symbol

iBAQ value

Protein Name

Gene Symbol

iBAQ value

Hemoglobin subunit
alpha

Hba

10.4652

Histone H4

Hist1h4a

10.3595

Histone H4

Hist1h4a

10.4645

Hemoglobin subunit
beta-1

Hbb-b1

10.1755

Hemoglobin subunit
beta-1

Hbb-b1

10.4148

Hemoglobin subunit
alpha

Hba

10.1626

Ac?n, cytoplasmic 1

Actb

9.96085

Histone H3.3

H3f3a

10.0084

Histone H2A type 1H

Hist1h2ah

9.9325

Ac?n, cytoplasmic 1

Actb

9.93263

Histone H2B type 1C/E/G

Hist1h2bc

9.93122

Histone H2A type 1H

Hist1h2ah

9.90304

Vimen?n

Vim

9.88636

Histone H2B type 1C/E/G

Hist1h2bc

9.82978

Fibromodulin

Fmod

9.87308

Myosin regulatory
light chain 2

Mylpf

9.69441

Histone H3.3

H3f3a

9.87054

Fibromodulin

Fmod

9.68789

Prolargin

Prelp

9.78965

Myosin light chain
1/3

Myl1

9.68597

6 month WT

6 month ENT1-/-

Protein Name

Gene Symbol

iBAQ value

Protein Name

Gene Symbol

iBAQ value

Histone H4

Hist1h4a

9.7883

Histone H4

Hist1h4a

10.1796

Histone H3.3

H3f3a

9.50788

Hba

9.88305

Hemoglobin subunit
beta-1

Hbb-b1

9.4768

Hemoglobin subunit
alpha
Hemoglobin subunit
beta-1

Hbb-b1

9.87388

Hemoglobin subunit
alpha

Hba

9.46214

Histone H2B type 1C/E/G

Hist1h2bc

9.83963

Matrix Gla protein

Mgp

9.42495

Histone H3.3

H3f3a

9.79044

Histone H2B type 1C/E/G

Hist1h2bc

9.38378

Ac?n, cytoplasmic 1

Actb

9.61476

Hyaluronan and
proteoglycan link
protein 1

Hapln1

9.25919

Histone H2A type 1H

Hist1h2ah

9.55621

Vimen?n

Vim

9.19089

Vimen?n

Vim

9.45731

Car?lage oligomeric
matrix protein

Comp

9.17949

Serum albumin

Alb

9.36014

Chondroadherin

Chad

9.16245

Hyaluronan and
proteoglycan link
protein 1

Hapln1

9.34007
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chondroadherin (CHAD). These proteins were not expressed as abundantly in the AF tissues
from the other experimental groups, including AF tissue from 6-month-old ENT1-/- mice.
5.5.3 Dysregulation of AF protein expression in ENT1-/- mice
To identify proteins dysregulated between experimental groups, we compared their
global protein expression signatures. At 2 months-of-age, 74 proteins were significantly upregulated and 121 proteins were significantly down-regulated in the AF of ENT1-/- mice
compared to WT (Figure 5.1A; Supplementary Table 5.1). The three most up-regulated
proteins in the AF of 2-month-old ENT1-/- mice compared to WT were chromodomain-helicaseDNA-binding protein 2 (CHD2), toll-like receptor 13, and cytochrome c oxidase subunit 6A2,
mitochondrial (COX6A2) (Table 5.2). The three most down-regulated proteins in the AF of 2month-old ENT1-/- mice compared to WT were equilibrative nucleoside transporter 1
(ENT1/SLC29A1), epiplakin (EPPK1), and tRNA modification GTPase, mitochondrial
(GTPBP3).
At 6 months-of-age, 109 proteins were significantly up-regulated and 114 proteins were
significantly down-regulated in the AF of ENT1-/- mice compared to WT (Figure 5.1A;
Supplementary Table 5.2). The three most up-regulated proteins in the AF of 6-month-old
ENT1-/- mice compared to WT were H-2 class II histocompatibility antigen, A beta chain (H2AB1), eosinophil-associated ribonuclease A family 1 (EAR1), and proto-oncogene vav (VAV1)
(Table 5.3). The three most down-regulated proteins in the AF of 6-month-old ENT1-/- mice
compared to WT were enoyl-CoA hydratase domain-containing protein 3, mitochondrial
(ECHDC3), equilibrative nucleoside transporter 1 (ENT1/SLC29A1), and folliculin-interacting
protein 2 (FNIP2).
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Table 5.2. Ten most up- and down-regulated proteins (ENT1-/- vs WT at 2 months) in
thoracic annulus fibrosus tissue by comparison using label-free quantification.
2 month ENT1-/- vs. 2 month WT
Protein Name

Protein Symbol

P-value (log10)

Log2 Foldchange

Chromodomain-helicase-DNA-binding protein 2

Chd2

1.94

8.64

Toll-like receptor 13

Tlr13

2.08

6.05

Cytochrome c oxidase subunit 6A2, mitochondrial

Cox6a2

2.61

5.39

Ubiqui?n-like protein 5

Ubl5

2.04

5.20

Mammalian ependymin-related protein 1

Epdr1

4.88

5.10

39S ribosomal protein L13, mitochondrial

Mrpl13

4.09

4.87

Small ubiqui?n-related modiﬁer 3

Sumo3

3.12

3.45

F-box only protein 50

Nccrp1

2.22

3.41

Catechol O-methyltransferase domain-containing protein 1

Comtd1

2.88

3.15

Cyclin-dependent kinase 4 inhibitor C

Cdkn2c

1.57

3.13

SHC-transforming protein 1

Shc1

5.47

-3.56

COX assembly mitochondrial protein 2 homolog

Cmc2

1.98

-3.65

Uridine phosphorylase 2

Upp2

1.44

-3.66

Arylamine N-acetyltransferase 2

Nat2

2.29

-3.75

Protein S100-A3

S100a3

1.98

-3.90

Unconven?onal myosin-X

Myo10

2.17

-4.01

Leukocyte surface an?gen CD47

Cd47

3.45

-4.58

tRNA modiﬁca?on GTPase GTPBP3, mitochondrial

Gtpbp3

2.14

-5.64

Epiplakin

Eppk1

3.33

-5.94

Equilibra?ve nucleoside transporter 1

Slc29a1

4.24

-6.70
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Table 5.3. Ten most up- and down-regulated proteins (ENT1-/- vs WT at 6 months) in
thoracic annulus fibrosus tissue by comparison using label-free quantification.
6 month ENT1-/- vs. 6 month WT
Protein Name

Protein Symbol

P-value (log10)

Log2 Foldchange

H-2 class II histocompa?bility an?gen, A beta chain

H2-Ab1

3.27

3.90

Eosinophil-associated ribonuclease A family 1

Ear1

1.44

3.85

Proto-oncogene vav

Vav1

1.37

3.69

Ribonucleoside-diphosphate reductase subunit M2

Rrm2

2.53

3.41

Large subunit GTPase 1 homolog

Lsg1

1.55

3.25

Aquaporin-4

Aqp4

3.01

3.24

39S ribosomal protein L21, mitochondrial

Mrpl21

2.12

3.22

Thymidine kinase, cytosolic

Tk1

1.35

3.14

Pep?doglycan recogni?on protein 1

Pglyrp1

1.33

3.11

Tyrosine-protein phosphatase non-receptor type substrate 1

Sirpa

2.35

2.92

Suprabasin

Sbsn

1.31

-3.24

Ra]lin-2

R]n2

3.03

-3.26

Mitochondrial coenzyme A transporter SLC25A42

Slc25a42

2.36

-3.62

Protein FAM63A

Fam63a

3.27

-3.67

Kera?n, type I cytoskeletal 28

Krt28

1.56

-4.34

tRNA modiﬁca?on GTPase GTPBP3, mitochondrial

Gtpbp3

2.88

-4.70

Retrotransposon gag domain-containing protein 4

Rgag4

1.37

-4.85

Folliculin-interac?ng protein 2

Fnip2

2.84

-5.88

Equilibra?ve nucleoside transporter 1

Slc29a1

4.07

-7.91

Enoyl-CoA hydratase domain-containing protein 3,
mitochondrial

Echdc3

4.23

-9.55
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When protein expression in the AF of 6-month-old ENT1-/- mice was compared to that of
2-month-old ENT1-/- mice, 196 proteins were significantly up-regulated and 152 proteins were
significantly down-regulated (Figure 5.1A; Supplementary Table 5.3). The three most upregulated proteins in the AF of 6-month-old ENT1-/- mice compared to the AF of 2-month-old
ENT1-/- mice were phospholipid scramblase 1 (PLSCR1), histone H2B type (HIST2/3H2B), and
syntaxin-11 (STX11) (Table 5.4). The three most down-regulated proteins in the AF of 6-monthold ENT1-/- mice compared to the AF of 2-month-old ENT1-/- mice were seminal vesicle secretory
protein 5 (SVS5), CD151 antigen (CD151), and keratin, type 1 cytoskeletal (KRT28).
The association between proteins up-regulated and down-regulated in the group-wise
comparisons was assessed by Venn analysis (Figure 5.2; protein lists provided in
Supplementary Table 5.4). This analysis identified unique protein subsets. For example, 8
proteins were altered in the AF of ENT1-/- mice at both 2 and 6 months-of-age compared to agematched WT mice (4 up-regulated and 4 down-regulated), including signal regulatory protein
alpha (SIRPA) and ENT1/SLC29A1. Nine proteins (3 up-regulated and 6 down-regulated) were
similarly altered in both WT and ENT1-/- AF tissue over time (i.e. 6 month WT vs. 2 month WT
and 6 month ENT1-/- vs. 2 month ENT1-/-), which are likely proteins associated with normal aging
and not ectopic AF calcification. Interestingly, no proteins were up-regulated, but 4 proteins were
down-regulated in the AF of ENT1-/- mice at both 2 and 6 months-of-age compared to agematched WT mice. Moreover, there was a significant decrease in the expression of these 4
proteins between 2 and 6 months-of-age within the ENT1-/- mice. The specific protein expression
signatures highlighted by Venn analysis may contain intriguing candidates for proteins
associated with the loss of ENT1, response of AF cells to ectopic calcification, and the
progression of ectopic calcification.
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Table 5.4. Ten most up- and down-regulated proteins (6 month ENT1-/- vs 2 month ENT1-/) in thoracic annulus fibrosus tissue by comparison using label-free quantification.
6 month ENT1-/- vs. 2 month ENT1-/Protein Name

Protein Symbol

P-value (log10)

Log2 Foldchange

Phospholipid scramblase 1

Plscr1

2.10128

4.61914

Histone H2B type 2-E;Histone H2B type 3-A;Histone H2B
type 3-B

Hist2h2be;Hist3h2ba;Hi
st3h2bb

1.76352

4.25247

Syntaxin-11

Stx11

3.30258

4.17425

Chi?nase-like protein 3

Chil3

3.59964

3.85929

Immunoglobulin J chain

Igj

1.66086

3.60815

Pep?doglycan recogni?on protein 1

Pglyrp1

1.30288

3.32934

Ig gamma-1 chain C region secreted form;Ig gamma-1 chain
C region, membrane-bound form

Ighg1

2.89917

3.11671

Myosin regulatory light chain 2, ventricular/cardiac muscle
isoform

Myl2

2.05704

3.10123

Heat shock protein beta-7

Hspb7

2.11972

3.04291

Protein S100-A14

S100a14

1.48626

2.93406

Phospholipase D4

Pld4

1.33725

-3.11552

Protein FAM63A

Fam63a

4.18547

-3.17555

RNA polymerase-associated protein LEO1

Leo1

1.41283

-3.40366

UBX domain-containing protein 7

Ubxn7

1.41298

-3.40834

Plasma membrane calcium-transpor?ng ATPase 2

Atp2b2

2.12708

-3.59366

Protein FAM180A

Fam180a

2.11488

-3.61968

TSC22 domain family protein 1

Tsc22d1

1.56829

-3.68562

Kera?n, type I cytoskeletal 28

Krt28

1.80506

-3.94231

CD151 an?gen

Cd151

2.40578

-4.33103

Seminal vesicle secretory protein 5

Svs5

1.63683

-4.3312
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a

b

Upregulated
6 month ENT1-/vs. 6 month WT

2 month ENT1-/vs. 2 month WT

SIRPA
C1QA
TNC
TIMP1

6 month ENT1-/vs. 2 month ENT1-/-

6 month WT
vs. 2 month WT

IGJ
IGH3
HMHA1

Downregulated
6 month ENT1-/vs. 6 month WT

6 month ENT1-/vs. 2 month ENT1-/-

2 month ENT1-/vs. 2 month WT

RNASE4
SLC6A6
GTPBP3
SLC29A1

6 month WT
vs. 2 month WT

TPPP3
UAP1
ADPRHL2
RAB4A

POSTN
GOLGA5
STK39
GALE
FNDC3B
CD2AP

Figure 5.2 Venn analysis of proteins altered with age and loss of ENT1 in thoracic annulus
fibrosus (AF) tissues. Venn diagrams depicting the association between proteins A. up-regulated
and B. down-regulated in the group-wise comparisons between 2-month-old ENT1-/- vs 2-monthold WT tissues (blue), 6-month-old ENT1-/- vs 6-month-old WT tissues (yellow), 6-month-old
ENT1-/- vs 2-month-old ENT1-/- tissues (green), and 6-month-old WT vs 2-month-old WT tissues
(red). Proteins that map to specific sectors of the Venn are presented in lists below the diagram.
The threshold for significance was set at >2-fold change, p<0.05. Only proteins with annotated
gene symbols using the UniProt database were included. n=3 mice per group; 4 thoracic
IVDs/mouse.
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5.5.4 Functional characterization of dysregulated proteins reveals candidate pathways for
DISH pathogenesis
To provide insight into the functional categories associated with the changes in protein
expression identified, we performed Kyoto encyclopedia of genes and genomes (KEGG) and
Gene Ontology (GO) analysis. At 2 months-of-age a single KEGG pathway was enriched for in
the proteins differentially expressed in the AF of ENT1-/- mice compared to WT: the HIF-1
signalling pathway which contained proteins up-regulated in ENT1-/- AF tissue compared to WT
such as plasminogen activator inhibitor 1 (PAI-1/SERPINE1) and the insulin receptor (INSR)
(Table 5.5). Surprisingly, there were no KEGG pathways enriched in the comparison between
AF tissues of ENT1-/- mice and WT at 6 months-of-age.
No GO terms were enriched in the comparison between AF tissues of ENT1-/- mice and
WT at 2-months-of-age. In contrast, GO analysis comparing proteins differentially expressed in
AF tissues of ENT1-/- mice to WT at 6 months-of-age identified numerous enriched terms (Figure
5.3). Enriched GO terms associated with biological processes included up-regulation of carbon
dioxide transport (including aquaporin 4; AQP4) and one-carbon compound transport (Figure
5.3A). Moreover, proteins associated with the GO term ossification such as matrix gla protein
(MGP), integrin binding sialoprotein (IBSP) and phosphoethanolamine/phosphocholine
phosphatase (PHOSPHO1) were significantly downregulated in the AF of ENT1-/- mice
compared WT at 6 months-of-age. Enriched GO terms associated with molecular functions
included up-regulated toll-like receptor binding and long-chain fatty acid binding along with
down-regulated calcium binding in the AF of ENT1-/- mice compared WT at 6 months-of-age
(Figure 5.3B).
GO analysis of proteins differentially expressed in the AF of ENT1-/- mice between 2and 6-months-of-age revealed a number of enriched biological processes upregulated in 6-month-
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Table 5.5. Dysregulated proteins annotated to the HIF-1 signalling pathway when protein
expression between 2-month-old ENT1-/- to 2-month-old WT is compared.

Term

Gene Count

% Genes of total

P-value

Fold Enrichment

HIF-1 signalling
pathway

4

5.5

8.90e-03

9

Protein Symbol

Fold-change

Gene Name

CAMK2A

2.2

Calcium/Calmodulin-dependent protein kinase II alpha

INSR

2.7

Insulin Receptor

SERPINE1

5.1

Plasminogen activator inhibitor 1

TIMP1

2.3

Tissue inhibitor of metalloproteinase 1
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a

6 month ENT1-/- vs. 6 month WT
GO Biological Process
Upregulated
response
response to
to cold
cold
antigen processing and presentation of

Protein

Log2 Foldchange

regulationofofmetallopeptidase
metallopeptidase activity
activity
regulation

ntigen
processing
and
presentation
ofof
exogenouse
peptide
MHC
class
antigen
processing
and
presentation
exogenouse
peptide
antigenvia
viaMHC
MHCclass
class
exogenous
peptideantigen
antigen
via
II IIII

Protein

Log2 Foldchange

8800

1.30

6600

2.59

CA2
4400

CA4

carbondioxide
dioxide transport
transport
carbon

2200

3.24

00

AQP4

one-carboncompound
compound transport
transport
one-carbon

Enrichment
Enrichment Score
Score

Downregulated

CYR61

-1.20

THBS3

-1.18

CHRDL1

-1.54

IBSP

-1.76

CTGF

-1.06

JUND

-1.43

PHOSPHO1

-1.56

MGP

-1.41

Protein

Log2 Foldchange

carbohydrate derivative binding

S100A8

2.45

fatty acid derivative binding

S100A9

1.84

long-chain fatty acid binding

SYK

1.86

Protein

Log2 Foldchange

FBLN1

-1.32

skeletal system morphogenesis
skeletal system morphogenesis
ossification
ossification
cartilage development
cartilage development
extracellular structure organization
extracellular structure organization

b

Enrichment Score
Enrichment Score

1
15 5

Part B: Proteome
1
10 0

5 5

0 0

extracellar matrix organization
extracellar matrix organization

GO Molecular Function
Upregulated
nucleotide binding

50

40

30

20

10

0

toll-like receptor binding

Enrichment Score

Downregulated
calcium ion binding
sulfur compound binding
glycosaminoglycan binding
heparin binding

Enrichment Score

40

30

20

10

0

extracellular matrix structural constituent

FBN1

-1.07

FBLN2

-1.33

COMP

-1.33

THBS3

-1.18

VCAN

-1.20

S100A1

-1.18

MATN3

-2.04

SMOC1

-1.45

SCIN

-1.01

ACAN

-1.12

PAM

-1.76

MGP

-1.41

Figure 5.3 GO analysis depicting enriched biological processes and molecular functions in
6 month ENT1-/- vs 6 month WT thoracic annulus fibrosus tissues based on protein
expression. A. The five most enriched GO terms for biological processes are presented based on
upregulated (green) or downregulated (red) proteins. B. The five most enriched GO terms for
molecular functions are presented based on upregulated (green) or downregulated (red) proteins.
The length of each column represents the enrichment score for a given GO term. Proteins
annotated to specific GO terms are listed to the right of the graph. n=3 mice per group; 4 thoracic
IVDs/mouse.
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old ENT1-/- AF, including neutrophil aggregation (Figure 5.4A). Enriched biological processes
down-regulated in 6-month-old ENT1-/- AF compared to 2-month-old ENT1-/- AF included
protein hydroxylation and terms associated with endochondral bone morphogenesis. Our analysis
also demonstrated an enrichment of GO terms for molecular functions, including up-regulation
of RAGE receptor binding and down-regulation of L-ascorbic acid binding in 6-month-old ENT1/-

AF compared to 2-month-old ENT1-/- AF (Figure 5.4B). Notably, dysregulation in the

expression of the calcium-responsive S100 proteins S100A8/9 were associated with multiple
enriched GO terms including RAGE receptor binding, neutrophil aggregation, and long chain
fatty acid binding.
5.5.5 Metabolomics reveals increased LysoPC levels associated with loss of ENT1
To assess metabolic disturbances associated with ectopic calcification, untargeted
metabolomics was used to investigate metabolite features in plasma and AF tissues from WT and
ENT1-/- mice at 2 and 6 months-of-age. To allow for direct correlation between datasets,
proteomic and metabolomic analyses were conducted on tissues isolated from the same mice (AF
from 4 thoracic IVDs per mouse for proteomics, 8 thoracic IVDs per mouse for metabolomics).
Furthermore, both plasma and AF tissue were analyzed from the same mice allowing for the
correlation of metabolite changes in the tissue to those in the plasma. Orthogonal projections to
latent structures discriminant analysis (OPLS-DA) revealed metabolic differences between
experimental groups. Metabolites that met our threshold for variable importance in projection
(VIP) score were further investigated as biomarkers of ectopic calcification and presented in
Tables 5.6 and 5.7. Analysis of the metabolic signature of plasma from 2-month-old ENT1-/- and
2-month-old WT mice identified a number of metabolites that play a role in discriminating the
two qgroups, including taurocholic acid (Table 5.6). Moreover, various phosphatidylcholines
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6 month ENT1-/- vs. 2 month ENT1-/GO Biological Process

Protein

Log2 Foldchange

negative regulation of
DNA duplex unwinding

S100A8

2.12

neutrophil aggregation

S100A9

2.03

Protein

Log2 Foldchange

SYK

1.88

BTK

1.98

Protein

Log2 Foldchange

peptidyl-proline modificaiton

P4HA1

-1.36

collagen fibril organization

PLOD1

-1.43

cartilage development involved
in endochondral bone morphogenesis

CRTAP

-2.00

protein hydroxylation

P4HA2

-1.15

Protein

Log2 Foldchange

oxidoreductase activity, acting on
NAD(P)H, oxygen as acceptor
superoxide-generating
NADPH oxidase activity

S100A8

2.12

S100A9

2.03

RAGE receptor binding

HMGB2

1.24

Protein

Log2 Foldchange

calcium ion binding

P4HA1

-1.36

extracellular matrix structural constituent

PLOD1

-1.43

L-ascorbic acid binding

CRTAP

-2.00

P4HA2

-1.15
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0
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phosphotyrosine residue binding
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0
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Enrichment Score

Downregulated
signaling receptor activity
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0
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Figure 5.4 GO analysis depicting enriched biological processes and molecular functions in
6 month ENT1-/- vs 2 month ENT1-/- thoracic annulus fibrosus tissues based on protein
expression. A. The five most enriched GO terms for biological processes are presented based on
upregulated (green) or downregulated (red) proteins. B. The five most enriched GO terms for
molecular functions are presented based on upregulated (green) or downregulated (red) proteins.
Proteins annotated to specific GO terms are listed to the right of the graph. The length of each
column represents the enrichment score for a given GO term. n=3 mice per group; 4 thoracic
IVDs/mouse.
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Table 5.6. Top 10 metabolites by S-plot VIP value with predicted ID from the comparison
between 2-month-old ENT1-/- and wild-type (WT) for both plasma and annulus fibrosus
tissue samples.

2 month ENT1-/- vs. 2 month WT Plasma
m/z ratio

Ionization
Mode

Metabolite ID

Level of ID

Adduct

514.2837

Neg

Taurocholic acid

1

M-H

Up or
down in
ENT1-/Up

514.2836

Neg

Taurocholic acid

1

M-H

Down

758.5693

Pos

Various Phospha?dylcholines

3

M+H

Up

325.1835

Neg

4-Dodecylbenzenesulfonic Acid

2

M-H

Down

515.2868

Neg

5-Heptyltetrahydro-2-oxo-3-furancarboxylic
acid

3

2M+HacH

Down

512.2677

Neg

Sulfolithocholylglycine

2

M-H

Down

339.1989

Neg

Canrenone

2

M-H

Down

480.2777

Pos

DL-Ornithino-L-alanine

2

2M+ACN+
H

Down

516.2850

Neg

LysoPC(P-16:0)

3

M+K-2H

Down

371.3150

Pos

Diethylhexyl adipate

2

M+H

Down

Adduct

Up or
down in
ENT1-/-

2 month ENT1-/- vs. 2 month WT Annulus Fibrosus
m/z ratio

Ionization
Mode

Metabolite ID

Level of ID

338.3417

Pos

Thromboxane

2

371.3150
174.0763
771.6446

Pos
Neg
Pos

Diethylhexyl adipate
N-Carboxyethyl-g-aminobutyric acid
Pentadecanoylcarni?ne

2
2
2

512.4156

Pos

PE-NMe(22:1(13Z)/24:0)

2

468.3892

Pos

Epoxyguaiene

2

556.4418

Pos

Cedryl acetate (ﬂavoring)

2

424.3627

Pos

PC(o-18:1(9Z)/22:0)

2

600.4680

Pos

DG(14:1n5/0:0/18:4n3)

2

408.3080

Pos

3-Methylbutyl 2-methylbutanoate

2

M+ACN+
H
M+H
M-H
2M+H
M+3ACN+
2H
2M+2H+3
H20
2M+2H+3
H20
M+H+NH
4
M+ACN+
H
2M+ACN+
Na

Down
Down
Up
Down
Down
Down
Down
Down
Down
Down
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Table 5.7. Top 10 metabolites by S-plot VIP value with predicted ID from the comparison
between 6-month-old ENT1-/- and wild-type (WT) for both plasma and annulus fibrosus
tissue samples.
6 month ENT1-/- vs. 6 month WT Plasma
m/z ratio

Ionization
Mode

Metabolite ID

ID
Level

Adduct

496.3401

Pos

2-Palmitoylglycerophosphocholine

1

M+H

Up or
down in
ENT1-/Up

520.3401

Pos

2-linoleoyl-sn-glycero-3-phosphocholine

1

M+H

Up

522.3554

Pos

LysoPC(18:1(9Z))

1

M+H

Up

338.3416

Pos

Guanosine hexaphosphate adenosine

2

M+3H

Up

780.5513

Pos

N/A

4

325.1835

Neg

N/A

4

568.3400

Pos

LysoPC(22:6(4Z,7Z,10Z,13Z,16Z,19Z))

2

M+H

Up

637.3050

Pos

D-Pantethine

1

566.3456

Neg

LysoPE(0:0/20:1(11Z))

3

525.3744

Pos

CL(a-13:0/a-21:0/a-17:0/i-24:0)

3

M+2ACN
+H
M+Hac+
H
M+3Na

Up
Up
Up

6 month ENT1-/- vs. 6 month WT Annulus Fibrosus
Up or
down in
ENT1-/Up

m/z ratio

Ionization
Mode

Metabolite ID

ID
Level

376.2594

Pos

Nordihydrocapsaicin (ﬂavoring)

2

371.3151

Pos

Diethylhexyl adipate

2

M+2ACN
+H
M+H

311.1675

Neg

Tetraalylammonium salt

3

M+Hac-H

Up

650.4386

Pos

3a, 16b-Dihydroxyandrostenone

2

2M+ACN
+H

Down

392.2538

Pos

N/A

4

496.3398

Pos

LysoPC(0:0/16:0)

1

M+H

Up

125.9863

Pos

Dichloromethane

2

M+ACN+
H

Up

681.2957

Neg

Copropporphyrinogen I or III

3

M+Na-2
H

Up

358.9795

Pos

3,4,8,9,10-pentahydroxy-6-oxo-6Hbenzo[c]chromene-1-carboxylic acid

3

M+K

Down

520.3394

Pos

LysoPC(18:2(9Z,12Z))

1

M+H

Up

Adduct

Up

213
(PCs) and lysophosphatidylcholines (LysoPCs) were found in both plasma and AF and contribute
to the differences in metabolic signature between 2-month-old ENT1-/- and 2-month-old WT
mice.

Analysis of

samples from mice at 6

months-of-age identified

numerous

glycerophosphocholines, PCs and LysoPCs in both the plasma and AF that mediate the different
metabolic signatures observed between ENT1-/- and WT mice (Table 5.7).
A subset of potential metabolite biomarkers predicted to be altered by loss of ENT1 but
not by age in either the plasma, AF, or both were confirmed with analytical standards in an
additional metabolomics validation run. Relative quantification of confirmed LysoPC
metabolites are presented in Figure 5.5A, and confirmed additional metabolites are presented in
Figure 5.5B. Of note, the LysoPC 18:2 isoform was elevated in 2-month-old ENT1-/- compared
to 2-month-old WT AF tissue, this was maintained at 6 months-of-age at which time it also
becomes elevated in the plasma of ENT1-/- mice. At 6 months-of-age, ENT1-/- mice also showed
increased levels of LysoPC 17:0 in both plasma and AF compared to 6-month-old WT, while
LysoPC 16:0 was increased in ENT1-/- mouse plasma compared to WT at this time point.
5.5.6 PI3K/Akt signaling may be associated with loss of ENT1 in AF cells
Multiple proteins identified by proteomic analysis mapped to various parts of the
PI3K/Akt signaling pathway. To visualize the proteins in this pathway differentially expressed
in the AF of ENT1-/- mice compared to WT, dysregulated proteins were mapped to the KEGG
PI3K/Akt pathway schematic (Figure 5.6). At 2 months-of-age upstream components of the
PI3K/Akt pathway are dysregulated in ENT1-/- mice, including the insulin receptor (INSR), the
guanine nucleotide exchange factor SOS1, tenascin (TNC), and inhibitor of nuclear factor kappa
B kinase subunit beta (IKBKB). At 6 months-of-age, alterations associated with loss of ENT1
also reach some of the most downstream components of this pathway including eukaryotic
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Figure 5.5 Relative intensity values of metabolite features validated by metabolomics.
Relative intensity of A. glycerophospholipid metabolites and B. non-glycerophospholipid
metabolites quantified in plasma and annulus fibrosus tissue samples from ENT1-/- and WT mice
at both 2 and 6 months-of-age. n=10 mice per group; 8 thoracic IVDs/mouse. *=p<0.05 by t-test.
LysoPC;Lysophosphatidylcholine.
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Figure 5.6 KEGG PI3K-AKT pathway schematic annotated with dysregulated proteins. A.
Annotation based on dysregulated proteins in the 2 month ENT1-/- vs 2 month WT comparison.
The receptor tyrosine kinase (RTK) INSR (Insulin receptor) and the ECM protein TNC (tenascin)
are upregulated in ENT1-/- annulus fibrosus tissues. The guanine nucleotide exchange factor SOS
(son of sevenless) and IκB kinase (IKK) are downregulated in ENT1-/- annulus fibrosus tissues.
B. Annotation based on dysregulated proteins in the 6 month ENT1-/- vs 6 month WT comparison.
Numerous ECM proteins are dysregulated at this time point, both up- and down-regulated. The
tyrosine-protein kinase SYK and glucose-6-phosphatase 3 (G6PC3) are upregulated in ENT1-/annulus fibrosus tissues. The g-protein couple receptor (GPCR) CHRM2 (Cholinergic Receptor
Muscarinic 2) and eukaryotic translation initiation factor 4E (eIF4E) are downregulated in ENT1/annulus fibrosus tissues. Upregulated proteins are represented by bright green coloring, and
downregulated proteins by deep red coloring. n=3 mice per group; 4 thoracic IVDs/mouse.
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Log2
Foldchange

SYK

1.86
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1.37

VTN

1.27

CHAD

-2.00
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-1.33

IBSP

-1.76

THBS3

-1.18

GPCR
Protein

Log2
Foldchange

CHRM2

-1.95
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translation initiation factor 4E (EIF4E2) and glucose-6-phosphatase catalytic subunit 3 (G6PC3).
Overall, the data suggests that receptor tyrosine kinases, numerous ECM proteins and GPCR
signaling are likely involved in PI3K/Akt dysregulation associated with loss of ENT1 in AF cells.

5.6 Discussion
In the present study, integration of quantitative proteomics and metabolomics allowed us
to identify potential molecular regulators of ectopic calcification and potential biomarkers in a
mouse model of DISH. The molecular underpinnings of DISH remain poorly understood since
the establishment of the first radiographic diagnostic criteria by Resnick and Niwayama in 19764.
Similarities between DISH and other calcification disorders such as AS (results in calcification
of the same joints as DISH but is inflammatory) or OPLL (results in calcification of the posterior
aspect of the spine, while DISH affects the antero-lateral spine) have led others to suggest
common pathological processes between these diseases21. DISH is associated clinically with
obesity and diabetes, suggesting that metabolic factors contribute to disease pathogenesis22.
Moreover, polymorphisms in COL6A1 have been associated with ectopic calcification in both
DISH and OPLL, although the underlying cellular mechanism has not been explored23. Part of
the difficulty in generating a molecular model of DISH pathogenesis is the lack of suitable animal
models to allow for high-throughput analysis of affected tissues along the continuum of disease
progression. Our group has described a mouse model of DISH arising from loss of ENT1 that
resembles DISH in humans16-18. In fact, a null mutation in the ENT1 gene in humans (SLC29A1)
has been shown to cause ectopic calcifications characteristic of DISH15. Using this model, we
aimed to identify the proteomic and metabolomic signatures associated with loss of ENT1 and
the presence of ectopic calcification in the annulus fibrosus. Integration of these data modalities
suggested a potential molecular mechanism leading to the signatures we observed.
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As expected, analysis of proteomic and metabolomic data showed substantial differences
associated with loss of ENT1 and presence of ectopic calcifications both in AF tissue and plasma.
At 2 months-of-age, the most abundant proteins identified in the AF were similar between ENT1/-

and WT mice. However, at 6 months-of-age loss of ENT1 was associated with alterations in

ECM protein abundance in the AF. These finding are consistent with our GO analysis which
identified a number of ECM and matricellular proteins downregulated in KO mice at 6 monthsof-age, including FBLN1, FBN1, MATN3, VCAN, ACAN, and IBSP as well as CYR61 and
CTGF. Moreover, at 6 months-of-age MGP was robustly expressed in the AF of WT mice (the
5th most abundant protein) whereas in the 2-month-old samples MGP was not in the 10 most
abundant. In fact, MGP expression was increased 2.81-fold in 6-month-old WT AF compared to
2-month-old WT AF which is consistent with previous findings of increased Mgp mRNA in old
compared to young AF tissue24 Altered MGP abundance is especially intriguing when taken in
context with MGP not being in the 10 most abundant proteins in ENT1-/- AF. This is reflected in
a 2.66-fold decrease in MGP expression in 6-month-old ENT1-/- AF compared to 6-month-old
WT AF, which matches our previous findings of decreased Mgp by gene expression in this
comparison17. These findings are consistent with previous studies suggesting that with age,
secretion of mineralization inhibitors by AF cells is increased to prevent spontaneous formation
of ectopic mineral in the aged intervertebral disc25. However, our findings show that in ENT1-/mice this compensation in MGP expression does not occur, perhaps contributing to propagation
of mineral formation in the AF.
Comparison of the proteomic signatures between samples showed that at 2 months-ofage, ENT1 is the most down-regulated protein in ENT1-/- AF cells. Interestingly, the leukocyte
surface antigen CD47 was decreased in ENT1-/- AF cells compared to WT at 2 months-of-age.
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Decreased CD47 expression is involved in displaying an “eat me” signal to phagocytes26; it is
tempting to speculate that this change may reflect clearance of abnormal cells in the AF
associated with loss of ENT1. Our analysis also demonstrated an up-regulation of the toll-like
receptor TLR13 in ENT1-/- AF tissues. Although TLR13 has only recently been discovered and
its function is not yet fully characterized, it is highly expressed in macrophages27. This finding
may support the notion that increased “eat me” signals attract macrophages to the AF in ENT1-/mice at 2 months-of-age. Interestingly, tyrosine-protein phosphatase non-receptor type substrate
1 (also known as signal regulatory protein alpha; SIRPA) is up-regulated in 6-month-old ENT1/-

AF compared to WT. Since SIRPA functions as a heterodimer with CD47 to create a “don’t eat

me” signal for phagocytes28, its increased expression may indicate a switch in AF cell signaling
to phagocytes, allowing for the accumulation of abnormal or potentially apoptotic cells in the
AF.
The transition from an “eat me” to “don’t eat me” signal could be further substantiated
by the fact that phospholipid scramblase 1 (PLSCR1) is the most up-regulated protein in AF
tissues from ENT1-/- between 2 and 6 months-of-age, associated with increasing severity of
ectopic calcification. PLSCR1 functions to flip the phospholipid bilayer of apoptotic cells,
exposing phosphatidylserine (PS) at the cell surface29 which can serve to nucleate mineral29. This
mechanism of mineral formation may be in keeping with our previous findings of increased cell
proliferation in the AF of ENT1-/- mice which was found to occur without a concomitant increase
in AF cellularity18. Together these findings allow us to propose a model in which cells of the
ENT1-/- AF undergo molecular dysregulation as early as 2 months-of-age, leading to the presence
of abnormal cells that may undergo apoptosis. These cells are typically cleared following
decreased CD47 expression resulting in an “eat me” signal to phagocytes; however, over time
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increased SIRPA expression reverses the phagocytosis of abnormal AF cells. The accumulation
of abnormal cells within the AF serves as mineral nucleation sites, promoting the accumulation
of ectopic calcification characteristic of the ENT1-/- mouse model.
Given the large number of dysregulated proteins identified by our comparisons, we
performed functional enrichment analyses. The only enriched KEGG pathway identified in the
comparison of ENT1-/- AF to WT at 2 months-of-age was unexpectedly the HIF-1 signaling
pathway. However, investigation of the specific proteins annotated to this pathway showed upregulation of the plasminogen activator inhibitor 1 (PAI-1/SERPINE1). Intriguingly, in a model
of soft tissue calcification following muscle injury, dystrophic calcification was prevented by
down-regulating the primary inhibitor of plasmin30. These findings may be similar to our model
where increased SERPINE1 may lead to decreased plasminogen/plasmin and therefore increased
AF calcification. Amongst the GO biological processes down-regulated in ENT1-/- AF compared
to WT at 6 months-of-age was the term “ossification”. Investigation of the specific proteins
annotated to this term showed changes in both inhibitors and promoters of mineralization. MGP,
an inhibitor of mineralization was down-regulated in the ENT1-/- AF consistent with our previous
analysis of gene expression17, but so were the promoters of mineralization IBSP and
PHOSPHO1. Although the relative contributions of MGP, IBSP, and PHOSPHO1 to AF
calcification should be assessed, this signature may be associated with heterogeneity in AF
calcification in ENT1-/- mice. Cells adjacent to areas of calcification may show reduced MGP
expression, while cells removed from sites of calcification may show decreased expression of
IBSP and PHOSPHO1 as they would normally in the tissue with age.
GO terms for “neutrophil aggregation” and “cellular response to molecule of fungal
origin” were associated with the progression of ectopic AF calcification (6-month-old ENT1-/-
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AF compared to 2-month-old ENT1-/- AF). Proteins annotated to this term included the calciumresponsive S100A8/9 proteins which form a heterodimer and are the most upregulated alarmins
associated with osteoarthritis31, as well as the tyrosine-receptor kinases SYK and BTK. SYK is
required for signaling in neutrophils and macrophages32. Though speculative, the up-regulation
of these pathways in the calcified AF may be indicative of an AF cell response to foreign
particulates, in this case mineralization, which involves either neutrophils mediating
inflammation or macrophages clearing away apoptotic cells. Intriguingly, S100A8/9 also
annotate to the GO term ‘RAGE receptor binding’, implicating the NF-kappa B pathway in the
ENT1-/- AF phenotype. Notably, phosphatidylserine is also known to stimulate RAGE receptors33
which we postulate may be directly involved in the initiation of ectopic mineral formation in the
AF of ENT1-/- mice.
Metabolomic analysis provided novel insight into the biology of AF calcification. We
identified potential IDs of metabolites dysregulated between ENT1-/- and WT AF tissues,
including

taurocholic

acid,

and

various

phosphatidylcholines

(PCs)

and

phosphatidylethanolamines (PEs). Validation with internal standards confirmed that multiple
LysoPC isoforms are elevated in both the AF and plasma of ENT1-/- mice compared to WT. The
most robust LysoPC with this signature is Lyso PC 18:2 which was increased in the ENT1-/- AF
at 2 months-of-age, and increased in the AF and plasma of ENT1-/- mice at 6 months-of-age
compared to WT. LysoPCs serve as intriguing candidates for biomarkers of DISH as this pattern
of localization may suggest a pathological process that initiates in the AF and becomes detectable
in the circulation at later stages of disease.
Importantly, integration of proteomics and metabolomics allowed for the development of
a proposed model of molecular alterations associated with ectopic calcification the ENT1-/- model
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of DISH. Numerous proteins identified by our analysis are involved in the PI3K/Akt signaling
pathway. We therefore mapped proteins dysregulated in the AF of ENT1-/- mice (both up- and
down-regulated) to the KEGG PI3K/Akt pathway to visualize where in the pathway processes
were altered. Importantly, caspase 3 (CASP3) protein expression is increased by over two-fold
in 6-month-old ENT1-/- AF compared to 2-month-old ENT1-/- AF. Elevated CASP3 is associated
with both propagating apoptosis and cleavage activation of phospholipase A234. Phospholipase
A2 is the enzyme responsible for the production of LysoPC; along with the increase in protein
expression of phospholipase A2 Group VII (PLA2G7) in ENT1-/- mice from 2 to 6 months-of-age
(Supplementary Table 5.3), increased activation of phospholipase A2 agrees with our
observation of increased LysoPC levels in 6-month-old ENT1-/- mice. Finally, there is also
evidence that adenosine dysregulation can lead to altered PI3K/Akt signaling via altered
stimulation of the adenosine receptor A2a35. This can explain how the phenotype observed in the
ENT1-/- AF can be initiated by increased adenosine levels mediated by PI3K/Akt signaling.
The current study has provided insight into the molecular pathogenesis of ectopic
calcification in a mouse model of DISH and allowed us to propose a model whereby
dysregulation of phagocytic signaling and cell apoptosis downstream of PI3K/Akt signaling
serve to nucleate mineral formation in the AF of ENT1-/- mice. Further studies are required to
characterize candidate effectors in situ as well as examine their potential roles in the initiation of
AF mineral formation and the pathogenesis of DISH to identify potential disease-modifying
therapeutics. Additionally, the potential of LysoPCs should be investigated as biomarkers of
DISH, as they may allow for the identification of early stage disease enabling potential
therapeutic interventions to be administered earlier with the goal of improving patient prognosis.
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5.7 Supplementary Tables
Supplementary Table 5.1. List of proteins dysregulated in the 2-month-old ENT1-/- vs 2month-old WT comparison.
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Supplementary Table 5.2. List of proteins dysregulated in the 6-month-old ENT1-/- vs 6month-old WT comparison.
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Supplementary Table 5.3. List of proteins dysregulated in the 6-month-old ENT1-/- vs 2month-old ENT1-/- comparison.
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Supplementary Table 5.4. List of proteins in Venn sectors.
71 elements included exclusively in "6KOvs6WT Up":
H2-Ab1
Ear1
Lsg1
Mrpl21
Slc2a4
Parvg
Rfc1
Casq2
Lamtor4
Uhrf1
Ca4
G6pc3
Wapal
Dera
Taco1
Tmem70
Rftn1
Isg20
Ccdc43
Letmd1
Slc25a21
Ercc6l
Isg15
Ucp1
Scyl2
Mrps15
Vav3
Focad
Med18
Mlf2
Krt83
Hist1h1a
Camk2b
Proz
Lipc
Fam136a
Trim10
Serpina3n
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Btnl10
Ptprd
Dars2
Fam101b
Slc37a2
Pnkd
Masp1
Smarca4
Rplp1
Xdh
Pbrm1
Slc25a35
Slc14a1
Acot11
Tnfrsf11b
Ylpm1
Postn
Hist1h1b
Poldip2
Mrps6
Nrp1
Mapk14
Pccb
Ssr4
Galnt3
Hsd17b8
Acadl
Mtnd2
Mrps22
Acadvl
Fads1
Pla2g7
Me2
152 elements included exclusively in"6KOvs2KO Up":
Plscr1
Hist2h2be;Hist3h2ba;Hist3h2bb
Stx11
Ighg1
Myl2
Hspb7
S100a14
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Vamp5
Wdhd1
Mpeg1
Mcpt8
Adrbk1;Adrbk2
Gimap8
Nat2
Spp2
Itgb2l
Myoz2
Smc4
Vcam1
Bhmt
Hk3
Ly6d
Sdr16c6
Ncapd2
Aes
Fmnl1
Elovl6
Rrm1
Ptpn6
Itga2b
Cd177
Phldb2
Padi4
Hspb11
Olfm4
Skap2
Gca
Mmp8
Btk
Npl
Camp
Lcn2
Ssbp2;Ssbp3
Elane
Ltf
Mmp9
Mcm5
Ca1
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Dock2
Tmem143
Arhgap25
Itga4
Bdh1
Mlkl
Ncf1
Cybb
Fermt3
Ighm
Coro1a
Tbl1x
Mpo
Mcm2
Epx
Ngp
Sdhaf1
Limd2
Kpna2
Ctsg
Mcm3
Treml1
Hmbs
Fxyd6
Mcm7
Tcn2
Mcm6
B4galnt1
Rgag4
Lsp1
Stmn1
Ciao1
Fam63b
Serpina3m
Inpp5d
Arhgdib
Lcp2
Alox12
Itgb2
Nup210
Lcp1
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Ear2
Itgam
Fam91a1
Tcap
Ikbkb
Serpina1d
Hsd11b1
Hcls1
Napsa
Tuba4a
Pcna
Prtn3
Lyz2
Prg2
Cpox
Myo1f
Hp
Zbtb3
Rbms1
Mcm4
Cdk1
Cyba
Hck
Spn
Slc9a3r1
Plac8
Aif1
Stom
Cfp
Cd48
Ncapd3
Apod
Top2a
Ptprc
Hmgb2
Rasgrp2
Uros
Plcg2
Fam49b
Myot
Dip2b
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Chi3l1
Rac2
Hist1h2ah;Hist1h2af;Hist3h2a;Hist1h2ab;Hist1h2ak
Serpinb1a
Alad
Get4
Psmb8
Ptgr1
Lbp
Pigq
Rpa3
Zc3h4
Ttr
Lipa
Gsto1
Nbeal2
Casp3
Tanc1
Tmcc1
Fen1
Dnmt1
Gclm
32 common elements in "6KOvs6WT Up" and
"6KOvs2KO Up":
Vav1
Rrm2
Aqp4
Tk1
Pglyrp1
Hemgn
S100a8
Ctse
Chil3
Plbd1
Ahsp
Ncf4
Synpo2l
Sp110
Syk
S100a9
Myo1g
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Dpep1
Ftl1;Ftl2
Tyms
Tfrc
Ca2
Cotl1
Vtn
Cd74
Pfkfb4
Fth1
Tomm7
Tbxas1
Rab32
Pbk
Atp2a3
4 common elements in "2KOvs2WT Up" and
"6KOvs6WT Up":
Sirpa
C1qa
Tnc
Timp1
3 common elements in "6KOvs2KO Up" and
"6WTvs2WT Up":
Igj
Igh-3
Hmha1
54 elements included exclusively in "2KOvs2WT Up":
Chd2
Mrpl13
Sumo3
Cdkn2c
Slc7a6
Slc20a1
Amy1
Tmem97
Slc30a5
Snrpg
Cxxc1
P2rx4
Ubac1
Msh6
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Ift22
Coq7
Gdf10
Vars2
Mmp25
Slc25a1
Lmf2
Podxl
Cpa4
Cyfip2
Insr
Ankh
Slc25a16
Mbnl2
Golga7
Ccny
Ttyh1
C1qtnf3
Smad1
Agps
Senp7
Mmp3
Edil3
Col14a1
Camk2a
Syngr2
Dixdc1
Mpc1
Acvr1
Kera
Ppp1r12c
Lsm8
Plcb1
Tmem205
Psmb3
Tpbg
Poglut1
Pls1
Ptdss1
Tusc3
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16 common elements in "2KOvs2WT Up" and
"6WTvs2WT Up":
Tlr13
Cox6a2
Ubl5
Epdr1
Nccrp1
Comtd1
Sbspon
Sepw1
Serpine1
Prrt2
Dyrk1a;Dyrk1b
Ccl9
Sost
Apobr
Rab5a
Mtatp8
77 elements included exclusively in "6WTvs2WT Up":
Eras
Kif5c
Odf2
Gm1564
Habp4
Echdc3
Serbp1
Unc13d
Hmgn2
Nmnat3
Bmp3
Sostdc1
Bloc1s1
Aph1a
Angptl7
Ptms
Ptn
Fbln1
Cemip
Dctn6
Carkd
Suz12
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Cd302
Rmnd5a
Ccl24
Cxcl13
Smim4
Impact
Hvcn1
Prnp
Tmem104
Spink3
Ifi203
Gpr56
Slpi
Znf22
Tyw3
C1qtnf5
Ncaph
Gosr1
Ube2g2
Nipsnap1
Fbxo28
Myoc
Mgp
Ihh;Shh
Cd55;Cd55b
Cdca8
Gys2
Mfap1
Bbox1
H2-Q8;H2-Q7;H2-Q9
Hmga2
Ifih1
F5
Cpa3
Trappc2l
Gpld1
Igk-V19-17
Hhip
Scrg1
Chad
Il17b
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Ctgf
Sdr39u1
Cyr61
Ccl6
Pdlim3
Srpx2
Klk1b22
Tmem65
Pon1
Eif4enif1
Timp3
Naa35
Rgs10
Sned1
73 elements included exclusively in "6KOvs6WT
Down":
Echdc3
Fnip2
Rgag4
Pid1
Camk1
Ihh;Shh
Pofut1
Chad
Hddc2
Eif4e2
Tgfbrap1
Chrm2
Ecrg4
Prnp
Ccl24
Fdx1l
Mfap5
Necap1
Lect2
Fbln1
Imp3
Gpt2
Krtap3-1;Krtap3-2
Il17b
Nle1
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Cd55;Cd55b
Chrdl1
Slc27a3
Eif2d
Cyp3a13
Smoc1
Htra4
Jund
Mgp
Kif3b
Nipsnap1
Rgs10
Comp
Chuk
Fbln2
Adamtsl4
Lims2
Crip2
Hmgn3
Cbx6
Ang
Csrp3
Smtnl1
Prrt2
Akap8l
Nutf2
Nebl
Gas1
Vcan
Cyr61
Pcolce2
S100a1
Dnm3
C1qtnf5
Prg4
Krt84
Hip1r
Cpxm1
Acan
Aamdc
Pea15
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Fbn1
Ctgf
Pate4
Ninj1
Scin
Qsox2
Xylt1
109 elements included exclusively in "6KOvs2KO
Down":
Ngef
Arl3
Tnks1bp1
Trmt61a
Sat2
Mfap2
Fkbp9
Dab2
Fkbp10
Tmem263
Filip1l
Arhgap10
Csrp2
Ikbip
Cltb
Pura
Znf148
Ptp4a2;Ptp4a1
Pdgfra
Wif1
Obsl1
Papss2
Smim5
Ehhadh
Nqo1
Dcakd
Ensa
P4ha2
Fgfr3;Fgfr1
Pdia5
Capn6
Colgalt2
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Scgb2b2
Col3a1
Col2a1
Slc26a2
Map1a
Snx4
Fap
Yipf5
Matn4
Pycr1
Map2k6
Tbc1d9b
Pmvk
Atxn7l3b
Cttnbp2nl
Fgl2
Epb41l1
Adhfe1
Morf4l2
Fam114a1
Serpinh1
Ints6
Wrb
Arl5a
Sec24a
P4ha1
Cadm3
Lepre1
Mapre3
Nenf
Plod1
Rpap3
Pias2;Pias1
Mtmr9
Aldh1l2
Col9a1
Sorcs2
Cd163
Matn1
Cgref1
Col11a1
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Rbm22
Sparc
Arhgap35
Cox7a2l
Asns
Snrnp27
Nfib
Lrrc16a
Pkd2
Zhx3
Rptor
Kdelc1
Numbl
Nfic
Thoc5
Triap1
Crtap
Ltbp4
Lyve1
Gss
Pvalb
Rtkn
Heatr5a
Fstl1
Zcchc8
Myo1c
Sac3d1
Amotl1
Ccdc58
Pld4
Leo1
Atp2b2
Fam180a
Tsc22d1
Cd151
Svs5
30 common elements in "6KOvs6WT Down" and
"6KOvs2KO Down":
Krt28
Fam63a
Slc25a42
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Rftn2
Sbsn
Hhip
Ubxn7
Aldh3a1
Commd9
Matn3
Ptms
Chadl
Ddah1
Pam
Ibsp
Nrbp2
Phospho1
Kif21a
Col11a2
Cryz
Cobll1
Eps8l2
Fndc3a
Uba3
Bcat1
Thbs3
Loxl4
Vit
Mxra7
Daam2
4 common elements in "2KOvs2WT Down" and
"6KOvs6WT Down":
Rnase4
Slc6a6
Gtpbp3
Slc29a1
6 common elements in "6KOvs2KO Down" and
"6WTvs2WT Down":
Postn
Golga5
Stk39
Gale
Fndc3b
Cd2ap
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89 elements included exclusively in "2KOvs2WT
Down":
Obfc1
Rras2
Ccdc6
Atp6v1g1
Nap1l4
Ciao1
Tceb3
Sh3bgrl2
Echdc2
Eif1;Eif1b
Mpi
Rprd1b
Scrn1
Dpp4
Tpt1
Cln5
Lgals3
Hba
Hmgb2
Rfc4
Sv2c;Sv2b
Ywhab
Fam63b
Rtn3
Ecm1
Akt1s1
Sf3a2
Dnase1l1
Ikbkb
Stk3
Clasp1
Hhipl2
Prps2
Kank3
Ubqln2
Cst3
Zak
Sec14l2
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Ndufb4
Sos1
Hm13
Zbtb8os
Eif5a;Eif5a2
Kbtbd11
Sar1a
Fxyd6
Mrpl51
Cnot11
Rbp1
Sept3
Pi16
Naa20
Tmem9b
Fam50b
Mrps25
Ebag9
Hspb11
Flad1
Plac9
Vamp8
Smarcal1
Tuba8
Trappc1
Fam91a1
Serpina1c;Serpina1a
Sdhaf4
Snrpd1
Cacna2d2
Llgl1
Vps53
Rfk
Hexim1
Bap18
Cd99
Aes
Stx11
Ppp1r2
Agpat9
Exosc5
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Pnpo
Aqp4
Shc1
Cmc2
Upp2
Nat2
S100a3
Myo10
Cd47
Eppk1
4 common elements in "2KOvs2WT Down",
"6KOvs6WT Down" and "6KOvs2KO Down":
Tppp3
Uap1
Adprhl2
Rab4a
123 elements included exclusively in "6WTvs2WT
Down":
Acss3
Emc8
Ablim1
Vapb
Dazap1
Ppia
Idi1
Ehd1
Bicd2
Ncbp1
Ccdc47
Ddi2
Mup3
Aco2
Mrpl9
Ahsg
Plcg1
Ppp1ca
Mgea5
Rcn1
Sort1
Rpl8
Acadm
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Sept8
Srsf5
Hmgcs1
Psmc1
Hnrnpf
Apom
Bloc1s5
Rnaset2
Tceb1
Aacs
Ublcp1
Rps14
Gtf3c1
Cycs
Ppfibp1
Gstz1
Acadl
Vmac
Rps17
Ndufab1
Mgll
Npm1
Ints4
Anp32b
Ctsh
Pccb
Cc2d1a
Ddhd2
Tmed9
Lrch3
Eci1
Cog4
Ctdsp1
Hsp90aa1
Snx27
Cyb5b
Cpsf3
Fbl
Homer3
Ppic
B3galtl
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Hint3
Morf4l1
Mmab
Dnajc7
Tm2d2
Rnf123
Kpna6
Drg1
Heatr3
Serpina3k
Brd7
Echdc1
Wasl
Nat10
Nop16
Ucp1
Preb
Sec23ip
Pi4kb
Rpl32
Baiap2
Znf326
Otud4
Ube4b
Fkbp7
Ndufc2
Man2a1
Zc3h11a
Grcc10
Ppp4c
Pgam1
Clcc1
Idh3g
Rnps1
Slc27a2
Adrb3
Akap2
Cd99l2
Vamp4
Lzic
Ralgapa1
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Ube2i
Pck1
Slc30a9
Bcas2
Ifit1
Gpx7
Diaph2
Mrps35
Slc12a5
Lsm7
Fuom
Fam195b
Sil1
Cisd1
Dhrs11
Appl2
Cox7a1
Rps27
1 common element in "2KOvs2WT Down" and
"6KOvs2KO Down":
Dap3
23 common elements in "2KOvs2WT Down" and
"6WTvs2WT Down":
Htatip2
Appl1
Loxl2
Hmgb1
Glul
Txn
Chordc1
Sgce
Fn3krp
Bpgm
Cyb5a
Rcn2
Rps26
Gcc1
Kel
Rbm8a
Fam49a
Hnrnpa3
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Serpina1d
Cmc1
Uqcr10
Crot
Plscr1
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CHAPTER SIX

STIFFNESS AND AXIAL PAIN ARE ASSOCIATED WITH THE PROGRESSION OF
CALCIFICATION IN A MOUSE MODEL OF DIFFUSE IDIOPATHIC SKELETAL
HYPEROSTOSIS (DISH)
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6.1 Co-Authorship Statement
Experiments were performed by M.A. Veras, D.E. Fournier, C.R. Brooks, and D.
Quinonez in the laboratory of C.A. Séguin. The manuscript was written by M.A. Veras with help
from D.E. Fournier and suggestions from M. Millecamps, L.S. Stone and C.A. Séguin. All
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6.2 Chapter Summary
This study was designed to assess pain and physical function in the ENT1-/- mouse model
of DISH. Our goal was to evaluate if progressive ectopic calcification of spinal structures in the
ENT1-/- mouse model was associated with altered mobility or behavioral indicators of pain.
A longitudinal study design was used to assess behavioral indicators of radiating pain,
axial discomfort, and physical function in ENT1-/- mice at 2, 4, and 6 months-of-age using the
von Frey, plantar acetone, grip force, FlexMaze, rotarod, tail-suspension, and open-field
locomotion assays. At 6.5 months-of-age, spinal cords were isolated for immunohistochemical
analysis of neuroplastic changes (GFAP, Iba-1) and pain-related peptides (CGRP).
Increased spine calcification (with age) was associated with significantly reduced
exploration in the FlexMaze assay in ENT1-/- mice compared to wild-type, in which mice must
undergo lateral flexion to explore the maze. These data, along with reduced self-supporting
behavior in the tail-suspension assay, suggest that ENT1-/- mice experience significantly more
flexion-induced discomfort compared to wild-type mice. Both male and female ENT1-/- mice at
all time points showed less rearing behavior in the open-field compared to age-matched wildtype, potentially attributed to increased pain and/or stiffness. Forelimb grip strength was less in
ENT1-/- mice compare to wild-type, in both male and female mice at 6 months-of-age. Lastly,
immunostaining of neural markers showed increased CGRP-immunoreactivity in the spinal cords
of ENT1-/- mice compared to wild-type, suggesting an increase in nociceptive neurons.
These data strongly suggest that ENT1-/- mice experience discomfort and stiffness
similar to humans with DISH. Our result in a preclinical model of DISH suggest that pain is
present from the earliest stages of spine calcification and may be associated with sex-related
differences.
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6.3 Introduction
Diffuse

idiopathic

skeletal

hyperostosis

(DISH)

is

a

non-inflammatory

spondyloarthropathy characterized by formation of ectopic mineral along the spine and within
the annulus fibrosus of the intervertebral disc (IVD)1,2. DISH is more frequently detected (but
not exclusively) in males compared to females3-5, but overall, the clinical features associated with
DISH are poorly understood. Multiple co-morbidities have been associated with DISH including
obesity, dyslipidemia, hypertension, and type 2 diabetes2. Further complicating matters, the
burden of back pain in people living with DISH is unclear since there are studies suggesting
symptoms of pain6-8 and others refuting symptoms of pain9,10. Instead, DISH is characterized
clinically by increased spine stiffness, decreased spinal ranges of motion6,11, and postural changes
(e.g., kyphosis)12,13. Of note, advanced DISH can cause severe symptoms, such as: dysphagia14,
dysphonia15, airway obstruction16, vertebral fracture17, or spinal cord/nerve compression18-20. To
date, the radiographic manifestations of DISH have not been correlated to symptoms.
Furthermore, since the etiology and pathogenesis of DISH remain elusive, there are no diseasemodifying or symptom-reducing treatments for people living with DISH (beyond surgical
resection of problematic mineralized tissue that often requires revision surgery)21. Instead,
conservative management (e.g., physical therapy) is advocated with the goal of alleviating pain
and stiffness and enhancing spine mobility, but there is a lack of empirical evidence showing its
effectiveness2,22.
The lack of longitudinal studies evaluating the clinical features associated with DISH is
attributed to the inability of the current clinical radiographic criteria to detect early disease23. For
this reason, preclinical animal models are vital to better understand the pathobiology of DISH. A
mouse model lacking equilibrative nucleoside transporter 1 (ENT1), previously characterized by
our group, develops ectopic calcification of the paraspinal tissues with remarkable resemblance
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to DISH24. Ectopic spinal calcification in mice lacking ENT1 is first detected in the cervical and
thoracic regions by 2 months-of-age and progresses caudally with age; by 12 months-of-age,
these mice develop severe hind limb paralysis due to spinal cord and/or nerve compression24. By
examining mice lacking ENT124 and human cadavers25,26, our group has confirmed similarities
in the radiographic and histological features of mineralized tissues in the two species.
Advances in the field of behavioral measurement in preclinical animal models have
established robust metrics whereby mice can be reliably evaluated for pain-associated changes.
For example, genetic knockout mouse models of IVD degeneration have shown increases in painassociated behaviors compared to wild-type controls, correlated to the severity of degeneration2729

. Furthermore, administration of analgesic treatment in these mice with IVD degeneration has

been shown to reduce cutaneous hypersensitivity and alleviate axial discomfort, demonstrating
the ability of these assays to detect behavioral changes30. Moreover, immunohistochemistry has
been used to verify molecular changes associated with behavioral indicators of back pain31. In
particular, nociceptive innervation and sensory nervous system plasticity can be evaluated using
markers of nociceptive neurons, microglia, and astrocytes, respectively.
For the first time, we have conducted a comprehensive longitudinal evaluation of pain
and mobility in the ENT1-/- mouse model of DISH using an array of behavioral and molecular
testing modalities. This enables us to evaluate symptoms of DISH throughout the disease
continuum, determine if the ENT1-/- mouse model recapitulates symptoms noted in humans, and
if pain-related symptoms are a feature of early-stage disease.
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6.4 Materials and Methods
6.4.1 Animals
Mice (Mus musculus) lacking ENT1 (B6.129X1-Slc29a1tm1Msg), generated by deletion of
exons 2-4 of the gene Slc29a1, were provided by Dr. Doo-Sup Choi (Mayo Clinic College of
Medicine and Science: Rochester, MN)32. Mice lacking ENT1 were backcrossed with inbred
C57BL/6NCrl mice (Charles River: Wilmington, MA) and the colony was maintained by
breeding heterozygous mice (ENT+/-) to obtain wild-type (ENT+/+) and knock-out (ENT1-/-)
littermates. Our animal facility maintains a controlled environment of 22-25°C, 40-60%
humidity, 12 h light/dark cycles starting at 07:00, and routine animal welfare-related assessments.
Mice were housed in standard polycarbonate cages (RC71D-PC, Alternative Design
Manufacturing & Supply: Siloam Springs, AR) with 2-4 same sex littermates, natural absorbent
bedding (Bed-o’Cobs ¼”, Andersons Lab Bedding Products: Maumee, OH), environmental
enrichment (Mouse House, Techniplast: West Chester, PA; and Nestlets, Ancare: Bellmore,
NY), and ad libitum access to water and a NIH-31 Modified Open Formula Mouse Diet (Item
No. 7013, Envigo: Madison, WI). All aspects of this study were conducted in accordance with
the policies and guidelines set forth by the Canadian Council on Animal Care and were approved
by the Animal Use Subcommittee of the University of Western Ontario: London, CAN (Protocol
No. 2017-154; Appendix C).
6.4.2 Characterization of Mobility and Behavioral Indicators of Pain
A total of 40 mice were studied (wild-type: n=10 females and 10 males; ENT1-/-: n=10
females and 10 males). A longitudinal study design with repeated measures was employed to
assess behavior at 2, 4, and 6 months-of-age (Figure 6.1A). Time points were selected based on
previous characterization of the development and extent of ectopic calcification in ENT1-/-
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Figure 6.1. Representation of experimental design and µCT analysis of progressive ectopic
calcification of spinal tissues in ENT1-/- mice. A, Wild-type (n=10 females and n=10 males)
and ENT1-/-mice (n=10 females and n=10 males) were tested for behavioral indicators of pain
and physical function at 2, 4, and 6 months-of-age. Data collection consisted of 7 behavioral
assays conducted over 3 testing days. Following each time point, µCT was implemented to
associate the extent of ectopic calcification to behavior. B, Three-dimensional renderings
(anterior view) of a representative male ENT1-/- mouse at 2.5, 4.5, and 6.5 months-of-age.
Inserted within each panel is a magnified posterior view of the cervical spine. Ectopic
calcification, defined as hyperdense tissue exceeding the upper range of cortical bone of the spine
(≥1278 HU) is pseudocolored in red. Black scale bars represent 10 mm and white scale bars
represent 1 mm. C, Quantitative analysis of ectopic calcification in ENT1-/- mice (n=10 females
and n=10 males), expressed as the ratio of hyperdense tissue relative to cortical bone tissue of
the spine (C1-T12). Linear regression analysis of female and male data considered each replicate
as an individual point. The goodness of fit values are presented as r2 and the slopes of these linear
regressions were significantly non-zero and not different between sexes (female: y=0.0093x –
0.0007; male: y=0.0096x – 0.0053). Data were pooled (right panel) in a single linear regression
to analyze the overall relationship between ectopic calcification and age. The mean replicate
value was considered for each time point (y=0.0094x – 0.0030). Red dashed lines represent the
calculated linear regression with dotted lines representing 95% confidence intervals. Data are
presented as scatterplots of each mouse (unique symbol) measured at each time point, or as
summary mean ± standard deviation.
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mice24,33. Ectopic calcifications (equivalent or exceeding the radiodensity of spinal cortical bone)
are often first detected radiographically at 2 months-of-age in the cervical spine, and progress to
also include paraspinal ligaments, rib entheses, and IVDs in the thoracic and lumbar spine at 6
months-of-age. All mice were habituated to the behavioral testing facility 2 weeks prior to the
first time point of testing. Habituation to assays was performed 1 week prior to testing. Testing
was then performed in the same sequence, during the same time of day (12:00 to 18:00) over the
span of three days (Figure 6.1A). Each testing day included 1 h of habituation to the testing room
and was interspersed by 1-2 days without testing. Mice were returned to their home cage after
each assay for at least 1 h to avoid interference between assays (except for von Frey/acetone and
open field/tail suspension, which were tested consecutively).
6.4.3 Behavioral Assays
FlexMaze. The FlexMaze apparatus was assembled based on previously published
specifications34. Each mouse freely explored the maze for a single duration of 20 min; passing
through the staggered gates between the neutral compartments on each end required the mice to
undergo lateral spine flexion. Video recordings were analyzed for the number of double gates
passed over the 20 min test period by a single observer blinded to genotype and sex.
Tail suspension. Spontaneous reaction to gravity-induced stretch was assessed in mice
suspended by the base of their tail for a 180 s test duration27. Video recordings were quantified
for the duration of time each mouse spent: self-supporting (i.e., holding onto the tape, base of
tail, or hind paw); rearing (i.e., trying to reach limbs/tail); stretching (i.e., reaching for the floor);
and immobile using ANY-maze™ video tracking system (Version 6.03, Stoelting Co.©: Wood
Dale, IL) by 2 independent, blinded observers and averaged.
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Open field activity pre- and post-tail suspension. Voluntary locomotion was quantified
for 5 min immediately prior (pre) and following (post) the tail suspension assay using open field
boxes equipped with infrared sensors (in XYZ planes) to assess movement-evoked discomfort
(VersaMax Legacy Open Field, Omnitech Electronics Inc.©: Columbus, OH). Measurements
included total distance traveled, average velocity, center time (i.e., time spent in the center of the
box), stereotypy time (i.e., repeated movement while stationary such as grooming, head
bobbing), vertical activity count (i.e., rearing on hindlimbs), and movement time (Fusion v5.6
r1159, Omnitech Electronics Inc.©: Columbus, OH).
Rotarod. Locomotor capacity was assessed with an accelerating rod (30 mm diameter;
AccuRotor, Omnitech Electronics Inc.©: Columbus, OH). The rotation speed of the rod increased
from 0-30 rotations per min over the course of 60 s and was maintained for an additional 240 s.
The experimental endpoint occurred when the animal fell from the rotating rod, detected by an
infrared sensor. Animals that fell off once within the first 30 s were placed back onto the rod,
and video recordings were used to confirm latency times.
Cold sensitivity. Cold allodynia was assessed by quantifying the total time mice engaged
in acetone-evoked behaviors (e.g., elevation, stamping, flicking, licking, or scratching of the
affected paw) after acetone was introduced to the plantar surface of each hind paw,
independently. Video recordings, 60 s in duration, of the first hind paw exposed to acetone (left)
were analyzed by a single observer blinded to genotype and sex.
Mechanical sensitivity. Calibrated von Frey filaments (Touch Test Sensory Probes,
Stoelting Co.©: Wood Dale, IL) were applied to the plantar surface of each individual hind paw
of mice for 3 s or until withdrawal, and the 50% withdrawal threshold was calculated35. The
stimulus intensity ranged from 0.07-10.0 grams, beginning with 1.4 grams. The subsequent
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filaments used were dependent on the first filament to evoke a positive response, followed by
five consecutive stimulations, using the up-down method35. The scores from both hind paws were
averaged for analysis.
Grip-force. Grip-force was assessed by measuring the maximum peak force produce, in
grams, at the point of release by the forepaws during axial-stretch using a digital force gauge
(Chatillon DFE Series, Ametek®: Berwyn, PA). For each mouse, peak grip-force was recorded
three times at 5 min intervals and the results were averaged.
6.4.4 Microcomputed tomography (µCT)
ENT1-/- mice were scanned following each time point of behavioral testing (2.5, 4.5, and
6.5 months-of-age) to correlate behavioral changes to radiographic features. µCT imaging was
performed using a cone-beam imaging system (eXplore SpeCZT scanner, GE Healthcare
Biosciences: London, CAN). Mice were anesthetized for µCT scanning using 2-3% inhaled
isoflurane (Catalog No. CA2L9100, Baxter: Mississauga, CAN) infused with oxygen at a flow
rate of 1.0 mL/min. To maintain sedation, a nose cone apparatus was used to administer 1.75%
inhaled isoflurane for 20 min while scanning was performed. During a single 5 min rotation of
the gantry around the animal, 900 X-ray projections were acquired (peak voltage of 90 kVp, peak
tube current of 40 mA, and integration time of 16 ms). Included in each scan was a calibrating
phantom consisting of air, water, and a cortical bone-mimicking epoxy with a known physical
density of 1.82 g/cm3 (450-SB3, Gammex Inc.: Middleton, WI). After scanning, the mice were
weighed, in grams, using a portable digital precision scale and monitored for successful recovery
from anesthesia before being re-introduced to their home cage.
The acquired images were reconstructed into independent three-dimensional volumes
with isotropic voxel spacing of 50 µm using a Feldkamp filtered back-projection algorithm36. To
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improve signal-to-noise characteristics, the volumes were spatially averaged to 100 µm voxel
spacing. Hounsfield units (HU) were scaled based on the average greyscale values of air and
water, -1000 and 0 HU, respectively. To standardize radiodensity measurements, multiple
regions of cortical bone in the spine were analyzed in mice at each age (n=9) to calculate a
radiodensity range for mineralized tissue of the spine (3SD = 289-1278 HU). Manual
segmentation was used to isolate a region of interest containing the cervical to thoracic spine and
associated sternocostal tissues for analysis of hyperdense tissue, defined as exceeding the
radiodensity of cortical bone (≥1278 HU). Internal organs were removed from the analysis of
hyperdense tissue. Custom software was used to assess body composition (e.g., total mass,
adipose and lean tissue) based on the whole body µCT scans, as described37. Imaging data were
analyzed using MicroView (Version 2.5.0-4118, Parallax Innovations Inc.: Ilderton, CAN) and
VGStudio MAX (Version 2.0.4, Volume Graphics GmbH: Heidelberg, DEU).
6.4.5 Immunohistochemistry
Mice were euthanized following the µCT scan at 6.5 months-of-age (196 ± 1.4 days) by
intraperitoneal injection of 50 mg/kg of pentobarbital sodium (Item No. 1EUF001, Bimeda©
Canada.: Ontario, CAN). The cervicothoracic spinal cord was collected from each mouse and
immediately fixed with 4% paraformaldehyde (overnight) and cryoprotected in 30% sucrose in
phosphate-buffered saline (PBS) for 24 h. Tissues were embedded in O.C.T Compound™
(Tissue-Tek®: Alphen aan den Rijn, NLD), sectioned transversely with a cryostat at a thickness
of 14 µm (CM3050 S, Leica Biosystems: Nußloch GmbH: Nußloch, DEU), and thaw-mounted
onto gelatin-coated slides. The cervical enlargement was divided and analyzed as upper, mid,
and lower regions from each animal, then immunohistochemistry was performed as previously
described38-40. Briefly, sections were washed twice in PBS and then blocked using 5% donkey
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serum in 0.1% Triton X-100 in 0.01-M PBS (PBST) for 2 h at room temperature. Sections were
incubated overnight in a humidified chamber at 4ºC in 5% donkey serum in PBST containing
primary antibodies directed against calcitonin gene-related peptide (CGRP, 1:750; Item No.
BML-CA1137, Enzo Life Sciences: Farmingdale, NY), ionized calcium-binding adapter
molecule 1 (IBA1, 1:1000; Item No. AB10341, Abcam: Cambridge, UK), and glial fibrillary
acidic protein (GFAP, 1:500; Item No. G3893, Sigma-Aldrich: St. Louis, MI). Sections were
rinsed 3 x 10 mins in PBST and then incubated for 45 min at room temperature with fluorescenceconjugated secondary antibodies diluted 1:500 in PBS: donkey anti-sheep (Item No. A11015),
donkey anti-rabbit (Item No. A21207), or donkey anti-mouse immunoglobulin G (Item No.
A21202, Thermo Fisher Scientific: Waltham, MA). Sections were rinsed 3 x 30 mins in PBS and
cover-slipped using Fluoroshield Mounting Medium with 4′,6-diamidino-2-phenylindole (Item
No. ab104139, Abcam: Cambridge, UK). Immunoglobulin G isotype controls for CGRP (1:750;
Item No. 5-001-A, R&D systems: Minneapolis, MN), IBA1 (1:1000; Item No. 02-6102, Thermo
Fisher Scientific: Waltham, MA), and GFAP (1:500; Item No. MA1-10406, Thermo Fisher
Scientific: Waltham, MA) and secondary-only controls were run in parallel.
Micrographs were captured using a Leica Microsystems DMI6000B fluorescence
microscope and DFC360FX camera with Leica Advanced Application Suite software (Version
2.7.0-9329, Leica Microsystems GmbH: Wetzlar, DEU). Micrographs were exported to ImageJ
software and converted to 8-bit RGB stacks for analysis41. A baseline signal intensity threshold
was generated for each antibody from the isotype and secondary-only controls. A region of
interest (ROI) was then manually defined around each left and right dorsal horn to independently
analyze laminae 1-4. The dorsal horn was differentiated from surrounding white matter based on
the greyscale density using brightfield images, and by characteristics of cell shape and density
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using DAPI images. The total area measured was consistent in each region of the cervical
enlargement analyzed. Sections were excluded when irregular shape or size of the dorsal horn
was observed due to tissue damage, artifacts, or folding. For each region of interest, the raw
integrated density of CGRP-, GFAP-, and Iba-1-immunoreactivity was measured and
standardized according to the area analyzed.
6.4.6 Statistical Analyses
Behavioural data from each mouse was analyzed as an experimental unit with repeated
measures over time. Observers were blinded to genotype and sex during assessment of results
and assay scoring. Interrater reliability was assessed for the tail suspension assay using two-way
mixed model and demonstrated strong absolute agreement with intraclass correlation coefficient
values of 0.93-0.98 (Version 25, IBM SPSS Statistics: Armonk, NY). Subsequent statistical
analyses were performed using GraphPad Prism (Version 8.0.1: San Diego, CA). The ShapiroWilk normality test confirmed when data was parametric. Mechanical sensitivity and
immunohistochemistry data were non-parametric. Sex was compared at each time point and
genotype to assess sex-related differences using unpaired, two-tailed t-tests. Since significant
sex-related differences were found in multiple measures, subsequent results were stratified by
sex. µCT data were tested using linear regression modeling. Most behavioral data were analyzed
using two-way-ANOVA with Sidak’s multiple comparisons to test differences between
genotypes and repeated measures. The exception being non-parametric data which required
Mann-Whitney tests for comparisons between groups, and Freidman’s or Kruskal-Wallis tests
with Dunn’s multiple comparisons to evaluate repeated measures. A p-value < 0.05 was
considered significant.
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6.5 Results
6.5.1 ENT1-/- Mice Show Progressive Ectopic Calcification of the Spine
µCT was used to evaluate the progression of ectopic calcification in the spine of ENT1-/mice. Hyperdense calcifications exceeding the radiodensity threshold of cortical bone (≥1278
HU) were first detected in the upper cervical region of the spine and in the sternocostal region
(n=19/20) at 2 months-of-age (n=20/20) (pseudocolored red in Figure 6.1B). Ectopic
calcifications were predominately localized to the soft tissues of the spine (posterior view inserts
in Figure 6.1B). The extent of ectopic calcification increased with age. Quantitative analysis
revealed a significant increase in the volume of hyperdense material with age within a region of
interest corresponding to the cervical to thoracic spine and associated sternocostal tissues in both
male and female ENT1-/- mice (e.g., female, 2 mo = 4.21 ± 1.79 mm3 and 6 mo = 14.96 ± 4.64
mm3; male, 2 mo = 3.41 ± 1.51 mm3 and 6 mo = 15.26 ± 5.19 mm3). To control for age and sexrelated differences in overall skeletal size, the extent of ectopic calcification was evaluated based
on the ratio of hyperdense tissue relative to normal cortical bone within the region of interest
(Figure 6.1C). Overall, there were significant positive linear relationships between the ratio of
hyperdense tissue to normal cortical bone and age in both female and male ENT1-/- mice (Figure
6.1C, left and middle panels). The slope of the curves was not different between that of male and
female ENT1-/- mice, suggesting that the progression of ectopic calcification was comparable in
both groups (p=0.85). As such, data obtained from female and male mice were pooled to
characterize the overall relationship between ectopic calcification and age in ENT1-/- mice
(Figure 6.1C, right panel). These findings are consistent with our previous characterization of
ectopic mineralization in ENT1-/- mice24.
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6.5.2 Behavioral Assessments of Axial Discomfort
Grip force assay. A modified grip force assay was used to measure peak strength during
axial stretch34. Female ENT1-/- mice demonstrated a significant reduction in grip strength
compared to wild-type at 2 and 6 months-of-age (Figure 6.2A). Male ENT1-/- mice showed a
similar reduction in grip strength compared to wild-type mice, with significant decreases detected
at 6 months-of-age.
Tail suspension assay. We next investigated whether ENT1-/- mice showed behavioral
indicators of axial stretch-induced discomfort. Previous studies using mouse models of lumbar
disc degeneration demonstrated that during tail-suspension, mice experiencing back pain spend
more time self-supporting and rearing than healthy controls27,34,38,42. Overall, ENT1-/- mice did
not exhibit behaviors indicative of stretch-induced discomfort (Figure 6.2B-D). Female ENT1-/mice spent significantly less time self-supporting compared to wild-type mice at each time point
(Figure 6.2B). A similar trend was observed in male ENT1-/- mice, although these differences
were not statistically significant compared to age-matched wild-type mice. There were no
differences in time spent self-supporting with age in either sex or genotype. No significant
differences were detected in time spent rearing during tail suspension between wild-type and
ENT1-/- mice at any of the time points assessed (Figure 6.2C). Male ENT1-/- mice showed a
reduction in time spent rearing with age, with a significant reduction at 6 months-of-age
compared to 2 months-of-age. No significant difference was detected in the time spent immobile
between wild-type and ENT1-/- mice during tail suspension at any of the time points assessed;
however, a significant increase in time spent immobile was observed in both female and male
ENT1-/- mice between 2 and 6 months-of-age (Figure 6.2D). In both wild-type and ENT1-/- mice,
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Figure 6.2. ENT1-/- mice show changes in grip force and lack of axial-induced discomfort
during the tail suspension assay. A, In the grip-force assay, peak force to the point of release
is recorded during axial stretch (measured in grams). Data are stratified by sex and are expressed
as summary means ± SEM (n=10 females and n=10 males, per genotype). Data from two female
wild-type at 2 months-of-age are missing due to non-compliance with testing. B-D, In the 3 min
tail suspension assay, spontaneous behaviors to axial stretch are recorded: (B) self-supporting,
(C) rearing, and (D) immobile. Data are the averaged scores from two independent blinded
observers, stratified by sex, and plotted as summary means ± SEM (n=10 females and n=10
males, per genotype). *P<0.05 by two-way-ANOVA or mixed-effects model with Sidak’s
multiple comparisons test.
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minimal time during tail suspension was spent stretching (12 s of the 180 s period) and no
differences were detected between genotypes (data not shown).
6.5.3 Behavioral Assessments of Physical Function
Open field assay. Voluntary physical activity was assessed for 5 min at each timepoint
in wild-type and ENT1-/- mice using the open field assay. No significant differences were detected
in locomotion (i.e., total distance traveled) between ENT1-/- and wild-type mice at any of the time
points assessed (Figure 6.3A). Similarly, no differences were detected in other voluntary
locomotion metrics captured in open field, including total movement time or rest time (data not
shown). Conversely, a marked reduction in vertical activity (i.e., rearing on hindlimbs) was
observed in ENT1-/- mice compared to wild-type at each time point, in both male and female mice
(Figure 6.3B).
We next evaluated the effect of axial stretch on locomotion by comparing the voluntary
activity of ENT1-/- and wild-type mice in the open field assay before and after tail suspension.
Tail suspension induced a reduction in voluntary activity (total distance traveled) in all groups
assessed, with no differences detected between wild-type and ENT1-/- mice (Figure 6.3C). In
contrast to locomotion, tail suspension induced a reduction in vertical activity in wild-type mice.
No change from baseline was detected in ENT1-/- mice since they demonstrated minimal vertical
activity prior to tail suspension (Figure 6.3D).
Rotarod assay. We next investigated if ENT1-/- mice demonstrated altered locomotor
capacity due to the presence of ectopic spinal calcifications using an accelerating rotarod assay
where the outcome measure was time to fall. No significant difference in locomotor capacity was
detected in ENT1-/- mice compared to wild-type at any of the time points examined in either male
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Figure 6.3. ENT1-/- mice are comparable to wild-type in physical function measures. A-B,
In the open field assay, baseline levels of voluntary locomotion were recorded for 5 mins. A,
Total distance traveled during the 5 mins in reported in meters (n=10 females and n=10 males,
per genotype). A single result from a female wild-type mouse at 4 months-of-age was removed
from analysis as an outlier. Data are stratified by sex and are expressed as summary means ±
SEM. B, Vertical activity count is measured when an infrared sensor in the Z-plane is disrupted
(n=10 females and n=10 males, per genotype). A single result from a male ENT1-/- mouse at 4
months-of-age was removed from analysis as an outlier. Data are stratified by sex and are
expressed as summary means ± SEM. C-D, The effect of axial induced stretch of voluntary
physical function was measured with 5 mins of open field following the tail suspension assay. A
difference score was calculated as the change in open field before and after tail suspension (Δ
difference = post – pre open field). The previously identified outlier were also removed from the
analysis of (A) difference in total distance traveled and (B) difference in vertical activity count.
E, In the rotarod assay, locomotor capacity was quantified by the time spent on an accelerating
rotating rod (n=10 females and 10 males, per genotype). Data are stratified by sex, expressed as
summary means ± SEM. *P<0.05 by two-way-ANOVA or mixed-effects model with Sidak’s
multiple comparisons test.
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or female mice (Figure 6.3E). Moreover, no change in performance was detected over time for
either genotype or sex.
FlexMaze assay. In the FlexMaze assay, mice undergo lateral spine flexion to progress
through the staggered gates and explore the maze34. When the average number of double gates
passed over the total assay duration was assessed, female ENT1-/- mice showed less activity than
age-matched wild-type mice, with a significant reduction at 4 months-of-age (Figure 6.4A). In
contrast, male ENT1-/- mice only demonstrated reduced activity compared to age-matched wildtype mice at six months-of-age. Male ENT1-/- mice also showed a significant decrease in
FlexMaze activity between 2 and 6 months-of-age.
Intriguing differences were also noted when behavior was assessed in discrete time
intervals during the 20 min FlexMaze assay (Figure 6.4B-C). In females, activity in the
FlexMaze decreased over the duration of the assay in both wild-type and ENT1-/- mice at all time
points assessed (Figure 6.4B). At 2 months-of-age female ENT1-/- mice showed reduced activity
compared to wild-type mice during the 5-10 and 15-20 min intervals. At 4 and 6 months-of-age,
female ENT1-/- mice showed reduced exploration during all intervals of the latter 15 min of the
test (5-10, 10-15, and 15-20 min) compared to age-matched wild-type mice. Comparatively in
males, activity in the FlexMaze was relatively stable over the duration of the assay in both wildtype and ENT1-/- mice up to 6 months-of-age (Figure 6.4C). At 2 months-of-age no difference
in activity was detected between male wild-type and ENT1-/- mice throughout the duration of the
assay. At 4 months-of-age, the activity of male wild-type and ENT1-/- mice decreased over the
duration of the assay. However, at 6 months-of-age, activity decreased over the duration of the
assay for male ENT1-/- mice but not male wild-type mice. No differences in activity were detected
between male wild-type and ENT1-/- mice at 2 or 4 months-of-age. At 6 months-of-age male
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Figure 6.4. ENT1-/- mice show reduced physical function during the FlexMaze assay. A-C,
In the FlexMaze assay, ambulation speed is measured as the number of double gates crossed per
minute during the 20 min test. Data are the scores from a single blinded observer, stratified by
sex, and plotted as summary means ± SEM (n=10 females and n=10 males, per genotype). A,
The total number of double gates crossed during the full duration of the test for both sexes.
*P<0.05 by two-way-ANOVA with Sidak’s multiple comparisons test. B-C, The 20 min test was
then segmented into 5 min intervals (0-5, 5-10, 10-15, and 15-20 minutes) and stratified for (B)
females and (B) males. Data are expressed as summary means ± SEM and are fitted with linear
regressions. *P<0.05 by unpaired, two-tailed t-test for differences between genotypes during
each interval.
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ENT1-/- mice showed reduced activity compared to wild-type mice, during the final 10 min of the
assay.
6.5.4 Behavioral Assessments of Sensitivity to Cutaneous Sensory Stimuli
Lastly, we assessed indicators of cutaneous sensitivity in the hindlimb, which in mouse
models of lumbar IVD degeneration are indicative of radiating pain27,34,38,42. No significant
differences were detected in sensitivity to cold between wild-type and ENT1-/- mice at any time
point (Figure 6.5A). This finding was consistent in female and male mice. Similarly, no
significant differences were detected in hindlimb mechanical sensitivity between wild-type and
ENT1-/- mice at any timepoint, in either male or female mice (Figure 6.5B).
6.5.5 ENT1-/- Mice Show Neuroplastic Changes in the Cervical Spinal Cord
To further investigate the association between ectopic spine calcification and indicators
of pain in ENT1-/- mice, we assessed molecular markers of neuroplastic changes in the cervical
enlargement of the spinal cord in mice at 6.5 months-of-age since at this age the cervical region
is most severely affected by ectopic calcification. Pain can be modulated by the neurotransmitter
CGRP and increased expression is associated with nerve hyperexcitability and sensitization43. In
both female and male mice, CGRP immunoreactivity was consistently elevated in ENT1-/- mice
relative to wild-type in the dorsal horn of the cervical spinal cord at all regions of the cervical
enlargement (Figure 6.6A). Increased levels of GFAP, a marker of astrocytes44, and IBA1, a
marker of microglia45, are associated with increased hyperalgesia. GFAP immunoreactivity
within the dorsal horn of the cervical spinal cord was significantly increased in both female and
male ENT1-/- mice compared to wild-type in all cervical regions except the most rostral region in
males (Figure 6.6B). No significant differences were detected in IBA1 immunoreactivity in the
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Figure 6.5. ENT1-/- mice show no difference in hind limb cold or mechanical sensitivity. A,
In the acetone assay, acetone is introduced to the plantar surface of the hind paw and the amount
of time mice spent in acetone-evoked behaviors was recorded (e.g., elevation, stamping, flicking,
licking, or scratching of the affected paw). Data are the scores from a single blinded observer of
the first hind paw tested (n=10 females and n=10 males, per genotype). Data are stratified by sex,
expressed as summary means ± SEM. *P<0.05 by two-way-ANOVA or mixed-effects model
with Sidak’s multiple comparisons test. B, In the von Frey assays, mechanical sensitivity is
measured by the response to the manual application of calibrated filaments using the Chaplan
up-down method. No differences between left and right hind paws was detected using MannWhitney’s test so data are averaged from both paws (n=10 females and n=10 males, per
genotype). *P<0.05 by Mann-Whitney tests for differences between genotype or Friedman’s
with Dunn’s multiple comparisons test for differences between time points.
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Figure 6.6. ENT1-/- mice show differences in neuroplasticity in the cervical enlargement of
the spinal cord at 6.5 months-of-age. A-C, Representative sections and fluorescence
quantification of the dorsal horn of the cervical spinal cord region. No differences were detected
between left and right dorsal horns using Mann-Whitney’s test, so data were pooled (n=3-4
females and n=3 males, per genotype). Due to anatomical and size differences in the cervical
spinal cord, the upper, mid, and lower regions of the cervical enlargement were analyzed
independently. The total area analyzed was standardized following the collection of the raw
integrated density measurement. Immunoreactivity was measured for (A) calcitonin gene-related
peptide (CGRP), (B) glial fibrillary acidic protein (GFAP), and (C) ionized calcium-binding
adapter molecule 1 (IBA1). Data are plotted as mean ± SEM (1-18 dorsal horns analyzed per
cervical enlargement region per mouse). *P<0.05 by Mann-Whitney test for genotype
differences and Kruskal-Wallis with Dunn’s multiple comparisons test for differences between
cervical regions.

320
dorsal horn of the cervical spinal cord between wild-type and ENT1-/- mice, in either males or
female (Figure 6.6C).

6.6 Discussion
The clinical features of DISH in humans are poorly understood and are typically reported
as generalized increased spine stiffness, with or without back pain, based on limited case reports
of late-stage disease6,11. As such, the impact of pain for people living with DISH is ambiguous.
The present investigation reports on behavioral indicators of physical function and pain in a
preclinical mouse model of DISH. We demonstrate that, compared to age and sex-matched wildtype mice, ENT1-/- mice show alterations in physical function as reflected by decreased grip force,
decreased vertical activity in open field and decreased activity in the FlexMaze. Furthermore,
ENT1-/- mice exhibit neuroplastic changes in the cervical spinal cord including increased
immunolocalization of CGRP and GFAP; indicators of pain. Taken together, these findings
demonstrate that the ENT1-/- mouse recapitulates key clinical features of DISH including
alterations in physical function and pain, providing new insight into the association between the
progression of ectopic spine calcification and detection of these features.
In humans, ectopic mineral formation associated with DISH occurs over an extended
period of time; calcifications are thought to initiate between 30 and 40 years-of-age, although
DISH is typically diagnosed between 50 and 70 years-of-age46. Recent studies by our group
characterized the morphological appearance of ectopic calcifications in human spines meeting
the diagnostic criteria for DISH25, and demonstrated that ectopic mineral forms by both
heterotopic ossification and dystrophic calcification of fibrocartilaginous tissues26. It is however
poorly understood when along the continuum of spine calcification symptoms are experienced.
The ENT1-/- mouse recapitulates key aspects of DISH pathogenesis, including the spatiotemporal
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pattern of progression and spinal tissues affected. In ENT1-/- mice, ectopic calcification is first
detected at 2 months-of-age and progressively affects spine anatomy more severely over time by
6 months-of-age24. In the current study, we show that behavioral signs of impaired physical
function and pain are detected in ENT1-/- mice as early as 2 months-of-age and increase over time
along with the spatiotemporal progression of ectopic calcification. These findings raise the
intriguing possibility that although DISH is described in the literature as largely asymptomatic
in early stages, the onset of ectopic calcification of spinal tissues may likewise impair physical
function and cause pain in patients.
Our analyses highlighted notable changes in physical function in ENT1-/- mice associated
with ectopic spine calcification and suggestive of pain. Similar to findings associated with IVD
degeneration34,47, ENT1-/- mice showed a pronounced reduction in activity in the FlexMaze assay
in which movement requires lateral spine flexion. Significant differences were detected in both
male and female ENT1-/- mice, suggesting that the stiffening of the spine previously demonstrated
in the ENT1-/- mice limited their ability to explore the maze and/or the ENT1-/- mice are in pain,
reducing mobility48. Of note, in addition to the reported decrease in the rate of maze exploration,
ENT1-/- mice showed consistent behavioural changes compared to age-matched wild-type mice
including hunched posture and altered gait patterns to maneuver through the gates of the maze.
Interestingly, similar functional changes have been reported in people living with DISH,
including greater thoracic kyphosis and reduced range of lateral flexion of the thoracic spine6,49.
The similarity between performance of ENT1-/- and wild-type mice in the Rotarod assay and in
overall locomotion in open field suggests a lack of general functional impairment associated with
spine calcification. However, the absence of vertical activity (e.g., rearing) demonstrated by
ENT1-/- mice in open field may also indicate a specific limitation in physical function and/or an
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avoidance of pain-inducing activities.
Our findings suggest that behaviors characteristic of stretch-induced axial discomfort
were not associated with spine calcification in the ENT1-/- mice. Previous studies using mouse
models of IVD degeneration demonstrated that during tail suspension, time spent rearing and
self-supporting increased with disease severity34,47. In contrast to these models, ENT1-/- mice
showed a reduction in time spent self-supporting in tail suspension compared to age-matched
wild-type mice. These findings suggest that ENT1-/- mice may not be experiencing axial stretchinduced discomfort during tail suspension but instead may be physically unable to perform the
hyperflexion movements due to increased spine stiffness. We also demonstrated that ENT1-/mice showed reduced grip-force during axial stretch compared to age-matched wild-type
controls. Similar to tail suspension, previous studies reported reduced grip strength during axial
stretch in mouse models of IVD degeneration as evidence of stretch-induced axial discomfort34.
Of note, similar reductions in grip-force have been reported for patients with DISH, used in the
clinical context as a surrogate measure of chronic pain and/or weakness6,13,50,51. Previous studies
demonstrated that increased stiffness of the lumbar spine in ENT1-/- mice was associated with a
concurrent decrease in muscle fiber elastic modulus in the adjacent paraspinal muscles (erector
spinae and multifidus) at 8 months-of-age48. This direct compensatory relationship establishes
that paraspinal muscular changes are associated with ectopic calcifications stiffening the spine
in ENT1-/- mice. It is unknown whether these changes include muscle atrophy and subsequent
weakness that could impair physical function, secondary effects of spine calcification that may
impact the behavior of ENT1-/- mice in both of these assays.
The current study demonstrates that, over the timecourse assessed, ENT1-/- mice did not
show evidence of mechanical or cold sensitivity in the hindpaw compared to age-matched wild-
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type controls, suggesting the absence of allodynia. However, a reduction in FlexMaze activity
and rearing behavior in ENT1-/- mice suggests that axial pain could be a contributor to the
observed changes. Behavioral measures of axial pain were further validated by molecular
analysis showing evidence of pain-related changes in the cervical spinal cord of ENT1-/- mice.
Increased levels of CGRP in the dorsal horn in ENT1-/- mice provides evidence of pain-related
neurotransmission by primary nociceptive neurons. Furthermore, elevated levels of GFAP in
ENT1-/- mice in the absence of increases in IBA1 levels suggests that astrocytes, not microglia
may be primarily responsible for the neuroplasticity observed. The detection of these neuroplastic
changes are consistent with mouse models of IVD degeneration that show axial pain52. This
implies that pain associated with neural changes are likely a significant feature of the preclinical
mouse model of DISH and need to be strongly considered as a relevant clinical feature in people
living with DISH. To date, the most comprehensive case-control study, including clinical
information on physical function, subjective surveys, and laboratory results, compared people
living with DISH to those with spondylosis and healthy controls6. The authors concluded that
chronic back pain, specifically in the cervical and thoracic regions of the spine, and upper
extremity pain are significant clinical features associated with DISH6. Subsequent studies have
either confirmed7,8 or refuted10 back pain as an essential clinical feature associated with DISH.
Taken together, our results show that ENT1-/- mice exhibit classic symptoms of reduced physical
function and axial pain associated with the presence of ectopic calcifications beginning even in
early-stage disease. These findings suggest that the burden of pain throughout the progression of
spine calcification in DISH should be evaluated, including in early-stage disease which is not
typically assessed in the clinic currently.
Studies using numerous models of pain in humans and rodents have shown sex-specific
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differences in pain perception53. Indeed, the current study shows numerous sex-specific
differences in the outcomes of the behavioral assays conducted. Overall, it appears that female
ENT1-/- mice exhibit signs of pain at earlier stages of disease progression than males. In both the
grip force and FlexMaze assays, female ENT1-/- mice showed significant differences from wildtype mice at 2 months-of-age, whereas significant differences were not detected in male mice
until 6 months-of-age. Since the extent of calcification is not different between female and male
mice at any time point, these findings suggest that female ENT1-/- mice may be more sensitive to
pain. This agrees with previous studies of inflammatory and chronic pain assays in rodents where
females had increased sensitivity in the majority of assays53. It is unclear what mechanism may
be responsible for sex-specific differences in pain perception. However, it has been proposed that
these differences may be mediated through COX (cyclooxygenase) activation since COX levels
differ between sexes, and estrogen modulates COX-2 levels53. The role of COX activation in
mediating the pain response in ENT1-/- mice could be examined in subsequent studies using
commercially available pharmacological inhibitors.
A strength of the current study is the longitudinal evaluation of behavioral-indicators of
pain focused on changes during early disease phases (e.g., 2 and 4 months-of-age). Overall, it
appeared that significant differences between ENT1-/- mice and WT became more common as
spine calcification progressed suggesting that the presence of small ectopic calcifications may
not produce severe symptoms immediately. Instead, perhaps there is a particular extent of
calcification that reaches a symptom-producing threshold in ENT1-/- mice, but this threshold is
not known. This may explain the variability reported in humans with DISH, depending where
they are along the disease continuum or based on their natural pain threshold. Therefore,
treatment strategies aimed to delay or halt the progression of ectopic calcification are extremely
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valuable. Of equal importance would be understanding the influence ectopic calcifications on the
biomechanics of spinal tissues and consequently on physical function in patients with DISH.
There are several considerations in the interpretation of our results. First, behavioral
testing in animal models requires care in the interpretation of data, as no single assay can confirm
or refute behavioral-indicators of pain. To address this limitation, our study was designed to
include multiple complementary assays that together inform on the physical function and pain
experienced by ENT1-/- mice. Second, the ENT1-/- mouse model differs from DISH in that it does
not show ectopic mineral formation at sites the appendicular skeleton (e.g., ankles, knees, elbow)
that can be affected in DISH pathogenesis. Because of this difference, assessment of changes in
physical function and pain in ENT1-/- mice was limited to axial pain, whereas in humans, pain
should be assessed in all affected joints. Finally, additional studies are needed to further explore
and differentiate symptoms of pain and physical dysfunction by pharmacological targeting of
inflammatory and nociceptive pain pathways.
In conclusion, this is the first evidence that pain and impaired physical function are
relevant features associated with the ENT1-/- preclinical mouse model of DISH. The ENT1-/mouse model of ectopic spine calcification recapitulates symptoms and physical dysfunction of
people living with DISH, and our longitudinal study design identified a continuum of
impairments to physical function and behavioral indicators of pain associated with progressive
spine calcification. Importantly, behavioral changes were noted as early as 2 months-of-age in
the mice but were more frequently detected at later time points as the severity of ectopic spine
calcification increased. Although the mechanism of pain could not be delineated in the current
investigation, our results provide the foundation for the application of future targeted treatments
to alleviate symptoms of DISH and/or modify the disease.
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7.1 Contributions and Significance of Findings
The overall goal of my thesis was to identify regulators of ectopic calcification in DISH.
Using a mouse model, I was able to investigate the molecular changes associated with DISH
pathology, as well as characterize potential symptoms associated with ectopic calcifications that
could be applied to the clinical condition. My lab has been studying the ENT1-/- mouse model of
DISH since it was serendipitously discovered that these mouse consistently exhibited
calcifications with advanced age that resemble DISH1. Since ENT1 directly transports adenosine,
and adenosine is known to mediate behavior associated with alcohol consumption, the ENT1-/mouse was initially used to study ethanol-mediated behaviors2. At Western, the ENT1-/- mouse
was used to study the regulation of nucleoside and nucleobase transporters in cardiac
microvascular endothelial cells3,4. In these initial studies, the phenotype of ectopic spine
calcification was not noted since experiments were conducted on mice less than 6 months-of-age
when ectopic spine calcification was not apparent at gross examination. The discovery of ectopic
calcification was based on the observation of hind limb paresis in ENT1-/- mice > 8 months-ofage. Examination of these mice at autopsy identified large calcifications impinging on the spinal
cord, prompting the micro-CT based studies we conducted which revealed DISH-like
radiographic findings1. Further work by our lab localized calcifications within the AF of the IVD
in ENT1-/- mice and demonstrated that alkaline phosphatase activity is altered at these sites, along
with a reduction in the expression of mineralization inhibitors5. Of note, the mechanism of
ectopic calcification did not follow a canonical pathway for ossification; the lesions did not
contain cells nor the organized structures of bone such as trabeculae or Haversian canals.
Therefore, we sought to identify the molecular pathways responsible for the presence of DISHlike ectopic calcified lesions in the AF of ENT1-/- mice using an unbiased approach.
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I began by investigating the transcriptome of WT and ENT1-/- mice as transcriptomic
technologies are the most complete high-throughput molecular biology tool to investigate
signaling and thus provided the largest net to capture differences. However, the transcriptome of
the distinct tissues within the IVD had not been established, and thus it was not possible to
determine how ENT1-/- mice vary from WT without establishing a baseline of gene expression.
Although a special research interest group had established robust markers for the young, healthy
NP due to the notion that IVD degeneration initiates in this tissue6, characterization of the AF
transcriptome and changes associated with age in the mouse IVD remained unknown . Therefore,
using microarrays studies in Chapter 2 first aimed to establish the gene expression signature
associated with the AF and changes associated with aging in the IVD. It was found that canonical
cartilage markers Prg4, Cilp, Ibsp, and Comp were enriched >50-fold in the AF compared to the
NP, making these potential tissue-specific markers in the murine IVD. Furthermore, we showed
that NP degeneration is associated with molecular functions linked to alpha-actinin binding and
cytoskeletal protein binding7.
With the baseline gene expression of IVD tissues established in the mouse, I moved on
to investigate the gene expression signature specifically associated with loss of ENT1 in the AF
coinciding with ectopic calcification (Chapter 3). I found that cell proliferation in the AF of
ENT1-/- mice was increased without a concomitant increase in cell number, leading us to develop
a theory that apoptotic cell bodies serve to initiate mineral nucleation from their exposed
phosphatidylserine membranes. Furthermore, we found that increased MAPK activation via JNK
phosphorylation was associated with this increase in cell proliferation in ENT1-/- mice, where we
posited that altered stimulation of the adenosine receptors could modulate PI3K/Akt signaling to
effect changes in MAPK signaling8.
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Transcriptomic studies implicated novel markers of specific IVD tissues and potential
players in the pathological calcification of ENT1-/- mice, but could not fully explain the
phenotypes observed. Moreover, gene expression changes do not necessarily correspond to
protein or metabolite changes. Therefore, I aimed to use other high-throughput “omics”
technologies to further substantiate our transcriptomic changes and further explore the phenotype
of ENT1-/- mice. However, the use of proteomics to study IVD biology has been limited to a few
studies of IVD degeneration in humans9-11, global characterization of the murine IVD12,13, and to
examine the effects mechanical loading on the IVD in mice14. The protocols and methodologies
for proteomics vary, making it difficult to compare datasets from one lab to another. Moreover,
there have been no metabolomic studies of murine IVD tissues to date, and the analysis of human
IVD tissues is limited to a single unbiased metabolite screen using high-resolution magic angle
spinning (HR-MAS) nuclear magnetic resonance (NMR)15, which is much less sensitive than
mass spectrometry (MS) based metabolomics16.
In Chapter 4 we therefore aimed to establish a protocol to generate proteomic and
metabolomic datasets from tissues isolated from the same animal that could be directly correlated
to one another. Our protocol for the parallel assessment of proteomic and metabolomic changes
in murine IVD tissues allowed for the quantification of over double the number of proteins from
our previous method12 by using fractionation paired with intensity based absolute quantification.
Furthermore, we avoided over-representation of ECM proteins in the IVD that could obscure
low-abundant protein signals, quantifying proteins from all cellular compartments in addition to
ECM. Additionally, we identified over 300 metabolites in mouse plasma and over 700
metabolites in the murine AF, a feat that has never been accomplished before.
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Having validated the quality of these methodologies, we applied them to tackle our
experimental question investigating the molecular pathology of DISH (Chapter 5). Proteomics
confirmed our previous findings of increased cell proliferation in the AF of ENT1-/- mice8 with
protein-level changes in cell cycle-related proteins and MAPK dysregulation. Moreover, we
confirmed previous findings of matrix gla protein downregulation1,5, associating decreases in
protein levels with ectopic calcification suggesting that this protein may play a central role in
limiting calcification in the AF in normal circumstances. Metabolomics revealed that numerous
LysoPCs are elevated in both the plasma and AF tissue of ENT1-/- mice by 6 months-of-age,
implicating fatty acid metabolism in DISH pathology. Importantly, integration of proteomic and
metabolomic data led to the development of a proposed mechanism regulating the molecular
pathogenesis of ectopic calcification in the ENT1-/- mouse model of DISH (Figure 7.1). We
found elevated CASP3 in the AF of ENT1-/- mice, which is associated with both propagating
apoptosis and cleavage activation of phospholipase A217. Phospholipase A2 is the enzyme
responsible for the production of LysoPC and increased activation of phospholipase A2 agrees
with our observation of increased LysoPC levels in 6-month-old ENT1-/- mice. Finally, there is
also evidence that adenosine dysregulation can lead to altered PI3K/Akt signaling via altered
stimulation of the adenosine receptor A2a18. This may explain how the phenotype observed in
the ENT1-/- AF can be initiated by increased adenosine levels mediated by PI3K/Akt signaling.
Finally, the burden of back pain in people living with DISH is still equivocal with some
studies suggesting DISH is painful19-21, while others suggest DISH is not painful22,23. We
therefore sought to evaluate the symptoms of pain and stiffness in the mouse model of DISH in
the hopes of providing evidence that pain may be an important symptom to better understand and
treat in DISH patients. Indeed, in Chapter 6 we report the first evidence that pain and impaired
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Figure 7.1. Schematic overview depicting our proposed model linking altered adenosine
signaling due to loss of ENT1 with ectopic calcification in AF tissue. A. Loss of ENT1 leads
to increased intracellular and circulating adenosine levels. Increased adenosine can increase
stimulation of the adenosine A2A receptor, which is a g-protein coupled receptor. Stimulation of
A2A receptor leads to a g-protein signaling cascade that downregulates PI3K-dependent
activation of Akt, leading to increased caspase 3 expression/activity (CASP3) and MAPK
pathway activation. Caspase 3 is responsible for triggering a cascade that leads to cell apoptosis
but can also cleave to activate the phospholipase A2 enzyme. Activated phospholipase A2
increases lysophosphatidylcholine levels (LysoPC). B. Once caspase 3 has triggered the
signaling cascade to induce cellular apoptosis, CD47 is downregulated, providing an “eat me”
signal for phagocytes to clear away cellular debris from the AF. However, over time the cell is
not able to maintain this “eat me” signal and increases levels of SIRPA (signal-regulatory protein
alpha) to switch to a “don’t eat me” signal to phagocytes. Concomitantly, phospholipid
scramblase (PLSCR1) activity is drastically increased resulting in a flipping of the phospholipid
bilayer to expose phosphatidylserine (PS) at the cell surface. PS then serves as a nucleator for
mineral deposits to form, which accumulate over time.
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physical function are relevant features associated with the ENT1-/- preclinical mouse model of
DISH. Specifically, we show that ENT1-/- mice experience severe discomfort during lateral
bending and this is associated with neuroplastic changes in the cervical spinal cord resulting in
increased markers of nociceptive neurons (CGRP) and astrocytes (GFAP). I believe that these
symptoms of pain and stiffness result from the physical presence of ectopic calcifications in the
spine, but cannot discount the possibility that molecular signaling between the IVD and dorsal
root ganglia/spinal cord could be partially responsible for the molecular phenotype observed.
These findings further substantiate that pain is likely a large component of DISH symptomology
and should be treated as such by clinicians.
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7.2 Limitations of Research and Future Directions
As with any study there are important limitations that may have influenced the
conclusions and should therefore be acknowledged. To begin with, mouse models of
intervertebral disc pathologies can only recapitulate human disease to a certain extent. The
murine IVD is smaller in size, though it has a similar structure and has been shown to be a good
model of human IVD geometry in terms of the relative disc height, width, and NP size24.
Moreover, murine IVD biomechanics measured by axial compression and torsion are comparable
to those of human lumbar IVDs when normalized for disc height25,26. We use mouse models
because they are more manageable than large animals in terms of size, lifespan, and cost, and
also permit genetic manipulation allowing for the investigation of specific genes in the context
of IVD function and disease. However, the IVDs of larger animals share similarities in size and
structure with human IVD tissues and, in the case of sheep, have been shown to have comparable
spine biomechanics despite being a quadrupedal animal27,28. Therefore, translational DISH
research should transition to large animal models in the future to better approximate human
pathology. Specifically, the boxer dog breed spontaneously develops hyperostosis and would
make an intriguing large animal model29.
Furthermore, the ENT1-/- mouse model of DISH is a whole-body knockout which makes
it difficult to delineate the relative contributions of systemic changes vs. tissue-specific to
pathological calcification. For instance, based on my studies it appears that MGP likely plays a
role in limiting tissue calcification in the AF, a process that is lost in ENT1-/- mice. It would
therefore be of interest to carry out studies whereby MGP is under/overexpressed in ENT1-/- mice
to evaluate whether the presence or absence of MGP is more important than the presence or
absence of ENT1 in pathological calcification, and when in disease progression expression of
these factors are most important. Since MGP knockout mice die within 1-3 months30, genetic
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modulation of MGP expression in the ENT1 KO mouse would have to be driven by an AFspecific CRE (though to date no AF-specific mouse strains have been reported).
Another limitation is that while ENT1-/- mice model the ectopic calcifications associated
with DISH exceptionally well, our group has found that DISH in humans involves both
dystrophic calcification and heterotopic ossification31, the later of which is absent from the ENT1/-

mouse model. Twy mice also develop amorphous, calcified lesions in the AF characteristic of

DISH but also show extraspinal manifestations of DISH not evident the ENT1-/- mice, such as
calcification of knee articular cartilage1,32. However, Twy mice also develop OPLL so it is not
possible to evaluate each disease separately in this model33,34. I would suggest investigating the
same mechanisms side by side in both of these models to really tease apart how ectopic
calcification and heterotopic ossification happens in DISH and OPLL, and if they differ. For
example, one could modulate PI3K/Akt signaling in vivo and examine the effects on both the
ENT1-/- and Twy mouse to determine if these two models respond similarly, and where they differ.
Our findings are also limited by the need for future validation of the candidate pathways
and/or biomarkers we identified. For instance, in Chapter 5 I suggest that LysoPC 18:2 could
serve as a potential biomarker for early stage DISH based on metabolomics studies in the ENT1/-

mouse. The use of LysoPC 18:2 as a biomarker must first however, be tested in human patients

that often present with comorbid conditions that may influence the use of metabolites related to
fatty acid metabolism as biomarkers. We have collected the plasma samples from DISH patients
and age/sex-matched patient controls to carry out a pilot study to test candidate LysoPC
metabolites as biomarkers using the protocols established in Chapter 4. The variation in human
plasma metabolites makes it challenging to develop any biomarker, let alone a biomarker in older
DISH patients that present with multiple comorbidities. However, should LysoPC levels be
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validated as a robust biomarker of early stage DISH, this could be applied in the clinic to allow
for diagnosis at an earlier stage of disease. Furthermore, if therapeutics were to be developed,
early diagnosis would allow for intervention at an earlier stage of disease likely resulting in a
better prognosis for DISH patients. I also identified potential biomarkers of DISH within AF
tissue, such as S100A9 and SIRPA that should be validated in situ by immunohistochemistry.
Should S100A9 and SIRPA serve as robust biomarkers in the mice, these proteins could be
evaluated in human cadaveric tissues to further compare the human pathology to the mouse
model.
Additional experiments should also be carried out with small molecules to directly
evaluate the contribution of PI3K/Akt signaling in DISH pathogenesis. These experiments could
be carried out using the 3-D micromass AF cell culture model that our lab has established in
which primary ENT1-/- AF maintain the phenotype of ectopic calcification in vitro5. For example,
Wortmannin is a well-known potent inhibitor of PI3K/Akt signaling that could be added to both
WT and ENT1-/- AF cells in culture to evaluate the contribution of this signaling pathway to the
induction of AF mineralization35. Alternatively, due to advances in cancer research, numerous
non-coding RNAs have been identified as modulators of PI3K/Akt signaling that could be used
to tease apart this pathway’s contribution to ectopic calcification in fine detail36. Finally, although
Chapter 6 used both behavioural assays and immunohistochemistry to suggest ENT1-/- mice
experience pain and stiffness characteristic of DISH, the relative contribution of pain to the
mobility phenotype should be assessed in mice treated with of an analgesic drug. For instance,
the administration of morphine and clonidine in a mouse model of back pain ameliorated
behavioral signs of pain37; these same drugs could be used in the ENT1-/- mouse model.

340
Taken together the studies presented in this thesis revealed novel markers of specific IVD
tissues, contributed to our understanding of the molecular pathology of DISH, and implicated
pain as a prominent symptom in DISH. Overall, I posit that dysregulation of phagocytic signaling
and cell apoptosis downstream of PI3K/Akt signaling serve to nucleate mineral formation in the
AF of ENT1-/- mice and that the physical presence of these calcified lesions results in the stiffness
and pain characteristic of DISH.
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Trainee Instructor, Graduate program in Musculoskeletal Health Research (2015 - present)
MSK9000: Musculoskeletal Health Research: Biomedical & Bioengineering Concepts (3 hour Lab Module).
Part of a trainee team that coordinated lab module for graduate students on molecular biology techniques.
Instructed the section on genotyping and polymerase chain reaction.
Trainee Guest Lecturer, Department of Physiology and Pharmacology (2016 - 2019)
Phys/Pharm 9550: Molecular Techniques. Delivered 1 hour guest lecture on qPCR primer design and
analysis.
Teaching Assistant, Department of Physiology and Pharmacology (2015 - 2018)
Phys/Pharm 3130Z/3000E: Human Physiology Laboratory Module

STUDENT SUPERVISION
2018-2019

2018

2017-2018

Dorothy Kawa – Undergraduate Honors Thesis Student, Department of Physiology and
Pharmacology
Project: Histopathological characterization of sex- and age-dependent intervertebral disc degeneration
in CD1 mice
Alexzandra Hughes-Visentin – CIHR Summer Student, Department of Physiology and Pharmacology
Project: Computed tomographical analysis of the effect of voluntary wheel running on calcifications
in a mouse model of diffuse idiopathic skeletal hyperostosis
Alexander Popa – Scholar’s Elective Program Undergraduate Research Student (3rd year)
Project: Investigating the effects of mechanical loading on calcification in a mouse model of diffuse
idiopathic skeletal hyperostosis

VOLUNTEER ACTIVITIES AND COMMITTEE MEMBERSHIPS
2018-Present
2018-2019
2017-2019
2017-2019
2017-2019
2018
2018
2018
2018
2017-2018
2017
2017
2016-2017

Co-President – Graduate Management Consulting Association (Western Chapter)
Trainee Representative – Graduate Studies Committee, Department of Physiology and Pharmacology
Trainee Representative – Department of Physiology and Pharmacology Graduate Student Council
Chair: Trainee Leadership Committee (TLC) – Collaborative Training Program in Musculoskeletal
Health Research
Trainee Representative – Bone & Joint Institute Management and Operations Committee (MOC)
Co-organizer and Volunteer – Bone & Joint Community Outreach at London Children’s Museum
Graduate Student/Bone & Joint TLC Booth Volunteer – Inspiring Young Women in STEM
Conference Western
Bone & Joint Representative – Science Rendezvous Western 2018 Planning Committee
CMHR Undergraduate Information Session Presenter (TLC Initiative) - Phys/Pharm 4980
Planning Committee – Canadian Bone & Joint Young Investigator Forum 2018
Trainee Presenter – The Arthritis Society Skeletal Biology Laboratories Tour Western 2017
Co-Organizer: Young Investigator Forum on Preclinical Musculoskeletal Health Research – Bone &
Joint Institute
Trainee Representative – Bone & Joint Institute Seminars Committee
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INVITED TALKS
1) Matthew A. Veras, Yong J. Lim, Miljan Kuljanin, Gilles A. Lajoie, Bradley L. Urquhart, Cheryle A. Séguin.
(2020). Regulators of ectopic calcification in a mouse model of DISH: A multi-omics perspective. Canadian
Arthritis Research Conference, Victoria, BC, Canada.
CONFERENCE PRESENTATIONS
1) Matthew A. Veras, Dale E. Fournier, Diana Quinonez, Magali Millecamps, Laura S. Stone, Cheryle A.
Séguin. (2019). Behavioral assessment of mobility and pain in mouse model of diffuse idiopathic skeletal
hyperostosis (DISH). ORS PSRS 5th International Spine Research Symposium, Skytop, PA, United States
[Poster award winner]
2) Matthew A. Veras, Matthew R. McCann, Neil A. Tenn, Cheryle A. Séguin. (2019). Transcriptional profiling
of the murine intervertebral disc and age-associated changes in the nucleus pulposus. London Health
Research Day, London, ON
3) Matthew A. Veras, Matthew R. McCann, Neil A. Tenn, Cheryle A. Séguin. (2019). Transcriptional profiling
of the murine intervertebral disc and age-associated changes in the nucleus pulposus. Gordon Research
Conference 2019 Cartilage Biology & Pathology, Galveston, Texas
4) Matthew A. Veras, Matthew R. McCann, Neil A. Tenn, Cheryle A. Séguin. (2019). Transcriptional profiling
of the murine intervertebral disc and age-associated changes in the nucleus pulposus. Gordon Research
Seminar 2019 Cartilage Biology & Pathology, Galveston, Texas [Selected from abstracts for oral
presentation]
5) Matthew A. Veras, Neil A. Tenn, Diana Quinonez, Miljan Kuljanin, Gilles Lajoie, James Hammond, S.
Jeffrey Dixon, Cheryle A. Séguin. (2018). Investigating potential regulators of ectopic calcification in a
mouse model of diffuse idiopathic skeletal hyperostosis using a multi-omics approach. Physiology and
Pharmacology Annual Research Day, London, ON, Canada [Poster award winner]
6) Matthew A. Veras, Neil A. Tenn, Miljan Kuljanin, Gilles Lajoie, James Hammond, S. Jeffrey Dixon, Cheryle
A. Séguin. (2018). Multi-omics approach reveals novel pathogenic indicators of DISH. American Society for
Bone and Mineral Research 2018 Annual Meeting, Montréal, QC, Canada [Selected from abstracts for oral
presentation in late-breaking research session]
7) Matthew A. Veras, Neil A. Tenn, Diana Quinonez, Miljan Kuljanin, Gilles Lajoie, James Hammond, S.
Jeffrey Dixon, Cheryle A. Séguin. (2018). Investigating potential regulators of ectopic calcification in a
mouse model of diffuse idiopathic skeletal hyperostosis using a multi-omics approach. Twelfth Fellows
Forum on Metabolic Bone Diseases, Montréal, QC, Canada
8) Matthew A. Veras, Neil A. Tenn, James Hammond, S. Jeffrey Dixon, Cheryle A. Séguin. (2018). Loss of
ENT1 alters cell cycle processes in the annulus fibrosus of the intervertebral disc. Canadian Bone & Joint
Conference 2018, London, ON, Canada
9) Matthew A. Veras, Neil A. Tenn, Hisataka Ii, Diana Quinonez, James Hammond, S. Jeffrey Dixon, Cheryle
A. Séguin. (2017). Loss of ENT1 alters cell cycle processes in the annulus fibrosus of the intervertebral disc.
Gordon Research Conference 2017 Cartilage Biology & Pathology, Lucca (Barga), Italy
10) Matthew A. Veras, Neil A. Tenn, Hisataka Ii, Diana Quinonez, James Hammond, S. Jeffrey Dixon, Cheryle
A. Séguin. (2017). Loss of ENT1 alters cell cycle processes in the annulus fibrosus of the intervertebral disc..
Gordon Research Seminar 2017 Cartilage Biology & Pathology, Lucca (Barga), Italy [Selected from
abstracts for oral presentation]
11) Matthew A. Veras, Neil A. Tenn, Hisataka Ii, Diana Quinonez, James Hammond, S. Jeffrey Dixon, Cheryle
A. Séguin. (2017). Loss of ENT1 alters cell cycle processes in the annulus fibrosus of the intervertebral disc..
London Health Research Day, London, Canada [Selected from abstracts for oral presentation]
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12) Matthew A. Veras, Neil A. Tenn, James Hammond, S. Jeffrey Dixon, Cheryle A. Séguin. (2017). Loss of
ENT1 alters cell cycle processes in the annulus fibrosus of the intervertebral disc. ORS PSRS 4th
International Spine Research Symposium, Lake Harmony, PA, United States
13) Matthew A. Veras, Neil A. Tenn, Hisataka Ii, Diana Quinonez, James Hammond, S. Jeffrey Dixon, Cheryle
A. Séguin. (2017). Loss of ENT1 alters cell cycle processes in the annulus fibrosus of the intervertebral disc.
Canadian Connective Tissue Conference, Montreal, Canada
14) Matthew A. Veras, Neil A. Tenn, Diana Quinonez, James Hammond, S. Jeffrey Dixon, Cheryle A. Séguin.
(2016). Characterization of changes in annulus fibrosus cell phenotype resulting from loss of ENT1. Canadian
Connective Tissue Conference, Hamilton, Canada
15) Matthew A. Veras, Neil A. Tenn, Diana Quinonez, James Hammond, S. Jeffrey Dixon, Cheryle A. Séguin.
(2016). Characterization of changes in annulus fibrosus cell phenotype resulting from loss of ENT1. Canadian
Bone & Joint Conference, London, Canada
16) Matthew A. Veras, S. Jeffrey Dixon, Cheryle A. Séguin. (2016). Characterization of changes in annulus
fibrosus cell phenotype resulting from loss of ENT1. Physiology and Pharmacology Research Day, London,
Canada
17) Matthew A. Veras, Neil A. Tenn, Diana Quinonez, James Hammond, S. Jeffrey Dixon, Cheryle A. Séguin.
(2016). Characterization of changes in annulus fibrosus cell phenotype resulting from loss of ENT1. London
Health Research Day, London, Canada
18) Matthew A. Veras, Jake Bedore, Cheryle A. Séguin. (2015). Investigating the effect of notochord-specific
Ccn2 knockout on gene expression in the intervertebral disc. Ontario Biology Day, Ottawa, Canada
19) Jake Bedore, Sunny Jang, Matthew A. Veras, Amanda Sauvé, Andrew Leask, Cheryle A. Séguin.(2015).
Assessing the effect of notochord-specific CCN2 deletion on intervertebral disc degeneration and behaviour
associated with back pain. Orthopaedic Research Society, Las Vegas, United States
20) Matthew A. Veras, S. Jeffrey Dixon, Cheryle A. Séguin. (2015). "Omics" approach to identify potential
regulators of ectopic mineralization in a mouse model of diffuse idiopathic skeletal hyperostosis. Physiology
and Pharmacology Research Day, London, Canada
21) Matthew A. Veras, Jake Bedore, Cheryle A. Séguin. (2015). Investigating the effect of notochord-specific
Ccn2 knockout on gene expression in the intervertebral disc. Western University Biology and Environmental
Sciences Research Day, London, Canada
22) Matthew A. Veras, Jake Bedore, Cheryle A. Séguin. (2015). Investigating the effect of notochord-specific
Ccn2 knockout on gene expression in the intervertebral disc. London Bone and Joint Annual Research
Retreat, London, Canada
23) Jake Bedore, Sunny Jang, Matthew A. Veras, Amanda Sauvé, Andrew Leask, Cheryle A. Séguin. (2015).
CCN2 deletion from the nucleus pulposus accelerates intervertebral disc degeneration and results in
behaviour associated with back pain in mice. The 8th International Workshop on the CCN Family of Genes,
Nice, France
24) Jake Bedore, Sunny Jang, Matthew A. Veras, Amanda Sauvé, Andrew Leask, Cheryle A. Séguin. (2015).
Assessing the effect of nucleus pulposus-specific CCN2 deletion on intervertebral disc degeneration and
behaviour associated with back pain. Canadian Connective Tissue Conference, Quebec City, Canada
25) Jake Bedore, Sunny Jang, Matthew A. Veras, Amanda Sauvé, Andrew Leask, Cheryle A. Séguin. (2014).
CCN2 secreted from notochord-derived cells regulates intervertebral disc development and protects from agerelated disc degeneration. Bone & Joint Injury Repair Conference, London, Canada
26) Jake Bedore, Matthew A. Veras, Sunny Jang, Amanda Sauvé, Andrew Leask, Cheryle A. Séguin. (2014).
Assessing the effect of nucleus pulposus-specific CCN2 deletion on intervertebral disc degeneration and
behaviour associated with back pain. Canadian Connective Tissue Conference, London, Canada
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PUBLICATIONS (* DENOTES CO-FIRST AUTHOR)
1) McCann MR, Veras MA, Yeung C, Lalli G, Patel P, Leitch K, Holdsworth DW, Dixon SJ, Séguin CA. (2017)
Whole-body vibration of mice induces progressive degeneration of intervertebral discs associated with increased
expression of IL1B and multiple matrix degrading enzymes. Osteoarthr Cartil May;25(5):779-789. (IF=4.9; cited 13)
DOI: 10.1016/j.joca.2017.01.004
2) Kerr GJ*, Veras MA*, Kim MKM, Séguin CA. (2017) Decoding the intervertebral disc: Unravelling the
complexities of cell phenotypes and pathways associated with degeneration and mechanotransduction. Semin Cell
Dev Biol Feb;62:94-103. (IF=5.5; cited 13) DOI: 10.1016/j.semcdb.2016.05.008
3) Veras MA, Tenn NA, Kuljanin M, Lajoie GA, Hammond JR, Dixon SJ, Séguin CA. (2019) Loss of ENT1
increases cell proliferation in the annulus fibrosus of the intervertebral disc. J Cell Physiol. 2019;234:13705-13719.
(IF=4.5, cited 1) DOI: 10.1002/jcp.28051
4) Veras MA, McCann MR, Tenn NA, Séguin CA. (2020) Transcriptional profiling of the murine intervertebral disc
and age-associated changes in the nucleus pulposus. Connect Tissue Res, 61:1, 63-81. [Selected as Editors’ pick]
(IF=2.2, cited 2) DOI: 10.1080/03008207.2019.1665034
MANUSCRIPTS IN PREPARATION/SUBMISSION

1) Bedore J, Veras MA, Jang S, Sauvé A, Tse J, Holdsworth DW, Leask A, Séguin CA. (In Revision) Lumbar
intervertebral disc degeneration and behavioural indicators of axial back pain in notochord-specific CCN2-deficient
mice. Sci Rep. (IF=4.0)
2) Veras MA, Lim YJ, Kuljanin M, Lajoie GA, Urquhart BL, Séguin CA. Protocol for the simultaneous assessment
of proteomic and metabolomic changes in mouse models of spine pathologies (Submitted to special call for protocols
at JOR Spine.)
3) Veras MA, Fournier DE, Quinonez D, Millecamps M, Stone LS, Séguin CA. Mice lacking equilibrative
nucleoside transport 1 recapitulate mobility and pain phenotypes of humans with diffuse idiopathic skeletal
hyperostosis (In preparation for submission to Arthritis Rheum)
4) Veras MA, Serjeant ME, Murray A, Séguin CA. Histological characterization of age-associated intervertebral disc
degeneration in CD1 and Bl6 mice (In preparation for submission to JOR Spine.)
5) Veras MA, Lim YJ, Kuljanin M, Dieters-Castator DZ, Lajoie GA, Urquhart BL, Séguin CA. Multi-omics
approach identifies novel lysophosphatidylcholine biomarkers and therapeutic targets of diffuse idiopathic skeletal
hyperostosis (In preparation for submission to Ann Rheum Dis.)
REFERENCES
Dr. Cheryle A. Séguin (PhD Supervisor, Acting Chair–Department of Physiology and Pharmacology, Schulich School of
Medicine & Dentistry, The University of Western Ontario)
Cheryle.seguin@schulich.uwo.ca
Dr. S. Jeffrey Dixon (PhD Advisor, Distinguished Professor Emeritus–Department of Physiology and Pharmacology, Schulich
School of Medicine & Dentistry, The University of Western Ontario)
jeff.dixon@schulich.uwo.ca
Dr. Bradley L. Urquhart (PhD Advisor, Associate Dean–Department of Physiology and Pharmacology, Schulich School of
Medicine & Dentistry, The University of Western Ontario)
brad.urquhart@schulich.uwo.ca
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